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 Abstract 
 
 
 
My PhD thesis comprises the development and application of novel strategies to analyse 
genome-wide association studies (GWAS) in the context of functional pathways. I propose 
pathway and gene-centric methodologies as complementary tools to the conventional single-
marker analyses to mine further the GWAS hidden information. I developed the cumulative 
trend (CT) test statistic that assesses the cumulative genetic variation of single nucleotide 
polymorphisms (SNPs) of genes that interact in the same biological pathway and tests the 
association between a disease and the pathway as an entity. I applied this methodology to the 
genotypic data of the Wellcome Trust Case Control Consortium (WTCCC) study on Crohn’s 
disease (CD), type I diabetes (T1D), rheumatoid arthritis (RA), bipolar disorder, hypertension, 
type II diabetes, coronary artery disease; I identified highly significant associations between the 
autoimmune diseases (CD, T1D, RA) and inflammatory pathways; almost no association was 
identified between the same pathways and the non-inflammatory conditions. I extended my 
approach to a pathway-based gene stability selection methodology, which selects associated genes 
in the context of associated pathways. This methodology can be used to prioritise genes for 
follow up studies. I applied it on two GWAS of RA with different ethnic background and typed 
on different platforms and I demonstrated replication at the pathway, gene and in-silico functional 
levels. I finally extended my approach on family trios designed GWAS. I applied it on two case-
control and family trio datasets of Kawasaki disease (KD). I explored the association between the 
TGF-β pathway and KD susceptibility. The involvement of this pathway in KD was further 
validated at the gene expression and protein levels. My proposed methodologies were tested on 
real datasets and provided reproducible results, which indicates rigor and robustness. I would 
therefore suggest their application to single or multiple GWAS as a complement to conventional 
single-SNP analysis. 
 3 
Table of  contents 
Abstract .................................................................................................................................2 
Table of contents ..................................................................................................................3 
List of figures ........................................................................................................................6 
List of tables..........................................................................................................................8 
Abbreviations ...................................................................................................................... 10 
Declaration of originality .................................................................................................... 11 
Publications ........................................................................................................................ 12 
Acknowledgements............................................................................................................. 13 
Preface................................................................................................................................. 15 
Chapter 1 A background review.......................................................................................... 18 
1.1 Brief overview of GWAS........................................................................................................19 
1.2 The motivation for the pathway-based approach ...............................................................21 
1.3 Pathway analysis scenarios ......................................................................................................21 
1.4 Pathway-centric statistical approaches ..................................................................................22 
1.4.1 Generic framework.........................................................................................................22 
1.4.2 Broad categories of testing procedures........................................................................24 
1.5 Technical challenges ................................................................................................................28 
1.5.1 Pathway collections.........................................................................................................30 
1.5.2 SNP-to gene mapping ....................................................................................................32 
1.5.3 LD pattern........................................................................................................................32 
1.5.4 Size matters ......................................................................................................................33 
1.5.5 Significant hits .................................................................................................................33 
1.5.6 Overlapping pathways ....................................................................................................34 
1.5.7 P-value threshold bias.....................................................................................................37 
1.5.8 Genotyping platform and genome coverage...............................................................37 
1.6 Limitations ................................................................................................................................39 
1.6.1 Associations that will be missed ...................................................................................39 
1.6.2 Discordant findings ........................................................................................................40 
1.6.3 Lack of replication ..........................................................................................................40 
1.6.4 Follow up on the results ................................................................................................41 
1.7 Advantages and advances .......................................................................................................42 
1.7.1 Overcoming the limitations in single-SNP analysis ...................................................42 
1.7.2 Robustness in genetic heterogeneity ............................................................................43 
1.7.3 Insight into disease..........................................................................................................43 
 4 
1.8 Summary....................................................................................................................................45 
Chapter 2 Pathway-driven analysis methodology ..............................................................46 
2.1 Hypothesis.................................................................................................................................47 
2.2 Aims ...........................................................................................................................................48 
2.3 Data ............................................................................................................................................49 
2.3.1 GWAS datasets................................................................................................................49 
2.3.2 Pathway selection ............................................................................................................51 
2.4 Test for pathway association - cumulative trend test statistic ...........................................52 
2.5 Variable selection and logistic regression .............................................................................57 
2.6 Model evaluation......................................................................................................................58 
2.7 Adverse and protective genotype analysis ............................................................................59 
2.8 Summary....................................................................................................................................60 
Chapter 3 Application to three auto-immune diseases ...................................................... 61 
3.1 Shared and unique pathways ..................................................................................................62 
3.2 Probing the signal of association ...........................................................................................64 
3.3 Identifying key genes in associated pathways ......................................................................70 
3.4 Genetic prediction of disease risk..........................................................................................73 
3.5 Validation Study .......................................................................................................................73 
3.6 Visualisation of genomic risk .................................................................................................75 
3.7 Discussion .................................................................................................................................79 
3.8 Summary....................................................................................................................................81 
Chapter 4 Pathway-driven gene stability selection.............................................................82 
4.1 Introduction ..............................................................................................................................83 
4.2 Pathway-based analysis............................................................................................................86 
4.3 Gene- based stability selection ...............................................................................................89 
4.4 Estimation of the significance of the observed overlap between studies ........................95 
4.5 Gene Ontology functional enrichment analysis ..................................................................97 
4.6 Summary....................................................................................................................................97 
Chapter 5 Application on two GWAS of rheumatoid arthritis............................................98 
5.1 Pathway associations................................................................................................................99 
5.2 Gene selection on associated pathways ..............................................................................101 
5.3 Functional enrichment of selected genes............................................................................111 
5.4 Discussion ...............................................................................................................................117 
5.5 Summary..................................................................................................................................120 
Chapter 6 Application to Kawasaki disease.......................................................................121 
 5 
6.1 Introduction ............................................................................................................................122 
6.2 Data and Methods..................................................................................................................123 
6.2.1 Clinical perspective .......................................................................................................123 
6.2.2 Subjects...........................................................................................................................124 
6.2.3 Materials .........................................................................................................................125 
6.2.4 Methods..........................................................................................................................128 
6.3 Results......................................................................................................................................130 
6.3.1 TGF-β signaling pathway and KD susceptibility .....................................................130 
6.3.2 TGF-β signaling pathway and coronary artery outcome ........................................133 
6.3.3 TGF-β signaling pathway and aortic root dimension..............................................135 
6.3.4 TGF-β signaling pathway and IVIG treatment response in the US subjects.......135 
6.3.5 TGF-β pathway transcript abundance and plasma levels in acute and convalescent 
KD 137 
6.4 Discussion ...............................................................................................................................140 
6.5 Summary..................................................................................................................................142 
Chapter 7 Conclusions ...................................................................................................... 143 
7.1 What has this thesis achieved ...............................................................................................144 
7.2 Future directions ....................................................................................................................146 
7.3 Closing remark........................................................................................................................147 
Bibliography...................................................................................................................... 149 
 
 6 
List of  figures 
Figure 1. 200 pathways as downloaded from KEGG and their gene sharing as a fraction of the 
smallest pathway under comparison...............................................................................................36 
Figure 2. Inflammatory response to a pathogen....................................................................................48 
Figure 3.  Pipeline of the pathway-based strategy for the analysis of GWAS data...........................51 
Figure 4. Histogram, density function and QQ plots of various distribution fits to permutation 
data of the cumulative trend test statistic ......................................................................................55 
Figure 5.  Skew normal distribution fit for 1,000 and 10,000 permutations for the IL1 pathway 
with CD ..............................................................................................................................................57 
Figure 6.  Fraction of the associated pathways selected on average by variable selection. .............65 
Figure 7.  Genes identified by variable selection in all 10 folds of cross-validation for T1D, RA 
and CD................................................................................................................................................71 
Figure 8.  ROC curves showing the average predictive performance of the models fitted for each 
disease during 10-fold CV................................................................................................................74 
Figure 9. The allelic architecture of the logistic regression models of disease risk...........................76 
Figure 10. Ratio of adverse/protective genetic variants carried by cases and controls and 
predicted log odds of disease...........................................................................................................77 
Figure 11. Variant SNPs carried by cases with T1D and controls......................................................78 
Figure 12. Schematic diagram of the proposed methodology .............................................................85 
Figure 13 2
1χ  transformation of the CT statistics in NARAC and WTCCC. ....................................87 
Figure 14. Overlap of NARAC and WTCCC pathway rank statistics. ..............................................88 
Figure 15. Log-transformed average model size as a function of the HyperLasso penalty f’.........91 
Figure 16. Gamma prior probability distributions over the penalty f’. ...............................................92 
Figure 17. Number of selected gene-blocks as a function of the selection probability cut-off πthr. 
that defines stable selection. ............................................................................................................93 
Figure 18. The trade-off between r common genes and FDR for different πthr and E[size]...........94 
Figure 19. Fraction of selected genes in WTCCC and NARAC which are common for 
E[size]=400 at different values of πthr. ...........................................................................................94 
Figure 20. Comparison of typed SNP content per gene block between selected and unselected 
gene blocks.........................................................................................................................................96 
Figure 21. Methodological flowchart of my approach as implemented on two GWAS of RA. ....99 
Figure 22. Similarity matrix plot in terms of gene composition for the 42 identified pathways. .102 
 7 
Figure 23. Stability paths of the 60 and 64 gene-blocks selected in WTCCC (a) and NARAC (b).
............................................................................................................................................................103 
Figure 24. Stability paths of known RA associations (a,b) and not selected genes (c,d). ..............104 
Figure 25. Cellular location of products of the selected genes. .........................................................112 
Figure 26. Cellular and functional map of non HLA genes identified by stability selection.........117 
Figure 27. Schematic representation of how genetic variation in genes in the second messenger 
signalling systems cause altered intensity and duration of cellular responses to multiple 
receptor mediated stimuli...............................................................................................................120 
Figure 28. TGF-β signaling pathway.....................................................................................................123 
Figure 29. The cohorts and the phenotypes that were examined in different stages of analysis..124 
Figure 30. Subjects analyzed in expression studies..............................................................................125 
Figure 31. Pedigree of  a family trio. ......................................................................................................128 
Figure 32. Significant SNP locations for TGFB2 (A), TGFBR2 (B) and SMAD3 (C) ..................132 
Figure 33. Heatmaps for Lymphchip array and Agilent array results for 5 genes of interest .......137 
Figure 34. RT-PCR analysis of transcript abundance in whole blood from KD patients during the 
acute and convalescent phase and association between genotype and gene expression ......139 
Figure 35. (A) Plasma levels of TGF-β2 in KD patients during the acute and convalescent phase
............................................................................................................................................................139 
Figure 36. Pathway-based analyses of GWAS in the perspective of an integrative genomics 
approach ...........................................................................................................................................147 
 
 8 
List of  tables 
Table 1. Publicly available servers that will perform pathway analysis on the user’s data...............28 
Table 2. Generic characteristics of pathway-based methods ...............................................................29 
Table 3. Publicly available pathway sources from which  pathway gene sets can be down loaded  
as flat text files on the user’s desktop.............................................................................................30 
Table 4. Summary of technical challenges in pathway-based analyses strategies of GWAS...........38 
Table 5. GWAS genotype data .................................................................................................................52 
Table 6.  Summary statistics of the overall study and the pathway trend test...................................62 
Table 7. P-values of the pathway statistic over all the examined pathways and the seven diseases.
..............................................................................................................................................................63 
Table 8.  Summary statistics of variable selection and logistic regression step .................................64 
Table 9.  Correlation coefficient of –log10 (P-value) with pathway size and number of significant 
hits .......................................................................................................................................................66 
Table 10. List of examined pathways with the corresponding numbers of genes and SNPs. ........68 
Table 11. P-values of the pathway statistic over the examined pathways without any SNPs with 
single-marker P<5x10-7.....................................................................................................................69 
Table 12.Top 42 pathways identified through pathway-based analysis in WTCCC (W) and 
NARAC (N) studies........................................................................................................................100 
Table 13. Pathway collection that the 42 associated pathways were taken from............................101 
Table 14. The 60 gene-blocks selected in WTCCC.............................................................................105 
Table 15. The 64 gene-blocks selected in NARAC.............................................................................107 
Table 16. Mapping of the union of WTCCC and NARAC selected genes back to the 42 
associated pathways. .......................................................................................................................109 
Table 17. The 21 identified genes that replicated in both WTCCC and NARAC and their most 
selected SNP. ...................................................................................................................................110 
Table 18. Gene ontology (GO) process enriched categories as derived by Gorilla for πthr=0.4..115 
Table 19. Gene ontology (GO) functional enriched categories as derived by Gorilla for πthr=0.4
............................................................................................................................................................116 
Table 20. Characteristics of  subjects in their respective cohorts ......................................................125 
Table 21. Characteristics of subjects in microarrays, RT-PCR and ELISA.....................................126 
Table 22. Contigency table of transmitted and not-transmitted alleles in family trios...................129 
Table 23. Versions of the TGF-β pathway and CT test statistic results...........................................131 
 9 
Table 24. TDT analysis of genetic variants and KD susceptibility in US/UK/Australian trios 
(n=451). ............................................................................................................................................133 
Table 25. Association of genetic variants and KD susceptibility in Dutch KD subjects and 
controls .............................................................................................................................................133 
Table 26. Case-control analysis of genetic variants and coronary artery aneurysms (CAA) in US 
subjects..............................................................................................................................................134 
Table 27. Analysis of genetic variants and CA Z-max in US KD subjects (n=176) ......................135 
Table 28. Association of genetic variants with Ao Z-max in US KD subjects (n=98)..................136 
Table 29. Association of genetic variants with IVIG treatment response in US KD subjects.....136 
Table 30. Transcript abundance patterns for differentially expressed genes in the TGF-β pathway.
............................................................................................................................................................140 
 
 10 
Abbreviations 
Abbreviation Definition 
ANOVA Analysis Of VAriance 
AoR Aortic root 
AUC Area Under the Curve 
BD Bipolar Disorder 
CA Coronary Artery 
CAA Coronary Artery Aneurysm 
CAD Coronary Artery Disease 
cAMP Cyclic adenosine monophosphate 
CD Crohn’s Disease 
CT Cumulative Trend 
CV Cross-Validation 
DAG diacyglycerol 
df Degrees of freedom 
eQTL expression Quantitative Trait locus 
FDR False Discovery Rate 
GO Gene Ontology 
HT Hypertension 
IHP International HapMap Project 
IKDGC International Kawasaki Disease Genetics Consortium 
ITP Inositol triphosphate 
ITPR Inositol triphosphate receptor 
kb kilobase pairs 
KD Kawasaki Disease 
LD Linkage Disequilibrium: the non-random association of alleles at two or 
more genomic loci 
MHC Major Histocompatibility Complex 
NARAC North American Rheumatoid Arthritis Consortium 
PCA Principal Component Analysis 
PCR Polumerase Chain Reaction 
QC Quality Control 
RA Rheumatoid Arhtiris 
ROC Receiver Operating characteristic Curve 
RT-PCR Real Time PCR 
SNP Single nucleotide polymorphism 
T1D Type I Diabetes 
T2D Type II diabetes 
tag-SNPs A representative single nucleotide polymorphism (SNP) in a region of the 
genome with high linkage disequilibrium (LD). 
TDT Transmission Disequilibrium Test 
TGF-β Transforming growth factor β 
TNF Tumor Necrosis Factor 
WTCCC Wellcome Trust Case Control Consortium 
 
 11 
Declaration of  originality 
 
 
 
 
 
 
This thesis describes my work undertaken jointly in the group of Prof. Michael Levin and 
the group of Dr. Lachlan Coin at the Department of Paediatrics and the Department of 
Epidemiology and Biostatistics at Imperial College, London. It is submitted in fulfilment of the 
requirements for the degree of Doctor of Philosophy. The work described here has not been 
submitted for any degree, diploma, or any other qualification. This thesis does not exceed 300, 
single-sided pages of double spaced text, not including the bibliography and appendices. 
This dissertation is the result of my own work and the close supervision and guidance of 
my supervisors and includes nothing that it is the outcome done in collaboration except what is 
detailed in the text below. 
The pathway collection that is described in Chapter 3 was assembled by Dr. Victoria 
Wright, who is a Research Associate at the group of Prof. Michael Levin. Ingenuity Pathway 
Analysis, as described in Chapter 5, was also carried out by Dr. Victoria Wright with the 
supervision of Prof. Michael Levin. The cellular map of the genes identified in Chapter 5 was put 
together by Prof. Michael Levin, as well as the plausible scenario that suggests their involvement 
in rheumatoid arthritis susceptibility.  
Microarray data analysis, RT-PCR and TGF-β2 measurements in plasma, as they are 
described in Chapter 6 were performed by Dr. Chisato Shimizu and Prof. Jane Burns’ group, 
Department of Paediatrics, University of California, San Diego and the International Kawasaki 
Disease Genetics Consortium. The interpretation of the results, other than the TGF-β pathway 
association with KD susceptibility was also done by Prof. Jane Burns and Dr. Chisato Shimizu. 
               Charikleia Eleftherochorinou 
               London, 29 June 2011 
 12 
Publications 
 
 
Publication list arising from the work described in this thesis at the time of submission. 
 
 
1. H Eleftherohorinou, CJ Hoggart, VJ Wright, M Levin, LJM. Coin, 2011. Pathway-driven 
gene stability selection of two rheumatoid arthritis GWAS identifies and validates new 
susceptibility genes in receptor mediated signalling pathways, Hum Mol Genet. doi: 
10.1093/hmg/ddr248  
2. C Shimizu, S Jain, KO Lin, D Molkara, JR Frazer, S Sun, AL Baker, JW Newburger, AH 
Rowley, ST Shulman, S. Davila, ML Hibberd, D Burgner, WB Breunis, TW Kuijpers, VJ 
Wright, M Levin, H Eleftherohorinou, L Coin, SJ Popper, DA Relman, W Fury, C Lin, S 
Mellis, AH Tremoulet, JC Burns. 2010. “Transforming growth factor-beta signaling pathway 
in patients with Kawasaki disease”, Circulation: Cardiovascular Genetics, 4(1)16-25 
3. H Eleftherohorinou, V Wright, CJ Hoggart, AL Hartikainen, MR Jarvelin, LJ Coin, M. 
Levin, 2009. Pathway Analysis of GWAS Provides New Insights into Genetic Susceptibility 
to 3 Inflammatory Diseases. PLoS ONE 4(11): e8068. doi:10.1371/journal.pone.0008068 
 13 
Acknowledgements 
This is the end of an era! And maybe my one and only opportunity to thank all the people 
who were by my side on this quite tough intellectual journey called a “PhD”.  
I feel the greatest need to first thank my supervisor Prof. Michael Levin, who gave me the 
opportunity to work with him that day of October 2007, when I knocked on his door. I deeply 
thank him for believing in me from the first instance, for always being supportive, encouraging 
and there to listen. I want to thank him for being so inspiring, for having big ideas, for giving me 
perspective, for keeping me enthusiastic and for all the trips that he has given me. I feel exactly 
the same need to thank my other inspiring supervisor, Dr. Lachlan Coin, who I look up to greatly 
for his super-bright mind and his admirably deep knowledge of the field. He has been like an 
elder brother to me at my workplace, very supportive and I am ever so grateful to him! I thank 
them both for their generosity, for letting me learn from their expertise and for letting me be 
myself at work. 
I really thank the Division of Medicine scholarship committee for funding my research 
plan for 3 years and especially Prof. Nikolas Mazarakis for all his support and for having faith in 
me. 
I would also like to thank Dr. Clive Hoggart for being instrumental in my knowledge of 
statistics and although he used to make fun of me in the beginning, he is one of the people that I 
really enjoy working with.  
A very special thank you to Prof. Jane Burns and Dr. Chisato Shimizu for trusting me 
with their data, for believing in me, for the exciting work we carried out together, for always 
being willing to collaborate and for inviting me to San Diego. 
I would like to say a very big thank you to Dr. Jethro Herberg, for being a supportive 
third supervisor and for always expressing interest in my well-being. Thank you to Dr. Victoria 
Wright for always helping me to understand the biology aspects of the work. 
A very big thank you to Prof. Marjo-Riitta Jarvelin for trusting me with the NFBC data, 
always showing interest in my work and for offering me opportunities to present it in meetings 
and conferences. 
 14 
I would also like to thank Ernest Turro for our conversations, the laughs and the food (!) 
that we shared the past two years sitting next to each other. 
I want to thank Koulis Papastathis, who was my supervisor in Greece and literally pushed 
me to come to the UK to follow my dream.  
A special thank you from the bottom of my heart to my friends in London, first Agapi 
Papadamou, who could potentially defend this thesis in my place, after having listened to it a 
million times; Reem Saleh, for always correcting my use of English and proof-reading my reports 
even when she left London; Dr. Georgios Tzimiropoulos and Dr. Stefanos Zafeiriou for the 
constructive feedback and the stimulating conversations on machine learning and statistical 
approaches and the invaluable advices; Kostas Chalikias, Aliki Stroumpouli, Ed Zukowski, 
Valentina Cipriani, Jennifer Daothong, Argiris Tzakas, Margarita Stapountzi, Lia Chatzinasiou, 
who have been by my side throughout this 3-year journey and all of them for having listened to 
every single presentation of mine, have given me feedback on figure drawings, concept 
formation, decision making and for always encouraging me to keep on going.  
My best friends in Greece, with whom I used to be inseparable, before I left and I miss 
them so much (!!): Eva, the one and only, for the unforgettable times, every single summer, and 
for bringing me back to reality every time I was drifting away, Kleopatra for constantly caring and 
transmitting her “positive” energy, Fotini, Natalia, Vaso and Anna for being by my side, via 
skype, mobile, emails, pushing me further and for making me forget about the stresses of work!  
Most of all, I need to thank my family, my shelter! My brother George, who will always 
find the way to make me laugh, my father Ilias, my role-model, who inspires me to be a good 
scientist and my mother Chaido, who inspires me to be a better person! (not that my father 
doesn’t ☺). Thank you for always being there and for being open-minded to letting me go. 
 15 
Preface 
 
 
 
 
 
 
 
 
 
 
Genome-wide association studies (GWAS) have revolutionized the field of human 
genetics in the post human genome era and have evolved to powerful new tools currently 
employed to explore human disease. Typical GWAS are designed to investigate associations 
between genetic markers, predominantly single-nucleotide polymorphisms (SNPs) and a trait of 
interest, predominantly a binary disease status. Over 900 GWAS have been completed to date 
and they have led to the discovery of >1,300 of genomic loci, which are associated with >220 
human traits. At the same time, GWAS, albeit their relative success, they have also caused a 
considerable amount of disappointment in that the delivered findings are disproportional to the 
cost and effort behind their design; the effect size of the identified loci so far is usually small with 
odds ratios (OR) varying from 1.1 to 3 and the studies to date have managed to explain ~5-10% 
of heritability of the common complex diseases under examination.  
There is much debate about the source of this 'missing heritability', but one possibility is 
that any common complex disease, arises on the basis of the cumulative effect of many variants 
yet to be discovered, because they are either rare (with potentially large effect) or have a small 
effect (but are potentially common). Such variants are challenging to identify when performing 
standard analyses of GWAS data that are ultimately limited by the number of genotyped cases in 
each study.  
 16 
The conventional statistical analyses of GWAS have largely focused on single-marker 
analysis, where each typed SNP is tested, independently to other typed SNPs, for its association 
to the disease. This strategy has been efficient to deliver the most prominent SNP-disease 
associations; nevertheless it has failed to expose the biological aspects of the polygenic basis of 
common disease susceptibility, as it is restricted by the multiple hypothesis problem. As hundreds 
of thousands or even >1M SNP statistical tests of association are carried out simultaneously, a 
proportion of them is expected to show evidence of association just out of pure chance; this is 
the multiple hypothesis problem. Stringent corrections need to be applied to the single SNP test 
statistics in order to adjust their P-values accordingly. Such multiple hypothesis adjustments 
procedures have been proven to allow only SNPs with great main effects to be discovered (e.g. 
OR>~3) leaving the majority of markers with modest effects not identified. 
The conceptual starting point of my work was that the analysis of GWAS data in the 
context of biological pathways could be a powerful way to overcome the limitations imposed by 
the stringent significance thresholds in the multiple hypothesis framework. It would also be a 
logical and biologically-driven basis for analysis compared to single-marker approaches that 
exploit no prior biological knowledge; I anticipated that such an approach could identify the 
cumulative signal of multiple moderately associated markers of interacting genes in functionally 
related pathways. Furthermore, a pathway-based strategy could provide insights into the 
combined effects of low penetrance variations underlying disease susceptibility and may indicate 
biomarkers for disease diagnosis.  
This thesis describes a novel approach to the analysis of GWAS in the context of 
biological pathways that could be used as a complement to conventional single SNP analysis 
strategies. The conceptual path goes from a cumulative trend statistic, that tests the association 
between the disease and a pathway as an entity, to a gene-based methodology that identifies the 
key player genes within associated pathways; it then continues to the use of those pathways and 
genes to predict disease outcome and to then gaining functional insight into disease pathogenesis 
mechanisms. It is an efficient approach for identifying the broader pathway functional setting and 
then prioritizing the candidate genes for follow up studies.  
In Chapter 1, I present a summary of pathway-driven and gene-based methodologies, 
where I have tried to provide a comprehensive overview of the field rather than being exhaustive. 
In the next chapters I describe the methodologies that I developed along with their application 
on complex diseases in the same order that my intellectual journey evolved.  
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In Chapter 2, I describe the materials and methods of the pathway-based approach that I 
developed during the first year of my PhD.  
In Chapter 3, I show the application of my methodology to the WTCCC study of seven 
common diseases, where I examined the association of inflammatory pathways with three 
autoimmune diseases and I present the original results that provided clear evidence to support 
my hypothesis.  
In Chapter 4, I describe my refined pathway-driven gene stability selection methodology 
that goes beyond simple pathway association testing to actually identifying the genes within 
associated pathways that drive predominantly the signal of pathway association.  
In Chapter 5, I present the application of the refined methodology on two GWAS of 
rheumatoid arthritis and I show how the approach provides reproducible results at the three 
levels of pathway, gene and in-silico cellular function.  
In Chapter 6, I describe the extension of my methodology to make it applicable on 
family-trio-based GWAS data, further to the typical case-control design, and I show the work I 
carried out on exploring the association between the TGF-β pathway and the Kawasaki disease.  
In Chapter 7, I summarize the milestones of this thesis, I discuss the conclusions of my 
pathway and gene-based analyses and I suggest potential future extensions of such analysis 
strategies. 
     
Chapter 1  
 
A background review 
 
 
 
 
 
 
GWAS have emerged as a powerful new approach to explore the genetic basis of 
complex disease susceptibility. The approach has been made possible by 1) the revolution in high 
throughput sequencing and genotyping technologies, which have facilitated the way to study large 
cohorts of cases and controls, 2) the identification of common sequence variation in a 
population, 3) the databases where genetic information is being deposited, which were made 
publicly accessible and 4) the HapMap project that revealed ~3,1 million of the ~11 millions of 
common SNPs within the four major ethnic groups in Europe, Asia and Africa, that is the 
Yoruba population in Africa, Asian individuals from both Japan and China and samples of 
northern and western European ancestry.  
In this chapter, I briefly touch on the basic design of a GWAS and I provide a short 
outline of the early analysis strategies and the motivation that led to the development of pathway-
based methodologies. I present the underlying hypothesis and the rationale behind pathway-
based analysis of GWAS and I describe the generic characteristics of relevant methodologies. I 
highlight the main technical challenges and I summarize the ways to overcome them as described 
in the published relevant literature. The main focus on this review is upon pathway-driven 
approaches, as their complexity is somewhat higher than that of gene-centric methods. However, 
the latter will also be covered. 
Chapter 1. A background review 
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1.1 Brief overview of GWAS  
A typical GWAS is designed to identify associations between a phenotype of interest on 
one hand, which is usually a binary disease status, and one or more genetic markers on the other. 
The typed genetic markers are predominantly SNPs and investigators look for allele-frequency 
differences between cases (individuals with a disease/condition) and controls (healthy 
individuals). They systematically investigate tag-SNPs selected to cover the entire human genome 
without an a priori specified hypothesis on the location. The approach that is followed is primarily 
indirect as these studies do not necessarily assume that the typed SNPs are causal but rather that 
they may be in close vicinity to functional mutations and therefore associated with the disease 
due to linkage disequilibrium (LD) - the non-random association of alleles at two or more 
genomic loci.  
Early association studies focused only on SNPs in candidate genes or regions that seemed 
likely to be associated with the disease because of biological function or previous study results 
(termed candidate genes studies). The major impediment to the application of these studies at a 
genome-wide level had been the high cost of genotyping along with the need for a large number 
of markers to provide human genome coverage. The large number of cases and controls to 
design a well-powered association study has also been a major hindrance. Early association 
studies were also limited by the modest number of polymorphisms available and it was not until 
the completion of phase I of the International HapMap Project (IHP)1 in 2005 that GWAS 
flourished. The progress in the high throughput genotyping technology was predominantly the 
reason why GWAS flourished, as cheap and fast genotyping platforms enabled the genotyping of 
millions of SNPs on tens of thousands of individuals. 
For the systematic search of the entire human genome with a length of approximately 3.3 
x109 base-pairs, in subjects of European ancestry only approximately 300k tag-SNPs are 
theoretically required to capture most of the genomic variation. The average number of typed 
SNPs per individual varies from 350k to 1M is some large studies and the number of individuals 
in a study varies from a couple of hundred to a few thousands. The genotype platforms also very 
between studies and it is important to note that chips are designed in different ways. For 
example, the 1M BeadChip Illumina specifically contains 950k tag-SNPs from the IHP project 
and 100k non-HapMap SNPs. In comparison, Affymetrix SNP Array 6.0 used an “unbiased 
selection of 482k SNPs from the SNP Array 5.0” and 424k SNPs from various sources 
(recombination hot-spots, mitochondria, etc) thus not following the tag-SNP approach based on 
the HapMap project2. Both platforms contain SNPs whose minor allele frequency is >5% in the 
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population. The newly introduced Omni 2.5M and 5M Illumina chips contain SNPs from the 
HapMap and the 1,000 Genomes Project (http://www.1000genomes.org/); they allow the 
genotyping of markers with minor allele population frequency  as low as 1% providing better 
genome wide coverage in both common and rare variants .   
Modern GWAS, in contrast to several years of relatively unsuccessful attempts, have 
identified and validated genetic determinants for several common diseases; to name a few, type II 
diabetes3, schizophrenia4, breast cancer5; prostate cancer6, multiple sclerosis7, rheumatoid arthritis8 
and other common diseases9. A rough estimate brings the number of successfully identified 
susceptibility genomic loci to >1,300 associated with >220 traits (first quarter of 2011) as 
reported in the catalog of published GWAS10. The recent explosion of results from GWAS might 
seem like a sudden development. Furthermore, the mass of generated data has also posed new 
challenges for statisticians and analysts who need to address the computational problems by 
developing novel robust and efficient analysis strategies.11 
A number of reviews on the contribution of GWAS to our understanding of disease, 
have highlighted the imbalance between the international effort and cost that has been devoted 
to undertake them, (often involving many thousands of patients and controls), and the value of 
delivered results so far.12-14 There is a general view that the GWAS to date have identified only 
the most significant associations, often explaining only a small fraction of the genetic 
contribution to disease. They have so far provided little biological insight into the 
pathophysiological disease mechanisms leading to each disease and the reason for that is mostly 
attributed to the standard analysis strategies.15-17 
The dominant approach to analyzing GWAS data is the single marker analysis, where 
each SNP is tested independently for its association to the trait. Naturally, when one is 
conducting simultaneously >500k SNP-disease association statistical tests (as many as the typed 
SNPs in the study), a fraction of those could show association due to chance, hence stringent 
“multiple testing” adjustments are required to control the number of false positive conclusions.18 
For many GWAS analysis strategies, the single-SNP association test statistic P-value<10-7 is taken 
as the significance level required to account for multiple testing. For this reason, conventional 
analysis strategies of GWAS have allowed only the most prominent SNP-disease associations to 
be discovered. Many of the true associations may be hidden within the expected false positive 
associations with P-values 10-7< P <0.05. There has thus been increasing recognition, that the 
single SNP analysis needs to be supplemented by novel approaches to fully utilize the huge 
amount of genotypic information available from GWAS.17,19 
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Several approaches have been suggested  to enable  multiple SNPs-disease association 
testing; amongst them are multivariate logistic regression with SNPs as covariates and the binary 
trait as the response variable and test for the significance of the main effects20-23; haplotype 
methods that test the association between multiple SNPs in genomic proximity and a disease24-28; 
epistatic effect modelling that tests interactions between variants.16,29-31 The results of multivariate 
logistic regression and epistasis modelling, albeit promising, have been limited by the huge space 
of possible marker combinations and haplotype strategies have been restricted by the 
computational burden of a genome wide scale scanning. Furthermore, these approaches have 
failed to expose the biological aspects of the polygenic basis of common disease susceptibility, 
and as a result myself and others have suggested that the joint variants in multiple genes 
interacting in functional pathways may provide a better understanding of disease pathogenesis. 
1.2 The motivation for the pathway-based approach 
Biological pathway-driven approaches may be a powerful way to overcome the limitations 
imposed by the stringent significance thresholds in the multiple hypothesis framework and may 
serve as a way to restrict the modelling of statistical interactions in the space of biological 
interactions. Such approaches could adopt and combine components of the aforementioned 
multiple-SNPs strategies under the umbrella of a “biological pathway”. They benefit from the 
prior biological knowledge on gene function and interaction within pathways to leverage the 
deeper mining of genomic data. Pathway-centric approaches hypothesize that complex disease 
pathogenesis is likely to depend on the genetic variation in multiple genes controlling each 
biological pathway, more or less as a domino effect. The predisposing or protective variants 
might differ at an individual’s level, but the cumulative effect across the genes in the pathway is 
expected to associate with a disease as a whole.  
Pathway-centric methodologies are appealing in that they bridge the biological knowledge 
with the statistical analysis of GWAS. Compared to single-SNP analysis that might come up with 
a hit in a gene dessert area and whose function is unknown, gene and pathway associations place 
the results into a functional perspective, are easily interpretable and can elucidate potential disease 
mechanisms.  
1.3 Pathway analysis scenarios  
There are three main scenarios under which a pathway-driven methodology seems the 
most suitable strategy to pursue. The first is to have already formulated a hypothesis that a 
pathway is likely to be linked to a condition. In such a scenario, the pathway(s) under 
examination are usually assembled based on the presumed biological processes involved in the 
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pathogenesis of a specific disease. The disease linked “pathway” is assembled from known 
biological interactions between genes in each functional group and then the prior hypothesis is 
tested via means of a pathway-statistic.32-35 A typical manifestation of this case is testing 
inflammatory pathways for their association to autoimmune diseases33 or the nicotine receptors 
pathway with smoking behaviour.34 That is a “hypothesis-driven” pathway-based strategy. 
The second scenario involves focusing on a restricted number of SNPs/genes, usually the 
top hits of a GWAS, and then examining the “enrichment” of those results in functional 
categories. Investigators that follow this strategy, usually rank the single-SNP results by 
decreasing significance and they choose an arbitrary P-value cut-off (e.g. P<10-4 or P<10-3) to 
define the SNPs to be taken forward to enrichment analysis; a list of molecular pathways or a 
dictionary of cellular processes is also necessary to provide the functional bins that the SNPs will 
be tested against.36-42 This strategy is quite popular as it does not require the formulation of a 
prior hypothesis and in addition it is an effective way to expose the aggregative trends of single-
SNP results into molecular pathways. That is the “hypothesis-generating” strategy. 
The third scenario is about the testing of several pathways for their link to a trait, with no 
prior hypotheses or specific focus on a set of SNPs.36,43,44 This is the “hypothesis-free” strategy as 
it blindly looks for pathway associations, in the same manner that one would perform single-SNP 
analysis to look for hits in the genome without any a priori speculations. The list of pathways is 
usually assembled by public databases, as they will be detailed in the following section. This 
strategy encompasses all available pathway knowledge and exploits a greater fraction of the typed 
genetic variation as opposed to the “hypothesis-generating” methodology that disregards markers 
that are not included in the final set. In this respect, this scenario takes into account SNPs that by 
themselves reach only a nominal association signal (e.g. P>10-4 or P<10-3) and can provide 
added information when regarded in the presence of other biologically interacting markers. 
1.4 Pathway-centric statistical approaches  
The statistical approaches to identifying genetic variation within groups of genes in 
pathways requires a pathway association test statistic, just as single-SNP approaches require an 
association test statistic.  
1.4.1 Generic framework 
The pathway statistic builds upon 3 generic steps: the null hypothesis of no association, 
the summary of the genetic variation along a pathway and the pathway statistic per se.  
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Null hypothesis. They broadly fall in two categories: the “self-contained” and the 
“competitive” methods, as nicely outlined in two recent reviews.45,46 Self-contained methods 
examine the absolute association between a pathway and a trait; that is they test the null hypothesis 
of no association between the joint effect coming from the set of pathway SNPs and the disease. 
The competitive methods, on the other hand, examine the relative association between the 
pathway and the trait; they test the null hypothesis of no association between the pathway SNPs 
and the disease conditioned upon the association of all the other SNPs/pathways in the study. 
Competitive methods are almost all “enrichment” procedures as described in the second scenario 
above. 
Summary of genetic variation. The genetic variation can either be summarized at one 
level where all pathway SNPs are considered jointly or at two levels, where the variation per gene 
is summarized at the first step and then all pathway genes’ variation is combined at the second 
step. This can be implemented either by combining the single-SNP test statistic P-values into a 
single testing framework or by using the raw genotypes. 
Pathway test statistic. To assess the significance of a pathway, one needs to use a 
pathway statistic to compare the observed genetic variation within each pathway against the 
expected variation under the null hypothesis of no association. The null distribution of no 
pathway-trait association is usually derived in 3 ways;  
(1) It is approximated analytically by a known distribution such as the χ2, the F or the 
hypergeometric; hence the pathway test statistic is one of the widely used χ2, F or the 
hypergeometric test statistics.  
(2) It is approximated empirically by a permutation-based procedure where sample 
phenotypes are permuted against the genotypes, the genetic variation is re-calculated under each 
permutation and the pathway P-value is defined as the fraction of permuted pathway statistics 
that are equal or bigger than the observed one.  
(3) Genotypes are randomized against phenotypes, in that random SNPs are selected 
across the genome to create “random” pathways of the same size as the one under examination; 
the pathway P-value is calculated as in (2). This procedure is trying to reflect the “random” 
genetic variation across the genome, nevertheless it is confounded by the differences in the gene 
size and LD patterns between the real pathway and the “random” versions of it.47 
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1.4.2  Broad categories of testing procedures 
Depending on the combination of null hypothesis, genetic variation summary technique 
and pathway statistic, I have broadly observed five trends of pathway methodologies. Those 
categories have evolved based on the published literature so far and they are not exhaustive or 
restrictive.  
P-value combination. These methods are self-contained, they require just the single 
SNP test statistic P-values as input and the pathway statistic is approximated analytically in the 
majority of the cases by a well-known test-statistic. A general framework for combining single 
SNP P-values assumes that K P-values are independent random variables and could be combined 
into a single statistic using the Fisher’s combination test48, which follows a χ2 distribution with 2K 
degrees of freedom (df), Sidak or the Simes’ combination test43. An alternative way would be to 
transform them into χ2 statistics with 1 df and sum them up to a single statistic whose null 
distribution is a χ2 distribution with K df. Another route is to transform them into z-statistics49 or 
to use directly the single-SNP test statistic, which could either be the Cochran-Armitage test for 
trend50 or the MAX-statistic51 and sum them or multiply them. The null distribution can again be 
approximated by a χ2 distribution with K df, by the multivariate Hotelling’s T2-statistic52 or 
empirically by permutations of the phenotype labels. Building upon P-value combining methods, 
the adaptive rank truncated product (ARTP)34 calculates the product of K smallest SNP P-values 
of a gene and then combines the products of the genes of a pathway into a test-statistic for 
pathway association. This category of methods benefits from the computational speed but 
assumes independence between the SNPs, which is strongly violated by the underlying LD 
patterns. Under the violation of this assumption, Fisher’s combination method should not be 
applied, Sidak’s and Simes’ methods underperform and the sum of χ2 dependent distributed 
variables does not follow the null χ2 distribution with K df.  
Multiple regression. A straightforward solution is multiple regression using the SNPs of 
a pathway as covariates and testing the goodness of fit via a test-statistic or via a permutation-
based approach on randomized SNP sets. Nevertheless it suffers from the large number of df in 
the model. Principal component analysis (PCA) is used to summarize the variation across SNPs 
of a pathway and to reduce the df  of the multiple logistic regression model. Multiple regression is 
then performed on a few principal components instead of using all the SNPs. PCA is a useful 
way to summarize the information across multiple SNPs, but it does not identify the most 
informative SNPs. The weights of the SNPs on each the first principal components are indicative 
of a SNP’s effect, nevertheless PCA is not a variable selection procedure. Chen et al36 used PCA 
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to summarize the pathway gene structure and then fitted the eigen-vectors in to a regularized 
regression model; on a similar basis Gauderman et al53 used the first K PCs that explain 80% of 
total variance as covariates on a multiple logistic regression model. Li et al54 used PCA on 
weighted scored SNPs before conducting regression analysis with a set of principal components 
as covariates; the weights were used to reflect the level of LD within loci. These methods are self-
contained, use raw genotypes and statistical significance is either assessed by a test statistic that 
tests for the null hypothesis of all β coefficients being zero or by permutations of phenotypes, 
where the β coefficients of the fitted model are compared to the null distributions of the β 
coefficients of the permuted models. 
Genetic similarity across individuals. The foundation of these approaches is based 
upon the genetic similarity across subjects and their test statistic resembles somewhat an analysis 
of variance (ANOVA) setting. These methods are self-contained, they use raw genotype data and 
the pathway statistic can be approximated analytically or empirically. In this category of methods, 
first the genetic similarity of K pathway typed markers is measured among all pairs of individuals 
and a test statistic compares the means between cases and controls. The genetic similarity 
amongst subjects is scored by “kernel” functions that measure the allele sharing between two 
individuals. Schaid et al55 used the Zglobal statistic, when Wang et al56 developed a modification of 
Zglobal by applying weights on SNPs based on a Fourier transformation. These statistics are 
greatly affected by the scoring of the kernel function; hence they are very powerful in the case of 
multiple associated SNPs with risk effects in the same direction, but quite weak in an opposite 
scenario. Mukhopadhyay et al57 developed the kernel-based association test (KBAT) that makes 
no assumptions about the directions of the SNP effects and does not use the correlation between 
the SNPs. Wessel et al58 on a similar note used the genetic similarity matrix and an F-test statistic. 
Wu et al59 used logistic kernel-machine regression model to model the genetic distances amongst 
subjects, incorporated them into a logistic model and tested for association using the Q statistic, 
which they compared to a χ2 scaled distribution.  
Enrichment. These methodologies are competitive, they use mostly single-SNP P-values 
and statistical significance is assessed either analytically or by permutation of 
genotypes/phenotypes. As already mentioned, this category of methods focuses only at the top 
of ranked single SNP P-values and tests for the enrichment of those in certain pathways. They 
require an arbitrary threshold to be set that will define which single-SNP results will be kept for 
subsequent analysis. The GSEA-SNP60, modified GSEA61 and SNP ratio test44 calculate the 
enrichment statistic as a proportion of the SNPs in a pathway that are significant compared to 
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fraction of significant hits in the rest of typed SNPs. Statistical significance is assessed via 
permutation of phenotypes. ALIGATOR37 uses a preselected P-value threshold to define a set of 
significantly associated SNPs and counts the number of genes that contain these SNPs, with each 
gene counted once and instead of permuting phenotypes to derive the null distribution it uses 
resampling of SNPs.  
Web-based enrichment of gene lists. These tools are similar to the previous category 
in that they also test for “enrichment” in biological pathways, but they differ in that they accept 
gene-lists as input and as they are web-based they used their already predefined pathway 
collections and gene annotations. Some widely used tools are summarized in 
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Table 1. One could use them as in Elbers et al62, where  they first selected all SNPs with single-
SNP P<0.003; they then assigned them to functionally relevant genes using “Prioritizer”63, which 
is a Bayesian approach that prioritizes genes by reconstructing functional gene networks based 
upon interactions from the Human Protein Reference Database (HPRD) , Biomolecular 
Interaction network Database (BIND) and KEGG. They then collected all those genes and 
explored 5 different pathway tools “Webgestalt KEGG”64, GATHER65, DAVID66, PANTHER67 
and “Webgestalt BioCarta”64,  to investigate whether they would provide consistent results. 
DAVID uses functional similarity scores to allocate gene lists into functionally related groups 
based on the functional similarity scores. GATHER assigns gene lists to functional 
groups/pathways via means of a Bayes factor68; this assesses the hypothesis that the distribution 
of functional groups/pathways vary across the genes under examination against the hypothesis 
that the distribution was identical. PANTHER maps the genes to pathways without conducting a 
statistical test, instead provides a list of all pathways those genes belong and then provides 
summary statistics on the mapped pathways. Webgestalt64 uses Fisher’s exact test to test for 
enrichment. A large repertoire of tools for enrichment analysis in Gene Ontology (GO) terms 
has also been developed in recent years, including GoMiner69, FatiGO70, BiNGO71, GO-stat72 and 
GeneTrail73.  
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Table 1. Publicly available servers that will perform pathway analysis on the user’s data 
Name Enrichement 
method 
Description URL Ref 
PANTHER None  
(by gene id) 
Maps genes to ~150 in-house 
pathways by protein sequence 
evolution 
http://www.pantherdb 
.org/pathway/ 
67  
DAVID functional 
similarity scores 
Groups genes upon functional 
similarity, then provides enrichment 
in KEGG, GO pathways, etc  
http://david.abcc. 
ncifcrf.gov/home.jsp 
74 
GATHER Bayes factor  Mpas gene lists to a variety of 
pathways, GO terms, protein binding 
http://gather.genome 
.duke.edu/ 
65  
WebGestalt Fisher’s exact KEGG, BioCarta http://bioinfo.vanderbilt 
.edu/webgestalt/ 
64   
Reactome hypergeometric Manually curated and peer-reviewed 
pathway gene sets 
http://www.reactome.org/ 
ReactomeGWT/ 
entrypoint.html#FrontPage.8093 
75 
GOrilla hypergeometric GO terms http://cbl-gorilla.cs.technion.ac.il/ 76 
1.5 Technical challenges  
Genes are variable in size, as well as LD pattern, they are variable in number of typed 
SNPs within and between genotyping platforms and pathways vary in the number of genes they 
contain. Pathways are differently defined between pathway collections; pathway gene lists are 
either incomplete or over-estimated. There is no golden standard as how to map SNPs to genes 
and genes to pathways. In addition to these technical challenges it is often necessary to 
distinguish between settings where a single SNP in the pathway is the causal or in high LD with 
the causal variant  which may be  driving the pathway association versus settings where additional 
independent susceptibility loci of modest effect are present.59 These differences reflect upon the 
various pathway-centric analyses and results could be biased for one or the other reason. All 
pathway-driven analyses regardless of the test of association per se, should adjust for these 
cofounders in order to ensure rigor and robustness. In the following sections I present those 
challenges and the way that some authors deal with them. Table 2 summarizes various pathway-
based approaches with an outline of their technical characteristics.   
.
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Table 2. Generic characteristics of pathway-based methods 
The first column shows the name, columns 2-4 list the input data, the null hypothesis tested and the pathway collection used, columns 6-9 show the technical steps each method 
followed, when columns 10-12 show whether the results were replicated and the most influential genes in the associated pathways were identified. Y=yes, N=no, NA=not 
applicable 
     
Adjustment for Findings 
Name Input  Hypothesis Pathway collection SNP-to-gene mapping LD Gene 
size 
Pathway 
size 
Single hits  Replication Follow up on 
genes 
Ref 
Multiple tools P-values competitive KEGG, BioCarta, 
DAVID 
SNPs with P<0.003, map SNPs to 
LD blocks 
Y N N Exclusion of 
MHC only 
Limited Y 62 
ALIGATOR genotypes competitive GO 2 approaches:within exons, 20kb, 
N:1 
Y Y Y N N N 37 
U-statistics  genotypes self-
contained 
2 pathways Not-specified Y N N Y  N Y  55 
Kernel-based genetic 
similarity  
genotypes self-
contained 
Simulated data simulation Y Y Y NA N N 57 
Conditional logistic regression genotypes self-
contained 
Axon guidance 
pathway 
Not-specified N N N N  Y Y 32 
Regression-based distance-
matrix analysis 
genotypes self-
contained 
Not specified Not specified Y NA NA N  N N 58 
ARTP genotypes self-
contained 
Not specified Not specified Y Y N N N N 34 
GRASS** genotypes self-
contained 
KEGG 20kb, N:1 Y Y N N N Y 36 
GSEA-SNP genotypes competitive In-house assembled 
gene-sets 
User-defined Y N Y N N N 60 
Modified GSEA genotypes competitive BioCarta, KEGG,GO 500kb, 1:1 most significant,  Y  Y N N N N 61 
SNP ratio test P-values competitive KEGG Not specified Y  N N N  N N 44 
EVA P-values competitive GO 1:1 N N N N Limited Y 41 
MetaCore P-values competitive GO 5kb, 1:1 weighted N Y N N N N 40 
ATOM** genotypes self-
contained 
Genes Not-specified Y N NA N N NA 54 
Multiple regression on PCs genotypes self-
contained 
Genes Not-specified Y Y NA N N NA 53 
VEGAS** P-values self-
contained 
Genes 50kb, N:1 Y  NA N N NA 77 
Logistic kernel machine 
model**  
genotypes self-
contained 
KEGG Annotation files Y Y NA N N NA 59 
Combination of P-values* P-values competitive KEGG, BioCarta Not-specified N N N N Y Y 43 
PRP* P-values competitive KEGG 500kb, 1:1 highest risk statistic N N N NA N N 42 
PINBPA* 
 
P-values competitive KEGG 1:1 N N N N N Y 49 
* Pathway-based method with some sort-of gene-based analysis 
** Gene-based method 
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1.5.1 Pathway collections 
The validity of pathway association studies is highly dependent upon the quality of 
pathway collection used. Incomplete, not-curated or potentially erroneous pathway gene 
collections are likely to lead to false associations. It is of surprise that the most widely used 
pathway collection is KEGG78 –also obvious from Table 2, albeit the fact that it is one of the 
least curated. BioCarta, Pathway Commons, MetaCyc, the Molecular Signatures Database 
(MSigDB) are a few more widely used (Table 3). Gene Ontology79 is a vocabulary of cellular 
processes and function that also contains pathways, but in the majority of the cases it is utilized 
as a functional category enrichment dictionary. In Pathguide investigators can find links and 
information on 325 biological pathway related and molecular interaction related resources to 
choose from for their analysis. 
Table 3. Publicly available pathway sources from which  pathway gene sets can be down loaded  as flat 
text files on the user’s desktop 
Name Description URL Ref 
KEGG Pathway maps and gene lists on 
metabolism, cellular processes, human 
diseases, drug development and more  
http://www.genome.jp/kegg/pathway.html 78 
Gene 
Ontology 
A controlled vocabulary of terms for 
describing gene product characteristics and 
gene product annotation data 
http://www.geneontology.org/ 79 
BioCarta Pathway maps and gene lists on 
metabolism, immunity, cell signalling, cell 
cycle regulation and more. 
http://www.biocarta.com/genes/index.asp NA 
Pathguide Lists all biological pathway related 
resources  
http://www.pathguide.org/ NA 
Pathway 
Commons 
A collection of~ 1,500 pathways as 
assembled by pathway and interaction 
information from nine other sources 
http://www.pathwaycommons.org/pc/ 80 
HumanCyc List of human classic metabolic pathways http://humancyc.org/ 81 
Reactome Manually curated and peer-reviewed 
pathway gene sets 
http://www.reactome.org/ReactomeGWT/ 
entrypoint.html#FrontPage.8093 
75 
KEGG and MetaCyc have collected mostly metabolic pathways, while Signal 
Transduction Knowledge Environment (STKE) and Reactome contain well curated, publicly 
available data on signaling pathways. STKE provides probably the most comprehensive 
description of signaling pathways, but these pathways are not connected to computationally-
accessible data of the participating molecules, such as sequence accession numbers.67. 
Webgestalt64 uses its own pathway database that is assembled by various gene and gene product 
sources, as well as pathway collections, such as KEGG and BioCarta.. Of major concern is the 
fact that the definition and classification of pathways is different between those public databases. 
For instance, “MAPK signalling” in KEGG is represented by 210 genes when it has only 87 in 
BioCarta. As another example, the “IL18 pathway” of KEGG, when examined for enrichment 
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in GO terms using GOrilla76 it comes up as “immune system response” and “interleukin 1 
receptor binding” with respect to most enriched process and function. Furthermore, updating 
and curation of databases and relevant tools is not synchronized and does not always reflect the 
biological knowledge to date67. At the same time, this variety of pathway sources, without any 
standards that they all comply to not only creates a problem of choice but also drives 
inconsistency of results62. 
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1.5.2  SNP-to gene mapping 
Another technical complexity is the mapping of SNPs to genes. To assign SNPs to 
genes, one can use absolute genetic distance within a window of each side of the gene or use 
relative distance that allocates each SNP to the nearest gene. Several windows from each side of 
a gene coordinates’ have been used, varying from 5kb40 to 500kb42. There is no gold standard. 
There is naturally a trade-off between capturing real genetic variation linked to a specific gene, 
and bringing in random noise due to variation unrelated to any gene. A choice of -+5kb reduces 
the likelihood of including random SNPs, nevertheless it is likely to miss potential true 
association that might lie further away from the gene boundaries; +-50kb is likely to include 
some cis acting promoters, +-500kb will include more regulatory elements, but this may be  at the 
expense of a great amount of noise. It has been suggested36,37 that choosing 20kB is not entirely 
arbitrary since a recent study of gene–expression showed that the majority of expression 
Quantitative Trait Loci (eQTLs) lie within 20kb of either side of genes.82 Other approaches 
consider only SNPs in exons37 or limit SNPs to those which are  non-synonymous.55 Several 
methods even assign only one SNP to a gene, usually the most significant.41,42,61 This strategy is 
not advised as it results in loss of power; it does not use the information from the LD pattern of 
a gene nor does it summarize the gene’s genetic variation effectively and it cannot identify 
multiple associated variants acting cumulatively within a gene. An alternative approach is that by 
Torkamani et al40, where they assigned one SNP to a gene but with a weighting that approximates 
the association-statistics of the gene.  
Inconsistency on the SNP-to-gene mapping between tools/studies could also be 
attributed to the human genome reference set used, the gene coordinates, the SNP reference 
number versions. Some tools use public reference sets, such as NCBI and EBI, when others use 
in-house composed references (Webgestalt, PANTHER, DAVID, GATHER). for all these 
reasons, researchers are advised to always report the version of the databases and the annotation 
files used, for their results to be reproducible. As a general comment, the lack of standardisation 
may explain differences in results between studies. 
1.5.3 LD pattern 
Gene and pathway-centric approaches are prone to being biased by the inflation of 
certain genomic areas due to differing LD patterns across the genome. This issue has been 
recognised by researchers and  therefore several strategies have been employed to deal with it. 
One way is to permute the phenotype labels and keep the underlying LD undisrupted.36,61 This 
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approach preserves the underlying LD patterns of the pathway SNPs but in the presence of 
population stratification or genotyping errors it may yield biased results.47 Other ways are PCA 
simulations based on LD structure as derived from HapMap.36,77 On a similar basis, another 
group proposed an optimally weighted markers association test, where weights are assigned to 
each marker in a manner that is proportional to the amount of information the marker captures 
for the trait locus, based on LD patterns as derived from HapMap.54 Holmans et al37 corrected 
for the LD between significant SNPs by normalizing the LD of a region to the average LD 
across the genome. In another study they first allocated SNPs to genomic regions based on LD 
structure and then mapped those blocks to genes.62 In Schaid et al55 they modelled the genetic 
similarity between cases and that of controls using U vectors, where the LD pattern was 
accounted for by the covariance matrices.  
1.5.4 Size matters 
Elbers et al62 assessed five different pathway tools on the same dataset and demonstrated 
explicitly that large genes, genes that reside in large LD blocks and large pathways are more likely 
to be denoted as associated, regardless of the pathway-approach used. The same has been argued 
by several other authors.36,37,45,83,84 With regard to pathway size, some investigators prefer to 
restrict their analysis to pathways of a certain size; for instance between 20 and 200 genes.84 
Holmans et al37 adjusted for GO category size via sampling random genes from the genome and 
simulating random gene lists with as many genes as the category contained in order to 
approximate the true null distribution of no association for every category. 
Others deal with gene size by giving smaller weights to the larger genes in their ridge 
regression model36. ALIGATOR37 allows for the varying sizes of genes by creating “random” 
genes with as many SNPs as the original. Thus, the probability that a gene is added to the list is 
proportional to the number of SNPs that it contains. GRASS36 uses permutation of phenotypes 
and standardization of the statistic contributed by each gene, but even so the authors found a 
modest correlation between gene/pathway size and the estimated P-values. 
1.5.5 Significant hits  
Another potential limitation is that pathway statistics can be driven by very significant 
hits in one pathway. It is possible that a single gene if not a single SNP along a pathway could be 
enough to drive the entire association signal of the pathway.84 For example, the MHC genomic 
region is strongly associated with most inflammatory and autoimmune diseases85 and therefore 
when testing inflammatory pathways that include this region, such as “Antigen processing and 
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presentation” pathways or the “Cell adhesion molecules”, the results might be biased. One 
strategy would be remove those genes and repeat the analysis: Elbers et al62 showed that the P-
values were affected when significant hits were removed, but the significance of several pathways 
remained. Another study84 on a pathway analysis of two GWAS on type II diabetes (T2D) 
picked-up an association with the “Wnt-signaling pathway”, which contains the TCFL2 gene, 
one of the strongest T2D associations. By excluding this gene and repeating the analysis, “Wnt-
signaling pathway” only reached a nominal P-value=0.002, which disappeared after Bonferroni-
correction at the pathway level. In an alternative strategy to measure the effect of single hits,  
others used a stepwise procedure where at each step the most significant SNP was removed and 
the statistic of association was re-computed.55 In another study, in their weighted genetic 
similarity matrices of individuals they weighed more the functionally relevant SNPs and therefore 
did not adjust for bias from single hits.58 Nevertheless, their proposed methodology could be 
reversed by giving less weight to the significant SNPs in order to measure the remaining joint 
effect of the not-significant SNPs. In one of the early studies that showed association between 
the axon-guidance pathway and  Parkinson’s disease (PD)32 the researchers used 1,412 SNPs of 
the pathway to fit a logistic model when 142 SNPs, that is 10.1% of the total were individually 
associated with PD. Nevertheless, the authors did not demonstrate which fraction of disease 
prediction those significant hits accounted for and what was the added value of the remaining 
pathway SNPs.  
1.5.6 Overlapping pathways  
The way that the gene products interact with each other at a molecular level is highly 
complicated. The same genes are involved in multiple different biological pathways and as a 
result pathways overlap in terms of gene composition.  This is explained by many cellular 
processes using the same genes for signalling, cell activation, cell turnover and repair. Figure 1 
shows the gene similarity matrix of 200 random pathways as downloaded from KEGG. It is 
obvious that the majority of them have at least half of their genes in common with other 
pathways. In a scenario, where a core of truly associated genes is involved in several pathways, 
any pathway approach would identify multiple pathway associations, when in reality only a small 
number of genes could account for the signal. Pathway-based approaches suffer from this 
limitation, as the implication resides in the complex biology and not the robustness of the 
method per se. Even multiple hypothesis adjustment at the level of pathways would not be 
adequate to solve this problem, as the interconnected associated pathways would still lie at the 
top of associations even though with adjusted P-values. Some investigators adopted a combined 
pathway and gene-driven methodology to look directly for the genes within associated pathways 
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that drive the signal for association. For example, Chen et al36 applied a dual regularization 
function that selects SNP effects within a gene by lasso penalty while simultaneously shrinking 
the estimates of the genes by ridge penalty. Schaid et al55 used a stepwise variable selection 
procedure to identify the most influential markers of the associated pathway(s). As I suggest in 
Table 4 my proposed strategy would be first to identify the associated pathways and then look 
for the genes that are most instrumental within the associated pathways. 
Chapter 3. Application to three autoimmune diseases 
 
    
 
Figure 1. 200 pathways as downloaded from KEGG and their gene sharing as a fraction of the smallest pathway under comparison  
Bright orange dots denote 100% genes in common and black stands for no genes in common. The gradient indicates the degree of overlap. 
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1.5.7 P-value threshold bias 
Methods that use a P-value cut-off to define a list of significant SNPs to be tested 
for enrichment in pathways will be biased by the inherent arbitrariness of the cut-off 
selection. O’Dushlaine et al44 argued that different cut-offs resulted in different associated 
pathways. Application of ALIGATOR37 showed that by varying the cut-off from 
P=0.0001 to P=0.05 different enriched categories arose. They also demonstrated that in 
the application of ALIGATOR on a GWAS of bipolar disorder (BD) the significance of 
over-represented GO categories increased as the cut-off was loosened, whereas the 
opposite was observed in Crohn’s disease (CD). It is likely that the cut-off should be 
chosen in relation to the genetic architecture of the disease and the number of significant 
hits in the GWAS. In the field of CD, which is a very diverse disease with more than 70 
associated loci identified to date86 the choice of  a very a stringent threshold is likely to 
create a SNP list with several true associations. Conversely in BD, whose genetic 
architecture is almost entirely unknown and very few hits have been discovered so far 
and with no outstanding P-values87, a more generous threshold should be used to allow 
for SNPs with modest effects to define enriched categories. Elbers et al62 demonstrated 
that with P-value threshold<0.003 no GO category would show enrichment due to the 
small number of significant genes of T2D.  
1.5.8 Genotyping platform and genome coverage 
Elbers et al62 showed that the Affymetrix GeneChip Human Mapping 500k array 
covers the whole genome but not all areas equally. For instance, they showed that the 
average number of SNP per pathway is 7.84 for the KEGG “fatty acid biosynthesis” 
pathway and 441.5 for the “antigen processing and presentation”. This affects the 
analysis as some pathways are better covered therefore more likely to come up in the 
analysis. Naturally one could argue that this also depends on the number of genes per 
pathway and the LD pattern across the interacting genes. O'Dushlaine et al44 also 
observed that for a pathway to be denoted as significant using their method, it would 
require at least 20 SNPs, therefore adequate SNP coverage of a pathway is essential for 
effective testing. 
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Table 4. Summary of technical challenges in pathway-based analyses strategies of GWAS 
Technical 
challenge 
Ways to tackle 
it 
Pros/Cons My suggestion 
Pathway 
collection 
KEGG, 
BioCarta, 
HumanCyc 
+: Pathway gene lists can be downloaded and 
customized 
-: Pathway versions might be incomplete, contain 
errors 
 Gene Ontology 
(GO) 
+: Well curated vocabulary of cellular functions 
-: Not all GO terms are supported with 
experimental evidence, caution required for misuse 
of terms 
 In-house 
pathway 
databases of 
online tools 
+: Quick computation of pathway enrichment 
statistics 
-: Rely on the quality of the provided pathways, no 
means of modifying them or testing users' custom 
pathway 
Try several 
versions of the 
same pathway; 
very discordant 
results should be 
suspicious; 
concordance of 
results on 
different pathway 
versions should 
be indicative of a 
real signal 
SNP-to-
gene 
mapping 
1:1, the most 
significant SNP 
of the gene  
+: Not biased by LD patterns, gene size 
-: Miss multiple associated hits in a gene, loses 
power in the presence of modest associations in 
moderate LD  
 N:1, using a 
window along 
the sides of a 
gene or focus 
on SNPs in 
exons only, etc 
+: multiple SNPs that act additively on the same 
gene 
-:Need to summarize LD, adjust for gene size, find 
a good trade-off between bringing in informative 
SNPs and random noise  
+-20kb is a good 
trade-off between 
random noise and 
informative 
SNPs, lots of cis-
regulatory 
elements fall 
within these 
boundaries 
LD 
Phenotype 
randomization 
+: preserves underlying LD 
-: in presence of population stratification yields 
biased results, might be computationally slow 
depending on sample size  
 Normalizing to 
average LD 
across the 
genome 
-: Does not favour pathways enriched in genes 
with LD patterns higher that those of the average 
LD across the genome;  
 
PCA 
+: reduces the df in a test statistic or the number 
of covariates in a regression model 
-:does not take into account the phenotype, thus 
PCs might not be the most discriminating between 
case/control 
Gene/ 
Pathway 
size 
Test statistics 
that are 
summarized by 
one weighted 
SNP  
+: all gene sizes become 1 
-: Loss of power if few hits on the gene / inflated 
result if several associated SNPs in a large gene 
 PCA As PCA above 
Phenotype 
randomization 
 
Assign SNPs to 
LD blocks and 
then LD blocks 
to genes; use 
either a scoring 
function or PCA 
on blocks  
Single hits Remove then 
and repeat 
analysis 
+: downstream results are unbiased by single hits 
-: interactions of modest risk variants with the 
single hits might result in loss of power 
 Stepwise 
variable 
selection 
-: model selection is cumbersome 
Follow up on 
pathway 
associations to 
find the key 
associated genes 
Overlapping 
pathways 
Stepwise 
variable 
selection 
-: biased by LD, model selection is cumbersome  
 
 Dual penalized 
regression on 
pathway and 
gene 
+: identifies pathways and genes simultaneously 
Adopt a gene-
selection 
methodology on 
associated 
pathways  
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Table 4.(continued) 
Technical 
challenge 
Ways to 
tackle it 
Pros/Cons My suggestion 
P-value 
threshold 
Rank SNPs in 
order of 
significance; 
compare the 
distribution of 
ranks between 
genes in a 
pathway to the 
rest  
+: based on the distribution of ranks; cut-off -free 
-: favours pathways in which a few genes have very 
large test statistics in comparison to pathways with 
several genes of approximately similar significance.  
 
Stringent vs 
Generous cut-
off 
+-: Generous: favours pathways/diseases with 
several variants of modest association; in diseases 
with several variants of strong associations it is 
likely to bring in noise  
+-:Stringent: Does not favour pathways with few 
associations and a lot of non-associated genes or 
large genes with several non-associated SNPs  
Try multiple 
thresholds/inspect 
results, decide 
based on the study 
sample size, the 
number of single 
hits in the study 
and the 
complexity of the 
genetic 
architecture of the 
disease 
Genome 
coverage on 
chip 
Imputation +: more coverage 
-: quality of imputed genotypes 
 
 
1.6 Limitations 
1.6.1 Associations that will be missed 
As already discussed, the success of pathway analyses depends upon the accurate 
annotation of the genes within the pathway as well as the richness of the pathway 
collections. What complicates matters is the lack of a consensus on pathway definition 
and the lack of a universal standard on what constitutes a pathway. Furthermore, current 
pathway gene lists represent the knowledge to date and their quality also depends on the 
electronic database maintenance and update.33 Pathway versions can also be quite 
different between public databases, as discussed above. As a consequence, genes that are 
not included in the list of pathways under examination for any of the aforementioned 
reasons, genes whose function is unknown and therefore are not involved in a molecular 
pathways, as well as SNPs that lie in gene desserts are bound to be missed. For example, 
when using a window of 20kb on each side of the ~18k human genes as downloaded 
from NCBI and mapping them to 1034 pathway gene lists as downloaded from KEGG 
and BioCarta, ~91K SNPs of the Affymetrix 550k chip and ~107k of the Illumina 550k 
BeadArray were mapped to pathways, which in practice means that 4/5 of the SNPs on 
the chip will not be analyzed by pathway approaches, unless the window around the 
genes is widened. 
Defining whether a particular SNP is part of a gene is also problematic, and can 
result in trans-regulatory SNPs being missed. Even cis-regulatory elements will be missed 
Chapter 1. A background review  
 40 
unless the window of SNP-to-gene assignment is wide enough. It is up to the researcher 
to decide whether promoters, enhancers, suppressors and the overall transcription 
regulation machinery should be considered as part of a gene function within a pathway. 
It should be noted that in the majority of public pathway gene lists, genes coding for 
regulators are not included as components of the pathways.  
1.6.2 Discordant findings 
GWAS have been plagued with false positive results at the single-SNP level and 
there are lessons to be learnt to avoid similar false positive associations using pathway 
approaches. Pathway-based results to date have a high degree of discordance between 
them. Pathway methods applied on the same datasets by different groups did reveal the 
same associated pathways. Elbers et al62 identified inflammatory pathways as being 
associated with T2D by analyzing two published GWAS, but did not validate the well-
established involvement of β-cell development and function in T2D pathogenesis. Other 
groups identified an association between the axon guidance pathway and Parkinson’s 
disease,32,88. Another study identified no signals of association between the axon guidance 
pathway and Parkinson’s disease by applying both single and multiple marker analysis on 
two PD sample sets. 89 As pointed out in a recent review45, the WTCCC BD dataset was 
analyzed by 4 different groups and the associated pathways did not match.37,40,41,90 It is 
likely that the results of pathway-based analyses will be difficult to compare between 
groups unless the same settings are chosen. All the technical issues discussed above 
hinder replication.  
1.6.3 Lack of replication  
The majority of pathway-oriented approaches published to date, were based on 
simulated datasets and a single GWAS.34,36,42,44,53-55,57,59,77 Therefore the results are 
questionable until they have been replicated on at least another independent dataset or 
they are further examined on gene-expression or functional studies. 
Very few groups have shown validation of their findings on real data. Wang et al33 
showed an association of the IL12/IL23 pathway with Crohn’s disease in 4 different 
datasets. Nevertheless, as 5 of the 20 pathway genes were confirmed CD susceptibility 
loci (IL18R1, IL12RB2 in moderate LD with major hit IL23R, JAK2, IL12B, TYC2)91, 
this replicated association should only be regarded as proof of principle. The study by 
Peng et al43 on RA demonstrated some level of replication by applying 4 different 
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enrichment methodologies on two independent datasets. However, the different 
methodologies yielded very discordant results when compared to each other. Moreover, 
the association signals were not corrected for multiple testing of pathways (they tested 
465 pathways). Their application of Fisher’s exact test identified 10 pathways that 
replicated, all of which contained the major single hits of RA and especially the MHC 
HLA-genes ("Cell adhesion molecules", "Antigen processing and presentation pathway", 
"Type I diabetes mellitus pathway", "Bystander β-cell activation pathway", "Th1/Th2 
differentiation pathway"). No adjustment was performed to remove the bias arising from 
the single SNP hits. They also reported that their pathway replication did not conform to 
their gene association results, as the associated genes were not components of the 
associated pathways. Lesnick et al32 validated their multiple logistic regression models on 
two GWAS of Parkinson's disease (PD), but the prediction of disease status was done 
independently on the two datasets with refitting of the models and it was assessed by a 
likelihood ratio test. This is not an out-of-sample validation; on the contrary this 
approach allows for over-fitting on both GWAS. As it was later shown by another group 
that attempted to replicate the results with a proper out-of-sample cross-validation 
method, the obtained predictive power (area under the receiver operating characteristic 
curve (AUC)=56%) did not live up to the originally reported (AUC=90%) by  Lesnick et 
al32. The same was observed by another group that did not manage to replicate the 
original published results.92 
In general, published attempts to replicate pathway approaches have yielded 
discordant results and over-fitting due to lack of secondary independent cohorts for 
testing has made interpretation of results difficult. As replication is now essential for 
single SNP analyses of GWAS to be considered true findings, we should expect to see 
replication in an independent datasets as a requirement for accepting pathway 
associations from GWAS. 
1.6.4 Follow up on the results  
In addition to the need for replication of the pathway findings on independent 
datasets, further investigation of associated pathways at the gene level is needed for 
clinical and biological use of the results. The majority of pathways are interconnected 
sharing several genes as I have shown before. As a result they tend to show up as 
associations in clusters. For instance, Peng et al43 identified a cluster of associated 
metabolic pathways ("Lysine degradation", "Glycerolipid metabolism", 
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"Glycerophospholipid metabolism", "Ether lipid metabolism") with RA. Taking into 
account that the KEGG “Ether lipid metabolism pathway” (18 genes) is contained 
entirely in the “lysine degradation pathway” (31 genes) which in its turn shares 7 genes 
with “glycerolipid metabolism” (42 genes), which also shares 12 genes with 
“Glycerophospholipid metabolism” (43 genes), then it would be reasonable to speculate 
that a core set of genes might be driving the multiple pathway associations. More 
importantly, without further dissection of the reasons for the association of multiple 
pathways, false inferences may be drawn from the results. Very few groups have tried to 
follow up on their results at the gene level. A very efficient approach was GRASS36, a 
regularized logistic regression algorithm that selects SNPs within gene by lasso penalty 
while simultaneously shrinking the estimates of the genes by ridge penalty. In essence, 
this is a way of testing for association of a pathway with a disease and simultaneously 
identifying the key genes within a pathway. Other groups37 prioritized the genes within 
associated GO categories based on their single-SNP P-value, which in essence 
contradicts the pathway concept that by definition supports the idea that SNPs with low 
P-values on their own may contribute altogether to the overall association of a  pathway. 
Schaid et al55 used stepwise variable selection and re-calculation of the pathway test 
statistic to denote the most influential genes. Peng et al43 replicated five pathways  across 
two studies for T2D, but their gene based methodology identified genes that were not 
parts of those pathways and this discordance was because the two methodologies- 
pathway and gene-based were applied separately. A safe strategy would be to apply a 
pathway-based approach followed by a gene-centred methodology on the associated 
pathways, so that the broader functional setting of a disease is identified initially and then 
the individual key genes can be exposed. 
1.7 Advantages and advances  
Pathway-driven approaches might have several technical challenges to face but 
they are powerful methodologies and if applied as a complement to conventional single-
SNP analysis strategies, they have the potential to both drive the field of GWAS forward 
and shed light into complex disease genetic mechanisms.  
1.7.1 Overcoming the limitations in single-SNP analysis  
Despite the technical challenges of pathway-based approaches, as discussed 
above, there is growing evidence that  pathway-driven methodologies are powerful new 
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tools that can overcome the limitations imposed by the stringent multiple hypothesis 
adjustments in the single-SNP analysis field.45  
Pathway-based methods would be expected to have increased power compared 
to single-SNP analysis when applied to small studies. Combining GWAS of the same 
disease to perform meta-analysis has been an effective way of increasing the sample size 
and the power to detect additional variants86,93 which has been used to increase the 
associations detected by single SNP analysis; however, this strategy is ultimately limited 
by the number of genotyped cases in each study. Furthermore, meta-analysis cannot 
always be applied, particularly for relatively rare diseases where all available cases have 
been used in the primary analysis.94,95 Approaches that allow genes and pathways to be 
identified using smaller cohorts are therefore urgently needed, and pathway-oriented 
methods are promising ways of increasing the value of GWAS data.  
1.7.2 Robustness in genetic heterogeneity 
Pathway approaches are expected to be more robust than single-SNP approaches 
to the effect of genetic heterogeneity between individuals, ethnic backgrounds, 
genotyping platforms and studies. Different individuals might possess different disease 
variants of the same gene or even in different genes that are bound to be missed by 
single-SNP analyses, nevertheless they will be captured by a powerful pathway-centric 
approach, as long as these genes are members of the same functional pathway.37 For that 
reason, true associations should be easier to replicate across different studies without the 
need to increase drastically the study size as would be required in meta-analysis. Multiple 
GWAS could be analyzed under a pathway-based concept in a way that is expected to be 
more powerful than simple meta-analysis based on P-values across studies.83 The genes 
might differ to an extent but the pathways should be resistant to genetic heterogeneity. 
As an example, Elbers et al62 replicated pathway results across two T2D datasets but 
reported that they were picking different genes. 
1.7.3 Insight into disease 
A pathway approach is more likely to yield insight into disease mechanisms than 
single-SNP analysis, in that associated biological pathways by definition implicate 
molecular function and interaction.37,45,83,96 
Several studies to date have documented the importance of biological pathways 
in disease pathogenesis For instance, accumulated evidence implicates the complement 
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pathway with age related macular degeneration,97 the important role of "IL23 pathway" in 
CD,33,98,99  the "Wnt-signalling pathway" association with T2D,100,101 the apolipoprotein E 
receptor mediated signalling pathways with Alzheimer’s disease,102 several interconnected 
metabolic pathways with obesity.103 
When findings from GWAS are viewed from the perspective of biological 
pathways, remarkable pictures begin to emerge. The genetic variants associated with 
diseases have been observed to cluster in related biological processes. Substantial 
evidence has linked immune response pathways to autoimmune diseases,104-108 metabolic 
pathways to metabolic traits,103 intracellular signaling pathways with neuropsychiatric 
disorders including bipolar BD,109-111 whose biological foundation does not seem to 
resemble that of classic neurodegenerative disorders such as Parkinson disease and 
Alzheimer disease, where recent cumulative evidence implicates the mitochondrial 
pathway as pathogenic lever.111-113 
On a different note, exciting unexpected pathway associations expose common 
genetic architecture between diseases of differing pathophysiology. For instance, the 
“Wnt signalling pathway” has been associated with T2D,101,114 as it has been involved in 
cancers of the blood, thyroid, breast, lung, prostate, and colon.115,116 Increasing evidence 
indicates that individuals with T2D are at elevated risk for several cancers, mostly of the 
colon, pancreas, and liver, the risk being more than twice as high for these T2D patients 
than for the general population.117-120 A hypothetical functional disease model upon the 
link between the “Wnt-signaling pathway”, diabetes and colorectal cancer was suggested 
in a recent review121.  
This example serves as a proof of concept that pathway-driven methodologies 
can pave the way to discovering new biology. The shared pathways between different yet 
co-occurring diseases may not explain entirely susceptibility to each disease but they 
might point to the mechanisms of elevated risks of one disease when already suffering 
from the other. On this basis, GWAS of different diseases, but yet with some common 
aetiology or co-occurrence, could be pulled together to increase the discovery power. 
This approach has already been followed for autoimmune diseases to expose common 
underlying autoimmune mechanisms43.  
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1.8 Summary 
In this review of existing pathway approaches I have discussed the range of 
different approaches used to date, and some of the advantages and disadvantages of 
methods proposed for pathway analysis.  
As already demonstrated, pathway-based approaches differ to a great extend with 
each other, all described methodologies have their relative strengths and drawbacks, they 
have several conceptual and technical challenges to address and as this pathway-centric 
concept is still in its infancy, no best pathway-based practice exists as yet.  
The published literature to date suggests that pathway approaches may be a 
powerful strategy to complement single-SNP analyses of GWAS; they offer advantages 
in enabling significant findings on smaller data sets and they allow biological 
interpretation of findings to be more readily established. Nevertheless they also present 
with several technical challenges that remain to be addressed. All these technical 
limitations have been presented and discussed above.  
 As the pathway based methodologies evolve to account for these drawbacks, and 
a more standardized approach to the application of pathway-driven analyses is adopted, it 
is likely that the pathway-centric methods will become an important step in the analysis 
of GWAS. 
 In the next chapters of this thesis I describe my own contribution to the 
development of pathway-driven methods, and my efforts to overcome the 
methodological difficulties and develop an improved analysis strategy. 
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Chapter 2  
 
Pathway-driven analysis 
methodology 
 
 
 
 
 
In Chapter 1, I reviewed the background in the conventional single-SNP analysis 
of GWAS, the need and rationale for pathway-based approaches, as well as the technical 
challenges of such methods. In this chapter I describe my work to develop a pathway-
centric method to GWAS analysis. Although, at this time (2011), the relevant literature 
includes many publications that report pathway-based methods, at the time I 
commenced my PhD (2008), there were very few published algorithms that approached 
the problem of GWAS analysis in a biological pathway-driven way. The landmark 
Wellcome trust Case Control Consortium (WTCCC) study of seven common diseases 
had recently been published, only with the single-SNP analysis results, whose numbers of 
identified loci were disproportional to the size and the cost of the study. The genotypic 
data from WTCCC were made available to my supervisors, and they were used as the 
initial dataset on which to develop a pathway based approach, as a complementary 
strategy to GWAS analysis.
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2.1 Hypothesis  
The principle hypothesis that drove my research is that evolutionary selection is 
likely to act on multiple genes that interact through functional pathways that are 
responsible for a phenotype, rather than only on single genes.  
If we consider the genetic regulation of the immune response, multiple genes 
contribute to the nature and intensity of the response to any pathogen - some acting as 
positive and others as negative regulators.122 The pattern of gene variants within 
inflammatory pathways retained in the population during evolution would be likely to 
depend on their overall effect on the immune phenotype that ensures survival against the 
major infectious diseases that cause death in early life123,124. At the same time, those gene 
variants, which result in rapid activation of a vigorous inflammatory response to 
infection may have the disadvantage of increasing the risk of auto-immune and 
inflammatory diseases later in life,125,126 as also demonstrated in Figure 2. Pro-
inflammatory mediators such as TNF, IL-12, IL-1, IL-6 and IFN-γ, which are essential 
for containment of microbial pathogens,127,128 are also associated with the inflammatory 
processes seen in common auto-immune diseases such as RA,129 CD,130 or T1D131. 
Conversely, treatments that reduce inflammation, such as anti-TNF therapy for CD or 
RA132 are associated with increased risk of opportunistic infection,133 suggesting that 
pathways which are involved in inflammatory diseases are also involved in resistance to 
infectious diseases. 
I, therefore, postulated that the genetic contribution to common autoimmune 
diseases would be determined by multiple gene variants in the same inflammatory 
pathways involved in host response to infectious diseases. I selected CD, T1D and RA, 
diseases with a substantial body of evidence suggesting involvement of inflammatory 
processes,129-131 as model diseases to test this hypothesis.  
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Figure 2. Inflammatory response to a pathogen.  
Pathogen recognised by pattern recognition receptors on phagocytic cell (A) or plasma opsonins (I). Signal 
induction (B) and first order inflammatory genes (C) are induced leading to release of inflammatory signals. 
These bind to receptors (D), leading to activation of signal transduction pathways and gene induction of 
second order inflammatory mediators (E, F). These act as effectors of the inflammatory response (Red 
Arrow) or as positive or negative regulators. Inflammation upregulates cell adhesion molecules (J) and 
those involved in transendothelial migration (K). Genetic variants (A-J) will interact to alter the intensity 
and nature of the response. EC= endothelial cell 
2.2 Aims 
The original aims of my PhD were:  
1. To develop a statistical method that captures the combined effect of multiple 
genetic variants with biological pathways and assesses their association to the 
disease as an entity. 
2. To validate the results of the pathway statistic by comparing the same pathways 
in different diseases.  I postulated that immune-mediated pathways would be 
involved in autoimmune and inflammatory diseases, but they would be unlikely 
to show evidence of association with non-inflammatory diseases.  
3. To develop a methodology for identifying the key susceptibility loci within 
associated pathways. 
4. To utilize the pathway information in building predictive models of disease and 
assess the added value to the findings of single-SNP analysis.  
5. To validate the predictive models in a second independent dataset.  
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Over the first year of my PhD, I developed a test statistic that captures the 
cumulative trend of multiple SNPs assigned to genes in a pathway and tests for 
association of the pathway with a disease of interest. I then incorporated this test statistic 
in a methodology for pathway-based analysis of GWAS data.  
In the proposed strategy, I initially construct the gene lists of the pathways to be 
examined and map SNPs to genes within 10kb of either side of the gene (this can vary, 
depending on user’s criteria). I apply the cumulative trend (CT) test statistic on the 
genotype data of the case-control study to obtain the list of pathways that show evidence 
of association. I then employ a variable selection procedure only on the SNPs within 
associated pathways to identify the individual markers primarily responsible for the signal 
of association. Variable selection and logistic model fitting are carried out under the 
framework of 10-fold cross validation to adjust for over-fitting. I then evaluate the 
predictive power of the models with Receiver Operating Characteristic (ROC) curves and 
explore the allelic architecture of the disease models by various methods. I finally identify 
the covariates that are persistently selected in all 10 logistic models and I performed 
functional annotation and extra pathway exploration, as those genes which show 
constant association with the disease therefore are likely to represent true findings. The 
flowchart of the proposed methodology is depicted in Figure 3, while each step is 
described in detail in the following sections. 
2.3 Data 
For the first phase of my work I used available GWAS datasets from published 
studies and pathways from public databases.  
2.3.1 GWAS datasets 
The WTCCC data. This data is publicly available (on application) genotypic 
data from the WTCCC study on 14,000 Caucasian UK patients and 3,000 controls 
genotyped on the Affymetrix 500K Mapping Array GWA GeneChip. The cohort 
included 7 common diseases; Crohn’s disease (CD), rheumatoid arthritis (RA), type I 
diabetes (T1D), hypertension, type II diabetes (T2D), bipolar disorder (BD) and 
coronary artery disease (CAD). The full clinical details, genotype data and initial analyses 
are described in The WTCCC134. In the original work, 16,179 individuals remained in the 
study after filtering for contamination, false identity, non-Caucasian ancestry and 
relatedness, while 468,919 SNPs passed all the quality control (QC) filters and the visual 
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inspection of the genotype call cluster plots. The QC filters excluded SNPs with 
MAF<1%, SNPs with a study-wide missing data rate >5%, or.1% with a study-wide 
MAF<5 and SNPs with Hardy–Weinberg exact P-value<5x10-7. I performed no extra 
QC procedures and I used the exact same filtered dataset as in the original publication134. 
In all analyses the X chromosome was excluded because I did not have access to the X 
chromosome of the study described below, therefore I would not be able to validate any 
models at the time. 
The 1966 Northern Finland Birth Cohort (NFBC). The cohort followed 
12,058 infants, born in 1966 for over 30 years, with documentation of all health events, 
and illnesses and genotyped using the Illumina Infinium 370cnvDuo array135. The same 
QC filters were used in this study too. Over the 30 years of follow up, 30 of the 4,763 
genotyped individuals (i.e. 0.6%) were diagnosed as having T1D. For that reason, this 
cohort was used to validate my findings from the WTCCC data analysis.  
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Figure 3.  Pipeline of the pathway-based strategy for the analysis of GWAS data. 
 
2.3.2 Pathway selection 
The pathways under investigation were defined from published annotation, and 
using previously defined “canonical pathways” from the KEGG and Ingenuity Pathway 
Analysis 6 databases. The majority of these pathways were collated by Dr. Victoria 
Wright, at the Department of Paediatrics, Imperial College, and the pathways 
downloaded from KEGG were also examined by her for their biological validity. The full 
details of the pathways used in my analysis, the genes comprising each pathway, and the 
overlap in genes between pathways are provided on the webpage 
http://www1.imperial.ac.uk/medicine/people/l.coin/. 
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I examined key canonical pathways associated with innate and acquired immune 
response to pathogens, such as those involving pattern recognition receptors (Figure 2A); 
signal transduction triggered through these receptors (B); the inflammatory genes 
induced (C); second order cytokine receptors (D) and their signal transduction pathways 
(E); leukocyte adhesion and transendothelial migration pathways (F), antigen processing 
and presentation (G), the complement pathway (H), and T and B cell activation pathways 
(I). As a negative control, I examined metabolic pathways such as the urea cycle, amino 
group metabolism and glycolysis, which biologically were not expected to impact directly 
on inflammatory disease susceptibility. The physical positions of all human genes 
(N=18,272) were downloaded from the ftp service of NCBI. SNP positions were taken 
from the Affymetrix annotation files. Gene to SNP mapping was performed by a routine 
that I developed. I used all SNPs within 10kb of either end of the gene. I examined 84 
pathways and sub-pathway combinations in total, where 1415 genes are involved and 
20,309 SNPs are assigned to them. In this thesis, all genes are referred to by their HGNC 
ID and SNPs are referred to by their dbSNP id. 
2.4 Test for pathway association - cumulative trend test statistic  
Having formulated the hypothesis, I had to develop the pathway statistic to 
assess the genetic variation within all genes of a biological pathway and its relation to the 
disease of interest. I opted for a permutation-based pathway statistic that would account 
for the underlying LD structure without being too computationally intensive.  
The data available from a case-control, study are represented in Table 5, where A 
is the high risk allele and a is the other.  
Table 5. GWAS genotype data 
 aa aA AA Total 
Cases r0 r1 r2 R 
Controls s0 s1 s2 S 
Total n0 n1 n2 N 
 
Assume that (r0, r1, r2) follows a trinomial distribution with probabilities for 
genotypes aa, aA, AA equal to p0, p1 and p2 respectively and that (s0, s1, s2) follows a 
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trinomial distribution with probabilities q0, q1, and q2. The null hypothesis of no 
association can be written as: 
    0 : , 0,1, 2i iH p q i= =               (2.1) 
To test H0 against any alternative using the Cochran – Armitage trend test, a set 
of scores x=(x0, x1, x2) must be assigned to genotypes (aa, aA, AA). From Sasieni
50, x = 
(0, 1, 2) is assigned for the additive model, x = (0, 1, 1) for the dominant and x = (0, 0, 1) 
for the recessive. I also assigned x = (0, 1, 0) for the overdominance heterozygous 
advantage/disadvantage model. Given the score x, the Cochran-Armitage test can be 
written as: 
                                                  
0
*
1/ 2[var ( )]
T
H
U
Z
U
=                                     (2.2) 
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2
0
1
( )i i i
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U x Sr Rs
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= −∑                                   (2.3) 
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 In practice, the iq  in (2.5) might not be known, therefore 0σ is estimated from 
the data by representing iq  as /in N . Thus, I have 
                                  
0
2 22
2 2
0
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var ( ) [ ( ) ]H i i i i
i i
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U N x n x n
N
σ
= =
= = −∑ ∑                 (2.5) 
The CAMAX statistic is the maximum of the 4 Cochran-Armitage test statistics 
under the 4 genetic models. 
          MAX x=(0,1,2) x=(0,1,1) x=(0,0,1) x=(0,1,0)CA = max (CA|  , CA|  , CA|  , CA| )             (2.6) 
To obtain the cumulative trend test statistic for pathway association, I sum the 
CAMAX Armitage trend test statistic over all of the n SNPs in a given pathway. If we 
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denote as ,MAX iCA  the MAX Armitage trend test statistic for the i
th SNP, then the 
cumulative trend test statistic for the pathway is 
                                                ,
1
n
pathway MAX i
i
CT CA
=
=∑ ,                                               (2.7) 
where n is the number of SNPs in the pathway.  
If the null hypothesis of no association was true, we would expect the sum of 
independent χ2 test statistics to follow a χ2 distribution with df as many as the number of 
test statistics in the sum. The ease of the expected null distribution was the reason that I 
developed the pathway statistic around the sum of single-SNP statistics. In this case 
though, as the test statistics are not independent, I had to approximate the null 
distribution parametrically. To estimate a parametric approximation of the null 
distribution of the statistic I fitted several continuous theoretical distributions. Goodness 
of fit was assessed by QQ-plots of the observed and theoretically distributed data and 
subsequently by the Kolmorogov-Smirnof goodness of fit test statistic that assesses the 
null hypothesis H0: The distribution fits the data. The skew-normal
136 approximation was 
finally preferred as it exhibited better fit than the Normal, Weibull, Gamma and χ2 
distributions (Figure 4) in the vast majority of pathways (80%). In the rest of the 
pathways the skew normal and the gamma distributions fitted almost equally well, 
suggesting a P-value of the same magnitude, therefore I opted for the skew normal fit on 
all pathways.   
Given N ordered data points 1Y , 2Y ,..., NY  the Kolmogorov-Smirnov test statistic 
is defined as  
                       
1
1
max( ( ) , ( ))i i
i N
i i
D F Y F Y
N N< <
−
= − −                                          (2.8) 
where F  is the theoretical cumulative distribution of the distribution being 
tested 
I show the fit of the skew normal to the empirical null distribution of cumulative 
χ
2 statistics in the top-left panel of Figure 4. 
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Figure 4. Histogram, density function and QQ plots of various distribution fits to permutation 
data of the cumulative trend test statistic 
The plot on the top left corner shows the histogram and the skew-normal density function fit of the 
cumulative trend test statistic calculated from 10000 permutations of cases/control label for the IL-1 
pathway in CD. The next five plots correspond to QQ-plots of the skew-normal, normal, weibull, gamma 
and chi-squared distribution fits to the same null distribution. The Pvalue of Kolmogorov-Smirnof 
goodness of fit test statistic is depicted in the legend of each plot. 
 
I estimated the parameters of a parametric approximation of the null distribution 
of the statistic by fitting a skew normal distribution to results obtained from 1000 
random permutations of case/control label. For each disease and pathway I chose 
location (µ ), scale (σ ) and shape (λ ) parameters which maximise the likelihood 
 ˆˆ ˆ( | , , ), [1,1000]jP CT jµ σ λ ∈                                                 (2.9) 
where each jCT  is calculated as the cumulative statistic under a random 
permutation of the case control labels and j is the index of a random permutation. The 
values of each parameter vary greatly with pathway size and single SNP significance. To 
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give an example, the mean of location (µ ) over 800 canonical KEGG pathways is 923 
and the standard deviation is σ=1367. 
I then estimated the significance as 
ˆˆ ˆ( | , , )
pathwayCT
P P x dxµ σ λ
∞
= ∫                                                  (2.10) 
where pathwayCT  is the pathway statistic under no permutation and 
ˆˆ ˆ( | , , )P x µ σ λ is the fitted skew normal distribution. This procedure was carried out 
separately for each disease and given pathway using the “sn” package in R137.  
I performed only 1000 permutations to save computational time. However, I 
examined the goodness of fit for a few pathways under 1000 and 10000 permutations. As 
it is shown in Figure 5 for the IL1 pathway with CD, the approximate distributions fit 
equally well the data and the derived P-value for IL1 was ~0.0026 for 1000 permutations 
and ~0.0028 for 10000. 
The statistical significance level was adjusted using the Bonferroni correction 
                                              adj
n
α
α =                                                         (2.11) 
where adjα is the adjusted significance level for n null hypotheses that are tested 
simultaneously with a significance level α per hypothesis. 
In terms of computational time performance, permutations for a pathway of 
<100 SNPs run in a couple of seconds and they scale up to 5 minutes for pathways of 
~5,000 SNPs. The algorithm is very fast and in the case that the pathways can be run in 
parallel on a server, the entire pathway-based analysis would take up only a few minutes.  
Chapter 2. Pathway-driven analysis methodology  
 
 57 
50 100 150 200
0
.0
0
0
0
.0
0
5
0
.0
1
0
0
.0
1
5
1000 permutations
Permutation sample data
D
e
ns
ity
50 100 150 200
5
0
10
0
1
50
20
0
1000 permutations
Theoritical quantiles
S
a
m
p
le
 q
ua
n
til
e
s
KS p-value= 0.8586
50 100 150 200 250
0
.0
0
0
0
.0
0
5
0.
0
10
0
.0
1
5
10000 permutations
D
e
n
si
ty
50 100 150 200
5
0
1
0
0
1
5
0
2
0
0
25
0
10000 permutations
S
am
pl
e
 q
u
a
nt
ile
s
KS p-value= 0.2106
 
Figure 5.  Skew normal distribution fit for 1,000 and 10,000 permutations for the IL1 pathway with 
CD  
The CT P-value derived by the top distribution was ~0.0026 and by the second ~0.0028. 
 
2.5 Variable selection and logistic regression  
The cumulative trend test statistic captures the effect of multiple SNPs assigned 
to genes in a pathway that may be implicated in a disease, but does not identify the 
individual markers primarily responsible for the evidence of association. I therefore 
employed a variable selection procedure to determine a subset of genes in associated 
pathways that are predominantly driving the pathway association signal in each 
inflammatory disease.  
Variable selection is a procedure of selecting a set of “most” influential variables 
(in this case the key responsible SNPs/genes) of an original pool of variables (in this case 
all the SNPs/genes within associated pathways) to build learning models (in this case 
predictive disease models). The procedure can be implemented by various algorithms. 
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Each algorithm fit models on subsets of variables and assesses the “relevance” of the 
subset to the outcome of interest based on a criterion (e.g. likelihood of the data given 
the model, FDR, a test-statistic of goodness of fit and others). The variable selection 
algorithm iterates until an optimal criterion is reached (e.g. maximum likelihood, 
minimum FDR, significant P-value of a test statistic and others) and the variables in the 
model are the “selected” ones. 
 Variable selection and model fitting was performed with the program 
HyperLasso138. No statistical interactions were taken into account. The algorithm is 
designed to fit a logistic regression model while performing variable selection to generate 
models with relatively few SNP covariates. The regression coefficients are given by 
maximum posterior estimates and sparse solutions are achieved by using a prior with a 
sharp peak at zero. The prior used was the normal–exponential–gamma (NEG) 
distribution and was specified on effect size at all SNPs resulting in an algorithm that 
chooses those SNPs which explain the greatest variation in the phenotype.  
HyperLasso was applied as to consider four types of SNP effects - additive, 
recessive, dominant, heterozygous advantage/disadvantage(overdominance) – and 
encoded genotypes accordingly – [0,1,2], [0,0,x], [0,y,y], [0,z,0], where the original 
genotypes are ordered as [AA, Aa, aa], where a is the minor allele. The values of x, y and 
z are arbitrary and affect the probability of each effect type being included in the model; I 
chose the values of x, y and z for each SNP separately such that the standard deviation 
over all SNPs of all four effect types was the same. This resulted in choosing the effect 
type with the largest gradient of the log-likelihood at each SNP, which is equivalent to 
choosing the effect type with the minimum P-value. At each position the encoded 
genotypes were centred to have mean zero. The algorithm runs with two parameters, 
shape λ and penalty ƒ’ of the prior distribution. In all analyses shape was set equal to 3.5 
and penalty equal to 40.  These values were selected after sensitivity analysis on the trade-
off between known hits and novel SNPs to be allowed in the models. 
2.6 Model evaluation  
To evaluate the performance of the predictive logistic models, I performed 10-
fold cross-validation (CV). As in the general case of k- fold CV, the dataset was divided 
into k subsets (in this study k=10) and each time, one of the k subsets was used as the 
test set and the other k-1 subsets were considered together to form a training set. 
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Variable selection and model fitting was performed on each kth training dataset separately 
and the predictive power of the kth fitted logistic model was evaluated on the 
corresponding kth training set. Then the average sensitivity/specificity across all k trials 
was computed to produce the average ROC plot. The area under the ROC curve (AUC), 
shows the predictive power of the model; an AUC of 100% represents a perfectly fitted 
model and an AUC of 50% represents a random model. The AUC of each kth fitted 
logistic model as well as the average AUC of all 10 models for each disease were 
calculated following the process outlined in Mason and Graham139.  
The procedure was repeated for each disease. Specifically, the initial cohorts of 
T1D, RA and CD (1963, 1860 and 1748 cases), were split into 10 datasets each of 196, 
186 and 174 individuals respectively. The control group of 2938 individuals was split into 
subsets of 293 individuals. During each trial, a control subset with each disease specific 
subset formed the test dataset for the particular disease, while the 9 remaining disease and 
controls subsets were put together to form the training set. 
2.7 Adverse and protective genotype analysis  
To better understand the genomic architecture underlying disease susceptibility at 
the allelic level, I probed the structure of my predictive models of disease risk. 
Considering that within each pathway some components act as positive and others as 
negative regulators of the overall pathway output, I reasoned that genotypes for each 
SNP may have different effects, either increasing or decreasing the risk of disease 
depending on the functional effect on the pathway. The contribution at each SNP was 
assigned as additive, recessive, dominant or heterozygous. Genotypes were encoded 
numerically on the basis of the genetic model at each SNP with respect to the minor 
allele (refer to Chapter 3, section §3.5). For each disease, I picked the logistic model 
trained on the first fold of the 10 fold CV to demonstrate the adverse against protective 
genotype effect. I repeat the same procedure for all models and the plots remain the 
same. The effect type at each SNP was also categorised as adverse (increasing disease risk) 
or protective on the basis of the sign of the coefficient (+ve or –ve) relative to this 
numerical encoding. I summed encoded genotypes at adverse and protective SNPs separately 
for each individual and calculated their ratio. 
I displayed all cases and controls in relation to the variants carried by each 
individual. Genotypes were coded by the variable selection algorithm coding scheme. 
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Cells were calculated as the product of the coefficients of the logistic model with each 
individual’s genotypes. Thus, for cell ( , )c i j  it would be  
( , ) ( )* ( , )c i j i gen i jβ=                                                   (2.12) 
where ( )iβ  is the logistic model coefficient at SNP i and ( , )gen i j is the 
genotype of individual j at SNP i. Cells were coded red at adverse SNPS, and green at 
protective SNPS. The intensity of the colour in each cell was calculated using the 
cumulative distribution function ( )cdf of the normal distribution as  
intensity 2*( ( ( ( , )) | 0, ) 0.5)cdf abs c i j µ σ= = − , 2( , )
j
c i jσ = ∑        (2.13) 
SNPs were ordered via a neighbour-joining based tree-clustering algorithm 
designed to place rows with similar patterns next to each other.  To do this I first 
calculated a distance between each SNP i  and k as 
2( , ) ( ( , ) ( , ))
j
d i k c i j c k j= −∑                                                 (2.14) 
and then calculated a neighbour joining tree from this distance matrix in a 
manner similar to Howe et al140. 
2.8 Summary 
In this chapter I described the driving hypothesis of my research and my original 
methodology to detect pathway-disease associations from GWAS data. I presented the 
datasets that I used and the statistical analysis that I applied. In the next chapter I 
showcase the results of this approach to the WTCCC study of seven common diseases. 
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Chapter 3  
 
Application to three auto-
immune diseases  
 
 
 
 
 
 
As described in the previous chapter I aimed to test the hypothesis that the 
genetic contribution to common autoimmune diseases would operate through biological 
pathways involved in the immune response. I developed a pathway-centric analysis 
methodology of GWAS and I applied on the WTCCC GWAS dataset of 7 common 
diseases; my analysis tested the association between 84 inflammatory pathways and three 
autoimmune diseases, RA, T1D and CD. The four non-autoimmune diseases of the 
WTCCC study (i.e. BD, CAD, T2D, HT) were used as negative controls. In this chapter, 
I present my results. 
Chapter 3. Application to three auto-immune diseases 
 
 62 
3.1 Shared and unique pathways 
The number of pathways, genes within them and SNPs used in the analysis are 
shown in Table 6. When the cumulative trend test statistic was applied to the seven 
diseases of the WTCCC study, highly significant associations were observed between 
several of the inflammatory pathways and the three autoimmune diseases (Table 7). The 
“Jak-STAT signalling”, “antigen processing and presentation”, “T cell activation 
pathway”, “cell adhesion molecules”, “hematopoietic cell lineage” and “NK cell 
mediated cytotoxicity” showed high levels of significance in all three diseases (P<10-4 to 
P<10-20). However certain pathways showed evidence for association with one disease; 
the pathways of “NOD2” (P<10-4to P<10-15), “IL-23” and “TNFα” (P<10-20), “IL-12” 
and “TGF-β “ (P<10-06), “TLR2 signalling” (P<10-5 to 10-9), “classical MAPK” (P<10-10) 
and “B cell activation” (P<10-8) with CD; “TLR3” (P<10-4), “T-cell activation via PLC” 
and “via NFAT” (P<10-4) and “ABC transporters” (P<10-16) with T1D; “TLR9 signalling 
via IRF5” (P<10-6) and “purine metabolism” (P<10-5) with RA (Table 7). 
Almost all of the pathways under investigation showed no evidence of 
association with the non-autoimmune diseases (Table 7). However, some signal of 
association was detected in pathways with a previously identified or biologically plausible 
link to a non-inflammatory disease. For instance, the association between the B cell 
signalling via protein kinase C pathway in B cells and bipolar disorder is consistent with 
reports that PKC (a constituent of this pathway) activity has a role in the 
pathophysiology of bipolar disease.141 No association was seen for metabolic pathways 
that are not expected to have a biological link to the autoimmune diseases (Table 7).  
 
Table 6.  Summary statistics of the overall study and the pathway trend test 
 
 
Overall study    
Inflammatory pathways  84 
Genes within inflammatory pathways 1415 
SNPs mapped to genes 20309 
Pathway statistic analysis results T1D RA CD 
Associated pathways 24 15 38 
Genes in associated pathways 989 878 1124 
SNPs in associated pathways 12663 12215 16284 
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Table 7. P-values of the pathway statistic over all the examined pathways and the seven diseases.  
P-values in bold and scientific format were denoted significant after Bonferroni correction for the number 
of pathways (N=84) at the 5% significance level. P-values equal to 0 represent P < 10-20. CD= Crohn’s 
disease, T1D=type 1 diabetes, RA=rheumatoid arthritis, HT=hypertension, BD=bipolar disorder, 
CAD=coronary artery disease, T2D, type 2 diabetes. 
PATHWAY CD T1D RA HT BD CAD T2D
Pattern recognition receptors
TLR21 3.5E-05 0.029 0.041 0.257 0.187 0.386 0.357
TLR2/11 9.1E-06 0.030 0.026 0.197 0.185 0.318 0.367
TLR2/61 2.4E-05 0.020 0.065 0.129 0.129 0.179 0.316
TLR31 0.001 3.3E-04 0.037 0.319 0.198 0.246 0.145
TLR4 (MyD88 dependent)1 0.020 0.010 0.040 0.199 0.102 0.469 0.335
TLR4 (MyD88 independent)1 0.018 0.018 0.029 0.152 0.124 0.343 0.262
TLR5/TLR7/TLR8/TLR91 2 0.127 0.062 0.397 0.380 0.154 0.342 0.119
TLR2-IRF5 2.7E-06 0.225 0.001 0.116 0.085 0.389 0.477
TLR2/1-IRF5 3.1E-09 0.228 0.001 0.129 0.066 0.453 0.442
TLR2/6-IRF5 8.1E-05 0.171 0.001 0.179 0.066 0.102 0.330
TLR4 (MyD88 dependent)-IRF5 0.022 0.076 0.017 0.173 0.078 0.555 0.482
TLR5/TLR7/TLR8-IRF52 0.441 0.804 0.032 0.315 0.013 0.394 0.004
TLR9-IRF5 0.002 0.058 1.6E-06 0.220 0.112 0.638 0.361
Signal transduction
Jak-STAT signalling 2.5E-07 1.9E-12 4.4E-09 0.005 0.011 0.166 0.045
MAPK: All 7.7E-09 1.5E-06 0.119 0.005 0.054 0.020 0.003
MAPK: Classical 1.8E-10 0.001 0.164 0.009 0.121 0.033 0.001
MAPK: JNK & p38 2.2E-06 2.72E-02 0.139 0.053 0.158 0.046 0.030
NFKB 0.030 0.016 0.010 0.842 0.533 0.333 0.294
NOD11 0.097 0.324 0.633 0.003 0.141 0.001 0.489
NOD2 (via GRIM19)1 4.4E-04 0.055 0.237 0.184 0.102 0.205 0.210
NOD2 (via RICK)1 1.3E-15 0.587 0.528 0.005 0.151 0.045 0.287
Second order cytokines
IL-11 0.003 0.217 0.127 0.101 0.157 0.516 0.496
IL-6 3.5E-04 4.2E-04 0.064 0.140 0.826 0.221 0.426
IL-10 8.4E-06 2.1E-04 0.083 0.378 0.683 0.116 0.836
IL-12 4.9E-06 4.32E-03 0.003 0.324 0.949 0.523 0.747
IL-18 0.017 0.062 0.032 0.220 0.391 0.287 0.287
IL-23 0.0E+00 0.017 0.063 0.012 0.709 0.637 0.301
TNF1 0.0E+00 0.017 0.026 0.045 0.244 0.635 0.283
TGF-β 2.6E-05 0.004 0.035 0.102 0.502 0.155 0.218
Antigen processing and presentation
All1 1.4E-04 0.0E+00 0.0E+00 0.012 0.016 0.256 0.577
MHC I 0.073 0.0E+00 0.0E+00 0.291 0.266 0.420 0.521
MHC II 1.9E-05 0.0E+00 0.0E+00 0.021 0.043 0.810 0.545
B – cell activation
All1 5.2E-08 0.005 0.656 0.005 0.026 0.196 0.006
AKT1 0.039 0.550 0.223 0.015 0.021 0.059 0.004
AP1 7.6E-11 0.037 0.578 0.146 0.136 0.403 0.004
NFAT 1.7E-04 1.72E-03 0.702 0.010 0.009 0.221 0.067
PKC1 0.037 0.050 0.553 0.245 1.1E-04 0.323 0.135
T – cell activation
All1 2.5E-11 1.3E-07 2.4E-05 4.1E-05 0.004 0.069 0.002
AP1 5.3E-07 0.002 0.112 0.124 0.293 0.516 0.003
NFAT 0.004 1.0E-04 0.025 0.021 0.004 0.452 0.047
PLC1 0.002 1.3E-04 0.009 0.028 0.153 0.480 0.007
ICOS/CD281 4.1E-05 0.227 0.029 0.001 0.060 0.024 0.352
Cytokines/receptors 4.3E-04 6.0E-06 2.5E-06 0.156 0.005 0.055 0.123
Cytokines/receptors/Jak-STAT/suppressors 2.4E-04 1.2E-09 1.1E-04 0.007 0.011 0.023 0.014
IFN-γ 1.7E-05 8.6E-06 0.018 0.065 0.089 0.186 0.630
Signalling molecules and interaction
Cell adhesion molecules: All 0.0E+00 0.0E+00 0.0E+00 0.081 3.1E-04 4.6E-04 2.0E-04
APC: T cell 5.0E-06 0.0E+00 0.0E+00 0.211 0.001 0.618 0.184
Tc cell: target cell 0.010 0.0E+00 0.0E+00 0.577 0.284 0.561 0.438
Th cell: B cell 2.5E-04 0.0E+00 0.0E+00 0.068 0.035 0.363 0.554
Leukocyte : platelet 0.208 0.868 0.631 0.208 3.5E-05 0.680 0.139
Leukocyte : endothelial cell 0.029 0.095 0.257 0.194 2.2E-04 0.190 0.452
Neural cells 7.6E-05 0.123 0.125 0.191 0.045 0.001 0.001
Cytokine-cytokine receptor interactions 4.2E-15 2.7E-12 0.002 0.042 0.026 0.194 0.104
Others
ABC transporters 0.021 2.2E-16 0.004 0.350 0.003 0.276 0.166
Cell communication 0.014 8.3E-05 0.007 0.064 1.6E-04 0.051 0.009
Complement: All 0.080 0.323 0.051 0.245 0.551 0.484 0.206
Haematopoietic cell lineage: All 6.3E-10 0.0E+00 0.0E+00 0.006 2.8E-04 0.019 0.070
Leucocyte transendothelial migration 0.013 0.575 0.102 0.418 0.003 0.059 0.203
Natural killer cell mediated cytotoxicity 3.3E-10 0.0E+00 1.4E-09 0.003 0.001 0.100 0.431
Neutrophil activation 4.5E-05 0.002 0.043 0.061 0.290 0.043 0.605
Purine metabolism 1.04E-02 0.026 3.2E-05 0.174 0.474 0.010 0.367
Pyrimidine metabolism 7.02E-02 0.160 0.039 0.389 0.377 0.590 0.280
Type 1 diabetes 4.8E-07 0.0E+00 0.0E+00 0.231 0.045 0.672 0.940
Non-inflammatory pathways
Urea cycle 0.928 0.081 0.771 0.318 0.153 0.257 0.069
Citrate Cycle (TCA cycle) 0.829 0.935 0.331 0.197 0.235 0.761 0.327
Arachidonic Acid metabolism 0.411 0.844 0.289 0.157 0.806 0.338 0.192
1
Addition of NFKB did not change the result
2
Although shown together, these were considered as separate pathways  
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3.2 Probing the signal of association 
In order to identify the genes within associated pathways that are primarily 
responsible for the evidence of each pathway association, I collected all the SNPs within 
genes of pathways with P<5x10-4 (significance level 0.05α = , Bonferroni corrected for 
approximately 100 pathways) and I applied HyperLasso138, a variable selection procedure 
to determine a subset of genes in associated pathways that predominantly account for the 
genetic effect. The procedure, under the framework of 10-fold CV to adjust for over-
fitting, was applied separately for CD, T1D and RA as different pathways (thus different 
sets of genes and SNPs) were found to be significant in each disease (Table 7 and Table 
8). As shown in Table 8, the models developed during CV consisted on average of 205 
SNPs (~149 genes) in T1D, 350 SNPs (~189 genes) in RA and 493 SNPs (~277 genes) 
in CD.  
Table 8.  Summary statistics of variable selection and logistic regression step1  
 
The pathway signal might arise from a powerful effect of a small number of 
variants within each pathway or from multiple variants each contributing a small effect. 
To explore both scenarios, I displayed for each associated pathway, the fraction of the 
pathway genes selected on average by variable selection (Figure 6).  
For some large pathways such as T cell activation (composed of 273 genes), 30-
45% of the genes contributed to the effect in all three diseases, while some small 
pathways (such as NOD2 or IL-23, composed of 4 and 7 genes respectively) were 
selected almost in their entirety.  
                                                 
1
 Numbers were rounded to the closest integer. 
Variable selection and model fitting T1D RA CD 
SNPs (in at least 1 fold) 665 1032 1589 
Genes (in at least 1 fold) 299 316 478 
SNPs in every fold 32 57 62 
Genes in every fold (any SNP of the gene) 52 88 118 
Genes in every fold (the same SNP selected) 29 48 55 
Average SNPs (per model, over all folds) 205 350 493 
Average genes (per model, over all folds) 149 189 277 
Average dominant SNPs (per model, over all folds) 54 77 100 
Average recessive SNPs (per model, over all folds) 48 104 145 
Average additive SNPs (per model, over all folds) 48 73 112 
Average heterozygous SNPs (per model, over all folds) 53 97 134 
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Figure 6.  Fraction of the associated pathways selected on average by variable selection.  
The bar charts show for each disease the average number of genes in a pathway that were picked out by 
the variable selection algorithm, divided by the total number of genes in that pathway and expressed as a 
percentage. Only associated pathways are shown. The total number of genes in a pathway is shown in 
parenthesis below the pathway name. Bar-charts are colour coded with respect to the disease of 
association. Pathways are shown grouped in functional categories. The error bars show the standard 
deviation as calculated by the 10 models. 
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The percentage of genes in a pathway contributing to the association differed in 
each disease, however not substantially. For example, in the leukocyte migration 
pathway, 20% of the pathway was selected in CD, 17% in RA and 12% in T1D. 
To examine potential bias that might be introduced by the significant hits in each 
pathway I calculated Pearson’s correlation coefficient (r2) between the 10log ( )P−  and 
the number of significant hits per pathway, where P is the P-value of the pathway 
statistic. To assess the bias from the pathway size on the cumulative trend test statistic, I 
calculated the r2 between the 10log ( *)P−  and the pathway-size in number of SNPs, 
where P* is the P-value of the pathway statistic after removal of significant hits. The 
correlation coefficient with respect to the pathway size was not alarming, while the 
strong correlation with the number of significant hits was somewhat expected. It would 
be surprising to see pathways with significant hits within them not to show association 
with the disease. Nevertheless, I was mostly keen to examine the extent to which SNPs 
with great marginal effects drove the association of a pathway as a whole. 
Table 9.  Correlation coefficient of –log10 (P-value) with pathway size and number of significant 
hits 
 Correlation coefficient with 
 T1D RA CD 
Pathway size (no of genes) 0.04 -0.017 0.490 
Significant hits 0.75 0.799 0.351 
 
In Table 10 I show the number of significant hits in each pathway. It is clear that 
several pathways were associated with a disease, although they had no mapped SNPs 
with individual single SNP trend test P<5x10-7 (WTCCC threshold). To name a few, 
“Jak-STAT signalling” with all three autoimmune diseases, the “B-cell activation” sub-
pathways and “Cell adhesion molecules” with CD, “IL6” and “IL10” with CD and T1D 
and “TLR2 signalling via IRF5” with RA. Interestingly, “T-cell activation via AP1”, 
although it contains 3 significant SNPs it was not found associated with either T1D or 
with RA, and “TNF” pathway showed no association with T1D despite its 1 hit. Of note 
is also the “Cell communication” pathway, which has 3 significant SNPs associated with 
T1D and 2 with RA, and was found to be only associated with T1D.  
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These findings encouraged me to believe that my pathway-based approach could 
be used as a complementary strategy to single-SNP analysis, as my results did not seem 
to be substantially biased by the single-SNP analysis results. Of course in the case of a 
pathway with numerous significant hits, such as the “Cell adhesion molecules” with 
several significant SNPs from the MHC genes, the pathway statistic is driven by the 
single-marker test results. However, variable selection on such a pathway is likely to 
identify additional components that may be associated, other than the obvious HLA 
genes and as it is shown in Figure 6, the variable selection algorithm picked up the ~40% 
of the Cell adhesion molecules pathway (~53 genes). 
To further investigate this matter, I repeated the cumulative trend test statistic 
calculation for each pathway with the significant hits excluded. As shown in Table 9 the 
majority of pathways retained the statistical significance even after the removal of highly 
associated markers. This provided evidence that the association was accumulated from 
several moderately significant markers and not only from a few hits. Not surprisingly 
very few pathways, such as the “TLRs” with CD, the “ABC transporters” with T1D and 
the “Haematopoietic cell lineage” with RA did not retain their significance when the 
highly significant hits were removed.  
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Table 10. List of examined pathways with the corresponding numbers of genes and SNPs.  
The column of significant hits shows the number of SNPs with individual trend test P < 5x10-7 within each 
pathway. The asterisk denotes association of a pathway with the disease. Pathways are color-coded based 
on their broader functional setting as in Table 7. The cut-off P < 5x10-7 is used as rule of thumb in GWAS 
single hit definition134. 
PATHWAY Genes SNPs CD T1D RA
Pattern recognition receptors
TLR2 31 219 6 0 0
TLR2/1 32 221 6 0 0
TLR2/6 33 244 6 0 0
TLR3 21 167 0 0 0
TLR4 (MyD88 dependent) 38 315 0 0 0
TLR4 (MyD88 independent) 39 503 0 0 0
TLR9 21 179 0 0 0
TLR2-IRF5 24 142 6 0 0
TLR2/1-IRF5 25 144 6 0 0
TLR2/6-IRF5 26 167 6 0 0
TLR4 (MyD88 dependent)-IRF5 30 218 0 0 0
TLR5-IRF5 11 61 0 0 0
TLR9-IRF5 17 119 0 0 0
Signal transduction
Jak-STAT signalling 123 1094 0 0 0
MAPK: All 291 4757 0 1 0
MAPK: Classical MAPK 174 3502 0 0 0
MAPK: JNK & p38 MAPK 154 1623 0 1 0
NFKB 20 210 0 0 0
NOD1 5 32 0 0 0
NOD2 (via GRIM19) 5 69 5 0 0
NOD2 (via RICK) 4 53 5 0 0
Second order cytokines
IL-1 19 230 0 0 0
IL-6 14 143 0 0 0
IL-10 9 114 0 0 0
IL-12 7 79 0 0 0
IL-18 16 165 0 0 0
IL-23 7 70 5 0 0
TNF 16 106 6 1 0
TGF-β 19 298 0 0 0
Antigen processing and presentation
all 104 436 0 52 23
MHC I 65 269 0 16 5
MHC II 28 194 0 31 16
B – cell activation
All 119 1660 0 0 0
AKT 18 159 0 0 0
AP1 88 1272 0 0 0
NFAT 27 546 0 0 0
PKC 21 499 0 0 0
T – cell activation
All 273 3883 0 2 1
AP1 114 1713 0 1 1
NFAT 81 1728 0 1 1
PLC 41 755 0 1 1
ICOS/CD28 18 153 0 0 0
Cytokines/receptors 39 311 0 1 0
Cytokines/receptors/Jak-STAT/suppressors 75 644 0 1 0
IFN-γ 12 117 0 0 0
Signalling molecules and interaction
Cell adhesion molecules: All 132 3330 0 48 24
APC: T cell 45 336 0 36 17
Tc cell: target cell 18 93 0 5 1
Th cell: B cell 29 187 0 31 16
Leukocyte : platelet 9 82 0 0 0
Leukocyte : endothelial cell 28 381 0 0 0
Neural cells 36 2352 0 0 0
Cytokine-cytokine receptor interactions 209 1880 0 1 0
Others
ABC transporters 34 616 0 9 3
Cell communication 99 1500 0 3 2
Complement: All 28 320 0 0 1
Haematopoietic cell lineage: All 88 798 0 9 4
Leucocyte transendothelial migration 89 1401 0 0 0
Natural killer cell mediated cytotoxicity 109 1192 0 12 2
Neutrophil 113 736 0 1 0
Purine metabolism 110 2226 0 0 0
Pyrimidine metabolism 59 556 0 0 0
Type 1 Diabetes 40 484 0 38 18
Non-inflammatory pathways
Urea cycle 28 164 0 1 0
Citrate Cycle (TCA cycle) 24 243 0 0 0
Arachidonic Acid metabolism 40 343 0 0 0
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Table 11. P-values of the pathway statistic over the examined pathways without any SNPs with 
single-marker P<5x10-7.  
P-values in bold and scientific format correspond to pathways that preserved their statistical significance 
even after the removal of the significant hits. P-values in italics stand for pathways that were statistically 
significant when the significant hits were included but not when they were excluded from analysis. 
Pathways are color-coded based on their broader functional setting as in Table 7. 
 
PATHWAY CD T1D RA
Pattern recognition receptors
TLR2 0.199 0.029 0.041
TLR2/1 0.157 0.030 0.026
TLR2/6 0.156 0.020 0.065
TLR3 0.001 3.3E-04 0.037
TLR4 (MyD88 dependent) 0.020 0.010 0.040
TLR4 (MyD88 independent) 0.018 0.018 0.029
TLR9 0.127 0.062 0.397
TLR2-IRF5 0.662 0.225 0.001
TLR2/1-IRF5 0.540 0.228 0.001
TLR2/6-IRF5 0.502 0.171 0.001
TLR4 (MyD88 dependent)-IRF5 0.022 0.076 0.017
TLR5-IRF5 0.441 0.804 0.032
TLR9-IRF5 0.002 0.058 1.6E-06
Signal transduction
Jak-STAT signalling 7.4E-09 1.9E-12 4.4E-09
MAPK: All 6.4E-05 0.001 0.119
MAPK: Classical MAPK 2.2E-05 0.001 0.164
MAPK: JNK & p38 MAPK 0.025 0.055 0.139
NFKB 0.825 0.016 0.010
NOD1 0.833 0.324 0.633
NOD2 (via GRIM19) 0.085 0.055 0.237
NOD2 (via RICK) 0.160 0.587 0.528
Second order cytokines
IL-1 0.003 0.217 0.127
IL-6 3.5E-04 4.2E-04 0.064
IL-10 8.4E-06 2.1E-04 0.083
IL-12 4.9E-06 0.004 0.003
IL-18 0.017 0.062 0.032
IL-23 4.5E-11 0.017 0.063
TNF 0.091 0.017 0.026
TGF-β 2.6E-05 0.004 0.035
Antigen processing and presentation
all 1.4E-04 3.1E-14 5.2E-11
MHC I 0.073 4.1E-05 0.004
MHC II 1.9E-05 1.4E-05 1.5E-10
B – cell activation
All 5.2E-08 0.005 0.656
AKT 0.039 0.550 0.223
AP1 7.6E-11 0.037 0.578
NFAT 1.7E-04 0.002 0.702
PKC 0.037 0.050 0.553
T – cell activation
All 2.5E-11 1.6E-06 1.4E-04
AP1 5.3E-07 0.002 0.189
NFAT 0.004 0.082 0.158
PLC 0.002 0.002 0.182
ICOS/CD28 4.1E-05 0.227 0.029
Cytokines/receptors 4.3E-04 9.6E-05 2.5E-06
Cytokines/receptors/Jak-STAT/suppressors 2.4E-04 7.1E-08 1.1E-04
IFN-γ 1.7E-05 8.6E-06 0.018
Signalling molecules and interaction
Cell adhesion molecules: All 0.0E+00 0.008 0.005
APC: T cell 5.0E-06 1.6E-10 0.0E+00
Tc cell: target cell 0.010 5.5E-07 8.3E-10
Th cell: B cell 2.5E-04 4.2E-08 0.0E+00
Leukocyte : platelet 0.208 0.868 0.631
Leukocyte : endothelial cell 0.029 0.095 0.257
Neural cells 7.6E-05 0.123 0.125
Cytokine-cytokine receptor interactions 4.2E-15 6.3E-05 0.002
Others
ABC transporters 0.021 0.004 0.312
Cell communication 0.014 0.345 0.265
Complement: All 0.080 0.323 0.528
Haematopoietic cell lineage: All 6.3E-10 5.5E-05 0.016
Leucocyte transendothelial migration 0.013 0.575 0.102
Natural killer cell mediated cytotoxicity 3.3E-10 0.046 5.2E-05
Neutrophil 4.5E-05 0.003 0.043
Purine metabolism 0.010 0.026 3.2E-05
Pyrimidine metabolism 0.070 0.160 0.039
Type 1 Diabetes 4.8E-07 8.0E-08 6.8E-10
Non-inflammatory pathways
Urea cycle 0.928 0.284 0.771
Citrate Cycle (TCA cycle) 0.829 0.935 0.331
Arachidonic Acid metabolism 0.41 0.84 0.29  
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3.3 Identifying key genes in associated pathways  
I reasoned that the genes, which were identified in all ten CV models for each of 
the three diseases, would represent the “core” genes showing consistent association with 
each disease. This core comprised a total of 52 genes in T1D, 88 genes in RA and 118 
genes in CD, and their overlap is shown in the Venn diagram (Figure 7). Only 12 genes 
were common to all three diseases, 11 were shared by CD and T1D, 5 shared by T1D 
and RA, and 26 were shared by RA and CD. The majority of identified genes were 
unique to each disease (Figure 7). Common to all three diseases are genes of the major 
histocompatibility complex (MHC): the class II molecule HLA-DQB1 (the selected SNP 
in the models was rs9273363 in T1D; rs9275418 in RA; rs9469220 in CD), the class I 
molecule HLA-C (rs9366778 in T1D; rs2524067 in RA; rs7452890 in CD) and the 
foetally-expressed non-classical class I paralogue, HLA-G (rs1632882 in T1D; rs1063320 
in RA; rs2253981 in CD); the protein phosphatase regulatory subunit PPP3R2 
(rs10512298 in T1D; rs10990238 in RA; rs10123826 in CD), the phospholipase 
PLA2G4A (rs12088162 in T1D, rs10912209 in RA; rs10494612 in CD) and genes 
associated with cell signalling: inositol 1,4,5-triphosphate receptor type 1 ITPR1 
(rs9850086 in T1D; rs2291861 in RA; rs2053502 in CD), the guanine nucleotide 
exchange factor VAV3 (rs4914946 in T1D; rs12752530 in RA; rs1418992 in CD), and 
the kinase PAK7 (rs6118724 in T1D, RA, CD) from the T cell activation pathways; and 
cell adhesion molecules: activated leukocyte cell adhesion molecule ALCAM (rs995470 
in T1D; rs3772556 in RA; rs7643160 in CD), a neuronal cell surface protein NLGN1 
(rs7430111 in T1D; rs9838752 in RA and CD), an integrin receptor subunit ITGA1 
(rs7731949 in T1D; rs11745801 in RA; rs2448420 in CD) and the cadherin CDH2 
(rs1404432 in T1D; rs1496479 in RA and rs2591108 in CD). 
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Figure 7.  Genes identified by variable selection in all 10 folds of cross-validation for T1D, RA and CD.  
Key genes that showed consistent association with each disease in all 10 logistic models of cross validation. Genes are grouped in their pathways, which are shown as bubbles. 
Pathways are colour-coded in agreement with the colors in Table 7, which in their turn represent broader cellular processes where the pathways are involved. Overlapping bubbles 
represent pathways that share key genes. Genes that were previously associated in GWAS are underlined. They “Type 1 diabetes mellitus pathway” highlighted in green contains 
genes that are exclusively found in this and no other of the rest of the pathways. 
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My pathway-based approach identified several genes that have been associated 
with autoimmune diseases in previous GWAS studies104,134,142-144 (Figure 7). These include 
for T1D, genes in the HLA region, the negative regulator of T cell activation CTLA4 
(rs11571304, rs3087243), the suppressor of T cell activation PTPN22 (rs6679677) and 
the interleukin 2 receptor alpha IL-2RA (rs2104286, rs6602360). For RA, PRKCQ 
(rs7096622), IL2RA (rs10795791) and IL2RB (rs3218253). Similarly for CD, the well 
established associations with NOD2 (rs2076756), IL23R (rs11805303, rs17375018) and 
the recently implicated IL12B (rs4921227) and STAT3 (rs744166) were all confirmed and 
these genes were selected in all models of CV. However, in addition to these, I identified 
other components of key pathways contributing to disease, such as RIPK2 (rs160448, 
rs160410) and MAP3K7 (rs791059, rs2069314) from the NOD2 pathway in CD. I also 
identified novel associated pathways for further exploration. For example in T1D, a 
number of genes controlling T cell activation were selected such as the calcium channel 
ITPR1 (rs9850086); the calcium dependent phospholipase PLA2G4A (rs12088162), the 
regulatory subunit of calcineurin PPP3R2 (rs10512298) and the calcineurin dependent 
transcription factor NFATC2 (rs6067742) suggesting a role for calcineurin /nuclear 
factor of activated T-cells (NFAT) signalling in susceptibility of T1D. 
TNF plays a critical role in inflammation in RA and CD129,130 and has been a 
major target for therapeutic antibody treatments. The TNF pathway was significant in 
CD only, and key components selected include two enzymes that are regulators of NF-
κB signalling – a negative regulator of NF-κB, the deubiquitinating enzyme CYLD 
(rs7342715) 145 and TNFAIP3 (rs7753394) both a deubiquitinating enzyme and a 
ubiquitin ligase.146 Both of these enzymes deubiquitinate NEMO and, when knocked out 
in vivo, lead to inflammatory bowel disease.147 Genetic variants near TNFAIP3 have 
recently been associated with RA (see below) as well as Ulcerative colitis and CD93,134 and 
was associated in my study for both CD (rs7753394) and RA (rs6920220) (see below). 
Considering the possible involvement of TLR signalling in RA, I found that only 
TLR9 signalling via IRF5 was significant among TLR pathways. TLR9 is constitutively 
expressed on ß-cells that are critical in the pathogenesis of rheumatoid arthritis.148 The 
plausibility of this pathway is strengthened by the finding that several genes downstream 
of TLR9 were also selected; IRF5 (rs3807306) and the negative regulators SOCS1 
(rs11074956, rs243325) and TNFAIP3 (rs6920220). It is of interest that recent studies 
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show an association of the IRF5 gene with RA149, and 2 studies link region 6q23, flanked 
by TNFAIP3 and OLIG3 with RA susceptibility.150,151  
3.4 Genetic prediction of disease risk 
I next investigated how well the pathway-centric combination of gene variants 
selected by variable selection could predict the disease status in individuals. The 
sensitivity and specificity of all 10 models for each disease are shown in ROC curves 
(Figure 8A-C). The area under the average ROC is 91%, 85% and 60% for T1D, RA and 
CD respectively, which correlates inversely to the number of SNPs fitted in the models 
for each disease. 
The fitted models, as expected, contained some of the well-established associated 
markers with each disease. To evaluate the added value of genes identified by my 
approach versus a single-SNP approach, I refitted the models excluding SNPs with 
single-SNP P < 5x10-7 as well as any SNPs in LD with these ( 2 0.3r ≥ ), and (for T1D 
and RA) any SNPs in the HLA genes; I also refitted the models with only covariates 
these excluded SNPs. As seen in Figure 8A-C, for all three diseases, the complete set of 
SNPs (green curves) had greater predictive value than the significant hits alone (red 
curves). For RA, the SNPs identified by my pathway approach excluding the significant 
hits (blue curves), have higher predictive value than the significant hits alone (red curves). 
For CD and T1D a large proportion of the predictive power comes from established 
associations (such as the HLA SNPs), however the SNPs identified by the pathway 
analysis have predictive power in the absence of these hits and also increase the 
predictive power in their presence. 
3.5 Validation Study 
The 10 CV logistic regression models trained on 90% subsets of the WTCCC 
T1D dataset were tested on 4763 individuals from the Northern Finland Birth Cohort of 
1966 (NFBC1966) of whom 30 developed T1D by age 30.135 As shown in Figure 8D, I 
predicted on average over 60% of the Finnish T1D cases with a false positive rate of 
10%, compared to 73%-10% in the original UK sample (Figure 8A). The AUC was 0.79. 
Most importantly the predictive power of the newly identified genes (blue curve) is 70%, 
this is exactly the same as in the WTCCC study.  
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Figure 8.  ROC curves showing the average predictive performance of the models fitted for each 
disease during 10-fold CV.  
True positive rate and false positive rate for predicting case-control status for T1D (A), rheumatoid 
arthritis (B), and Crohn’s disease (C) of the WTCCC dataset. Each green coloured curve corresponds to 
the average ROC of the 10 fitted logistic models of CV. Red curves stand for the average performance of 
the models fitted only with pathway SNPs with single-SNP P<5x10-7 and any SNPs in LD with these (r2 ≥ 
0.3). Blue curves show the average performance of the 10 models fitted during CV, when all SNPs with 
single-SNP P<5x10-7 and any SNPs in LD with these (r2 = 0.3) were excluded from analysis. The plot in 
panel (D) shows the performance of a single model – this justifies the jagged lines - trained on the WTCCC 
T1D cases and controls dataset and tested on a separate study of the Northern Finland Birth Cohort of 
1966 (NFBC1966) with 4763 individuals, 30 of whom developed T1D by age 30. This model has the same 
AUC as the average of the 10 CV models fitted on the WTCCC and trained on the NFBC. 
 
Although the SNPs meeting GWAS significance accounted for a considerable 
proportion of the predictive power, the additional SNPs identified by my approach 
contribute to the predictive power (Figure 8D, red curve) and have predictive value on 
their own (Figure 8D, blue curve). 
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3.6 Visualisation of genomic risk 
I reasoned that each SNP has a different effect on disease predisposition either 
increasing or decreasing the risk due to its functional effect on the regulation of the 
overall pathway output. I categorized SNPs as adverse or protective on the basis of their 
coefficient in the CV model (relative to the minor allele for additive effects). As shown in 
Figure 9, each SNP exerts an adverse or protective effect through dominant, recessive, 
additive or heterozygous modes. In T1D for example, there are two adverse HLA-DQB1 
variants (rs9273363/rs9275418) and two protective HLA-DQA1 variants 
(rs9272723/rs9270986), and PTPN22 (rs6679677) is adverse for both T1D and RA. Very 
few SNPs were selected in more than one diseases and I observed either same or 
opposite direction of the coefficients in the models of different disease. In the case of a 
real effect, this could be attributed to differential patterns of LD with the actual SNP or 
in my opinion to some residual over-fitting that I didn’t account for. As a general 
comment, in T1D I observed a number of SNPs with large adverse effects acting in a 
dominant and additive manner. Furthermore, there are more adverse than protective SNPs 
with large effect size (>0.3). In RA, there are SNPs with large additive adverse and protective 
effects (middle panel, Figure 9). In contrast, in CD there are fewer SNPs with large effect 
size (>0.3) but these act in a heterozygous and recessive manner (bottom panel, Figure 
9). Three SNPs of PPM1A have large heterozygous effects (rs7154773 having a risk 
effect, and rs8019531 and rs8012815 having protective effects). Smaller recessive adverse 
effects were seen in the case of IL6R (rs11265618) and RHOA (rs9814873), and protective 
effects in FHIT (rs10510813).  
To explore these differences further, for each genetic mode I calculated the sum 
of encoded genotypes at SNPs which act according to this genetic mode, weighted by 
their coefficient in the logistic regression model. This is a partitioning of the estimated 
log-odds of disease according to genetic mode. I calculated the significance of differences 
in these sums between cases and controls in the 10% test data set. For T1D, cases and 
controls had a significantly different sum of additive (t-test, P=2x10-6) and dominant (t-
test, P=2x10-6) effects; whereas for RA additive (t-test, P=2x10-14), dominant (t-test, 
P=6x10-4) and recessive (t-test, P=0.014) are significantly different; and in CD additive 
(P=4x10-3) and heterozygous (t-test, P=0.04) are significantly different. 
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Figure 9. The allelic architecture of the logistic regression models of disease risk.  
Minor allele frequency vs. beta coefficient for each SNP retained in the fitted logistic regression model 
from first round of cross-validation. Additive, recessive, dominant and heterozygous effects are displayed 
by black squares, blue dots, mauve triangles and cyan diamonds respectively. Adverse vs. protective SNPs 
have a positive vs. negative beta value respectively. Labels are given for all SNPs with beta greater than 
0.25 
 
The ratio of adverse to protective variants carried by each individual was positively 
correlated with the log odds of disease risk (Figure 10). In Figure 11, I plot for every 
individual (columns) their genotype at each SNP, with red indicating an adverse and green 
indicating a protective SNP (rows). The intensity of colour reflects the effect of the SNP in 
the model (see section 3.8). Each individual seems to carry a unique combination of 
adverse and protective variants, which may represent a personal “genomic fingerprint” of 
disease predisposition. Despite the vast number of different combinations, a pattern is 
A 
B 
C 
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revealed where patients (left side) compared to healthy individuals (right side) are seen to 
carry a higher number of adverse genotypes and fewer number of protective genotypes and 
vice versa. 
.
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Figure 10. Ratio of adverse/protective genetic variants carried by cases and controls and predicted 
log odds of disease.  
Predicted disease log-odds (y axis) in cases (red) and controls (green) vs. the ratio of the number of adverse 
to protective encoded genotypes according to genetic mode for T1D, RA and CD in the training set (top 3 
panels), and the test set (bottom 3 panels). For each dataset, the log-odds of disease increases with 
increasing ratio. (Pearson’s r2 examined on the test set was 0.51, 0.54, 0.58 for T1D, RA, and CD 
respectively) 
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Figure 11. Variant SNPs carried by cases with T1D and controls.  
(a) Predicted probability of being a case, (b) Actual case or control status. Patients shown in red and controls in green. The model correctly assigns the majority of cases at the 
extreme left, and controls at extreme right, with less predictive ability in the middle. (c) Individual patients or controls are displayed in columns and each row represents one SNP. 
Red indicates an adverse and green a protective SNP. Black indicates zero contribution of the SNP as the individual carried zero of the SNP adverse/protective allele. Intensity of 
colour indicates disease log-odds from the predictive model. The magnified sections show regions where very marked differences between cases and controls can be readily seen. 
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3.7 Discussion 
My analysis places the genetic basis of common autoimmune disease in a pathway 
context. Although there has been increasing evidence15,104,152,153 that multiple genes, which 
functionally interact in a variety of pathways, are associated with autoimmune diseases, I have 
shown directly that variation in conserved canonical inflammatory pathways underlies genetic 
susceptibility to T1D, RA, and CD. My results suggest that generic activities involved in innate 
and adaptive immunity, such as T-cell activation, antigen presentation and cell adhesion, 
constitute common underlying processes of autoimmune predisposition. In addition to these 
shared pathways I identified a number of disease-specific pathways, which indicates distinct 
modulating mechanisms for each condition. 
At the gene level, my analysis identified new genes associated with each disease, as well as 
replicated previously identified loci, which confirm the consistency of my approach to results 
from previous studies. Of particular interest is the fact that my analysis identified IL12B, 
ICOSLG and STAT3 for CD, were only identified in a meta-analysis of three separate GW 
scans144, as well as STAT4 with T1D , which was found associated with the disease .in a follow-
up candidate gene study154 and not on the original WTCCC study. The latter findings serve as a 
proof of concept that genes with moderate effects, which are missed by single-SNP analysis of 
GWAS can be extracted via a pathway based approach.  
Pathway-based approaches have been employed in studies of obesity155, Parkinson 
disease32, Breast cancer22, hyperlipidaemia156, age-related Macular degeneration157 and the 
WTCCC dataset40, but have focused less on the underlying mechanisms that affect disease 
occurrence. My approach provided a new insight in the number of pathways, the genes 
implicated and the underlying genetic architecture for disease risk, due to my strong unifying 
hypothesis that autoimmune genetic influence operates through functionally interacting genes 
involved in inflammatory pathways. In many diseases the relevant pathways are not yet as clearly 
identified. However, as the understanding of function of genes increases158,159, the same approach 
may be readily applied to other diseases. 
My findings provide new insight into the genomic architecture underlying common 
disease risk. Most studies to date have reported the odds ratio at each single locus separately as a 
measure of increased risk. My results suggest that disease in any individual occurs as a result of 
altered balance between adverse and protective variants at several loci that affect the overall function 
of key pathways in opposite directions such as through positive or negative regulatory effects. 
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Similar mechanisms have been suggested in studies that used simulated data to model the effect 
of multiple genetic variants.160,161 Furthermore the majority of studies have focused on additive 
SNP genetic models, but I have shown, in addition, that dominant, recessive and heterozygous 
effects contribute risk in all three diseases. The relative contribution of each type of effect differs 
between the three diseases, with dominant and additive effects contributing more in T1D, 
dominant and recessive effects in RA and heterozygous effects in CD. 
I have been able to identify gene/SNP sets within inflammatory pathways which can be 
used as predictive markers of disease. The high performance of the logistic models in T1D and 
RA raises the possibility of genomic disease prediction and diagnosis, with greater accuracy than 
by using combinations of single genes in previous analysis.156,160 
The validation of my T1D models on a different population provides the most stringent 
test of my approach. The predictive models trained on the UK WTCCC samples predicted 
development of T1D in 60% of the Finnish patents who developed disease by age 30. I 
speculated that the level of prediction did not reach that of the WTCCC CV models, partially 
due to the use of SNPs imputed in the Finnish samples with a imperfectly matched reference 
population and partially because the Finnish population differs significantly from UK Caucasians 
in haplotypic structure.162 However, the predictive power was kept very high and to my 
knowledge higher than any other study has shown.163-165 Although much of the predictive power 
in T1D was due to HLA genes effects, I have shown that remaining SNPs in my predictive 
models have substantial predictive value in their own right, and in RA, the genes not meeting 
GWAS significance provide better predictive value than the significant hits. The lower predictive 
performance of the models in CD may reflect that this disease (which has a number of well 
recognised clinical phenotypic subgroups160) is more heterogeneous in its genetic origins, a 
possibility also suggested by the higher number of SNPs identified by variable selection in CD. 
Nevertheless, environmental factors are beginning to be identified for some autoimmune 
disorders and integrated into models of pathogenesis. For example, smoking is an established 
risk factor for RA166 and there has also been evidence of a strong interaction between HLA-
genes and smoking for the development of future RA. Similarly, smoking and dietary influences 
have been identified as an important risk factor for CD.167 I would expect that the inclusion of 
environmental factors, gene-gene and gene-environment interactions (if data is available) will 
improve these predictive models. 
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My approach suggested a new picture of how variation in multiple genes linked in 
functional pathways contributes to autoimmune disease susceptibility and provides a useful tool 
to reveal the hidden information of GWAS that would be missed in single SNP analysis.  
3.8 Summary 
In this chapter, I presented the results of my pathway-based analysis on the WTCCC 
dataset and I showed that it is a powerful approach to directly identify plausible pathway-disease 
associations between inflammatory pathways and autoimmune diseases. I also showed that my 
methodology is able to reveal additional susceptibility markers (further to the single-SNP hits) 
that drive predominantly the pathway associations and can also assist in disease prediction. In the 
next chapter, I go on to improve the pathway-driven analysis by addressing some of the 
limitations of my approach and by taking the gene selection part a step forward.
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The application of my proposed strategy on the WTCCC dataset yielded promising 
results; nevertheless I identified a number of methodological limitations that had to be addressed 
before applying it on multiple datasets.  
To start with, the gene prioritization methodology was entirely based on the gene 
inclusion frequency in 10 models of a CV procedure. It is argued that 10-fold CV is a robust 
technique to provide a reliable estimate of the out-of-sample prediction error but this does not 
necessarily imply that it works as efficiently in identifying relevant predictors. It has been 
suggested that relevant predictors could be efficiently identified by the inclusion frequency in 
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resampled datasets168,169 and on these grounds I set out to refine my gene-based selection 
procedure. 
At the same time, my methodology had not been substantially validated at the pathway 
and gene level on two independent GWAS of the same disease, because I initially had no access 
to such datasets. During the second year of my PhD, I obtained access to a second GWAS on 
RA and I used it to verify my findings. In this chapter I go beyond a simple pathway-based 
analysis of GWAS, to identify the genes within associated pathways that are predominantly 
responsible for the pathway association signal. To achieve this I recast the question of how to 
associate genes with a disease as a pathway-driven stability selection problem.  
4.1 Introduction 
Stability selection is a technique that is based on subsampling (in this case of individuals) 
in combination with variable selection algorithms.170 Variable selection methods attempt to 
identify combinations of variables (in this case SNPs) that best explain the outcome (disease 
status). Regularization parameters control the number of variables selected: smaller models 
(stronger regularization) result in lower FDR but may miss real associated variables; larger 
models (weaker regularization) detect more real associated variables but also admit more false 
positives. Stability selection170 involves variable selection on multiple random sub-samples of the 
data (in this case individuals), and across multiple regularization parameter settings.170 Variables 
which are consistently chosen are reported as ‘stably selected’. 
I employed the stability selection concept in a pathway-based analysis setting that 
accommodates for validation on a second GWAS. The suggested strategy is called “pathway-
driven gene stability selection” and it is conducted in the following steps: Pathway-based analysis 
of a GWAS is carried out using the CT test statistic, as described in Chapter 2. Pathway 
association results are adjusted for multiple testing. The same analysis is carried out in parallel on 
a second GWAS dataset. The CT test statistic P-values are ranked in ascending order in both 
studies. A pathway rank percentage cut-off analysis is carried out to identify the threshold on 
pathway rank significance, above which, all pathways will be considered to show evidence of 
association with the disease in both GWAS datasets. Only the associated pathways are taken 
forward to the gene-selection procedure. Gene-based stability selection is applied to identify the 
most influential genes within associated pathways. This procedure is performed separately for 
each GWAS, but the settings are such to adjust for each study sample size and equalize the 
discovery power between studies. Equalizing the power between studies aims for the same 
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amount of information to be extracted by smaller studies as in the larger and then 
hypergeometric modelling is used to assess the overlap. The selected genes in each study are 
compared between studies and the significance of the observed overlap is calculated. I consider 
that any genes which are associated with disease in both studies and go beyond the expected 
overlap by chance are true positive associations. The genes that are identified in one study but 
not the other are deemed “suggestive associations”, as GWAS undertaken on two different 
populations may indeed identify different genes underlying the disease in each population. The 
selected genes are taken forward to an in-silico functional enrichment analysis in GO categories. I 
consider as very plausible true associations the genes that are enriched in the same functional 
categories in both studies, on the grounds that the same biological pathway might be associated 
with a disease at a population level, but different genes and variants could be responsible at an 
individual’s level. Nevertheless those genes, albeit different, might be involved in the same 
cellular process having a similar function along the pathways. The flowchart of my proposed 
methodology is given in Figure 12.  
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Figure 12. Schematic diagram of the proposed methodology 
 
The technical steps of the proposed methodology are explained in detail in the following 
sections of this chapter. The methodology was developed and is illustrated through the 
application of my approach on two RA case control GWAS; the WTCCC RA study, of 1,860 
cases and 2,938 controls typed on the Affymetrix 500k chip9 and the North American 
Rheumatoid Arthritis Consortium (NARAC) study of 908 cases and 1260 controls genotyped on 
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the Illumina Humanhap550k.8 The results of this analysis are shown separately and discussed in 
Chapter 5.The overlap in typed SNPs between these two platforms is ~10%. 
4.2 Pathway-based analysis  
Pathway-disease associations were examined by the CT test statistic. To recap, the CT 
test statistic171 assesses the null hypothesis that the pathway does not comprise any genes that are 
associated with the disease. The null distribution is obtained by fitting a skew normal distribution 
to 1000 CT test statistic under permuted phenotype labels. In this work, I observed that the ‘sn’ 
package in R, which is the package I used to fit the skew normal distribution, does not allow the 
calculation of the lower tail of the cumulative distribution in log space, which enforces a lower 
bound on the reported significance levels. To address this problem, I calculated P-values by 
fitting a gamma distribution. I used the Kolmogorov-Smirnof test statistic, as well as visual 
inspection of QQ plots to establish that the gamma distribution provides as good a fit as the 
skew-normal. Correction for multiple testing and dependence between pathways due to shared 
genes was performed via the method of Benjamini-Hochberg-Yekutieli, which controls the FDR 
under dependency. The FDR was set at α=0.05. I tested 700 curated, biological pathways, as 
assembled from KEGG, BioCarta and GenMAPP. By using 3 public databases, one could argue 
that I am creating an additional multiple testing problem by bringing in different versions of the 
same pathways. In my case and as I show below, I do not employ and multiple testing 
correction, as I tackle the problem of overlapping pathways with a gene selection procedure and 
I control the FPR using the hypergeometric distribution. The procedure described above was 
applied independently to WTCCC and NARAC.  
I calculated the 2
1χ -scores from the CT P-values and found that the correlation between 
the two studies was highly significant (Spearman’s r2=0.69, P < 2.2x10-16). This correlation 
persisted even after removal of pathways that included strong and confirmed associated loci with 
RA, such as the HLA genes within the MHC region (Spearman’s r2=0.32, P < 2.2x10-16). Pair-
wise correlation of pathway statistics between studies (which were carried out in independent 
populations and on different genotyping platforms) should indicate common genetic variation 
associated with RA. Ranking of the pathways in both studies revealed that the top 6% of ranked 
pathways in NARAC laid in the top 10% of pathways in WTCCC.  
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Figure 13
2
1χ  transformation of the CT statistics in NARAC and WTCCC.  
The plot shows the 
2
1χ  scores of the CT P values in NARAC (x-axis) plotted against those in WTCCC (y-axis); the 
42 pathways from the top ranks of both distributions are shown in red.  
 
I then plotted the overlap between WTCCC and NARAC pathways as a function of 
pathway rank cut-off in Figure 14a. The maximum overlap was achieved for the first 2% of 
pathways (i.e. 14 pathways) that are mostly dominated by the known RA associations. I observed 
a second peak in overlap at the 6% top ranked pathways, where 70% of those were common 
between the studies. In the plot of Figure 14b I show (as a function of NARAC pathway rank) 
the maximum pathway rank in WTCCC amongst all pathways more significant than a given 
NARAC pathway rank, and vice-versa in Figure 14c). I observed a step-change in the plot b) at 
~6% of all pathways (42 pathways), at which the maximum WTCCC rank goes from ~10% to 
~45%. Conversely, in Figure 14, I observed a similar step change at 2% (14 pathways), where the 
rank goes from ~10% to ~70%, which indicates that WTCCC derived pathway statistics may be 
less reliably reproducible in NARAC. In other words, the top 6% of NARAC ranked pathways 
laid within the top 10% of WTCCC ranked pathways. By selecting 6% as the threshold of 
pathway rank in NARAC, I achieved a good trade-off between choosing a small set of highly 
overlapping pathways (which may miss genuine signals) and a larger set of less overlapping 
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pathways (which may bring in more noise). At the same time it provided a good balance between 
introducing noise and increasing the computational demands of the variable selection step, and 
potentially missing genuine association signals. I suggest using the inflection point in maximum 
path rank as a useful diagnostic for deciding which threshold to apply in future applications of 
this methodology.   
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Figure 14. Overlap of NARAC and WTCCC pathway rank statistics.  
a) Overlap of WTCCC and NARAC selected pathways as a function of percentage rank cut-off. The x-axis shows 
the percentage of ranked pathways that is used as a cut-off. The y-axis shows the fraction of pathways that are 
common between WTCCC and NARAC for a certain percentage rank cut-off . b) Top rank percentage in WTCCC 
as a function of NARAC rank threshold. c) Top rank percentage in NARAC as a function of WTCCC rank 
threshold.  
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4.3 Gene- based stability selection  
The genes that comprised the 42 associated pathways were taken forward to the gene 
stability selection methodology. 
The gene selection methodology was entirely based on the concept of “stability 
selection”170 adjusted to be applicable on SNP/gene data. Stability selection, as mentioned in 
§4.1, requires a variable selection algorithm with a regularization parameter that controls the 
number of variables selected. In the original implementation of stability selection the Lasso 
variable selection algorithm was used and the authors then showed that a “randomised Lasso” 
algorithm gave better selection properties. I used the HyperLasso variable selection algorithm138, 
which has similar properties with the randomised Lasso (Phil Brown and Jim Griffin 
contribution to the discussion of Meinshausen and Puhlman paper170 and the author response). 
The HyperLasso has two parameters, shape λ and penalty f’, the regularisation parameter. I fixed 
the shape parameter at λ = 1 as it was found to have negligible impact on the size of the selected 
models. I defined a grid of penalty values f’∈Λ⊂(0,45), in increments of 3. For each value of 
f’∈Λ I generated 1000 random sub-samples each consisting of 50% of the individuals, sampled 
without replacement, case control ration remained constant, and generated a set of selected 
SNPs for each sub-sample using HyperLasso.138 The upper and lower bounds were chosen to fit 
models of plausible size (between 1 and ~2000 covariates).  
I then calculated the selection probabilities for each gene. In order to avoid spuriously 
selecting large genes, I first split genes into LD based gene-blocks on the basis of recombination 
rates estimated using LDHat172 on HapMap Phase II data. I assumed that the LD structure of 
the study samples was the same as that in HapMap. I assigned every position with recombination 
rate >= 15cM/Mb as the border of an LD region (corresponding to LD-regions with average 
size 35kb). The selection probability of a gene-block π(g|f’) was defined as the fraction of sub-
samples in which at least one SNP in a gene-block g was selected. The stability path of a gene-
block was defined as the selection probability over the range of all penalty values f’∈Λ. 
In order to extract the ‘stably selected’ variables, Meinshausen and Buhlman170 suggest 
choosing a threshold πthr, such that 0<πthr<1 and retaining everything with π(g|f’)> πthr , for 
some small f’∈Λ. However, this focuses only on a single point of the stability path. I propose 
instead to weight the selection probabilities along all points of the path according to a prior 
belief p(f’) as to the reliability of inferences made at each f’∈Λ and then retain all genes with 
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weighted sum 
'
( ') ( | ') thr
f
p f g f
λ
π π
∈
>∑  The WTCCC study had greater power as it was more 
than twice the size of NARAC, and so it generated substantially larger models for the same value 
of f’. In order to equalise the power between these two datasets, I derived study-specific prior 
weights so as to equalise the expected model size (E[size]), such that in the smaller study more 
weight is given to the models fitted under looser values of f’ and vice-versa.  
I assumed a gamma prior probability for the penalty with shape parameter k and scale 
parameter θ,  
'
1 1( ' | , ) '
( )
f
k
f f eκ ϑκ θ
κ θ
−−Γ =
Γ
            (4.1) 
 
with support truncated to lie within the lower and upper bound of the grid Λ. Therefore 
the expected probability of inclusion of a gene g, was given by the integral  
   ( | , ) ( | ') ( ' | , ) 'g g f f d fπ κ θ π κ θ= Γ∫
                 
(4.2) 
which I approximated by 
'
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            (4.3)
 
where ∆f’ is the size of the intervals over which I approximated the continuous 
integrands by their values at f’. In order to define the parameters of the gamma prior, I noticed 
that the model size could be approximated by an exponential function of f’ (Figure 15), and fit 
the model  
log( ( ')) 'size f A Bf= +              (4.4) 
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Figure 15. Log-transformed average model size as a function of the HyperLasso penalty f’.  
The y-axis shows the log-transformed model sizes and the x-axis shows the penalty f’. The dashed lines represent 
the fitted least-squares line as described in Equation [4.4]. WTCCC models are almost twice as large as the NARAC 
models for the same’ f, due to the dependency of f on study sample size. 
 
The expected posterior model size was given by 
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,
           (4.5) 
which leads to an expression for the shape parameter κ in terms of the scale parameter θ 
and the expected model size E[size] 
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log( [ ]/ )
log(1/(1 ))
AE size e
B
κ
θ
=
−
              (4.6) 
Furthermore, I sought to equalise the spread of the posterior distribution of the model 
size by setting the scale parameter of the integrand in Equation 4.5 to be the same in both 
studies, which leads to an expression of the scale parameter of one study in terms of the other. 
    
1 *(
.....................
)
....
NARAC
WTCCC
NARAC NARAC WTCCCB B
θ
θ
θ
=
− −          (4.7)
 
Subsequently, the stably selected gene-blocks were defined as those with π(g|κ,θ) >= πthr. 
I calculated results for a range of E[size]∈[100,1000] (increment of 100) and πthr ∈[0.01,0.9] 
(increments of 0.1). 
Throughout I set the mean of the NARAC gamma prior distribution to be θNARAC / 
κNARAC = 10, from which for each E[size] I could calculate θNARAC and κNARAC using Equation 4.6, 
subsequently calculate θWTCCC from Equation 4.7 and then κWTCCC again from Equation 4.6. The 
corresponding prior distributions for each study and for different expected sizes E[size] are 
shown in Figure 16.  
 
 
Figure 16. Gamma prior probability distributions over the penalty f’.  
The distributions are given for different expected sizes E[size], as calculated from Equation (4.4) and Equation (4.5) 
for WTCCC (left panel) and NARAC (right panel). The expected model size (E[size]) controls the distribution in 
such a way that in the smaller study more weight is given to the models fitted under looser values of f’ and vice-versa 
The total number of selected genes per study for various values of E[size] is shown in 
Figure 17. I calculated the number of selected genes which overlapped between the two studies, 
the median FDR and its 95% confidence interval (CI) amongst these common genes. The FDR 
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was defined as the fraction of overlapping genes which would have been expected to be selected 
by chance alone and was calculated using the hypergeometric distribution. I defined the FDR in 
terms of genes rather than gene-blocks as I found this to be more conservative, due to the fact 
that the number of possible gene-blocks is much larger than the number of possible genes, 
whereas the two studies almost always selected the same gene-block within a common gene for 
πthr >0.2. 
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Figure 17. Number of selected gene-blocks as a function of the selection probability cut-off ̟thr. that 
defines stable selection.  
Results are depicted for WTCCC (left panel) and for NARAC (right panel) and they are color-coded to reflect 
different expected sizes.  
In this study, I opted for πthr =0.4 and E[size]=400, as thus I achieved a good trade-off 
between maximising the number of observed common gene-blocks between studies, while 
controlling the FDR (Figure 18). This resulted in selecting 58 genes in WTCCC and 61 genes in 
NARAC (that is 60 gene-blocks in WTCCC and 64 gene-blocks in NARAC), of which 21 were 
common (hypergeometric test P = 10-21) and the median FDR is 5% with 95% CI of [0%-19%] 
as shown in Figure 19. These findings are fully discussed in Chapter 5, but they are briefly 
mentioned here to justify the steps and the decision-making in the analytical process. 
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Figure 18. The trade-off between r common genes and FDR for different ̟thr and E[size]. 
The solid lines show on the left y-axis the number of common genes selected in WTCCC and NARAC for different 
values of πthr (x-axis) and expected model sizes E[size] (depicted in different colors). Dashed lines show (1- median 
FDR) on the right y-axis and the 95% CI of the median is shown as error bars. 
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Figure 19. Fraction of selected genes in WTCCC and NARAC which are common for E[size]=400 at 
different values of ̟thr. 
The number of selected genes per study (nWTCCC, nNARAC) is shown above the curves followed by the number of 
genes in common (r) and the hypergeometric probability of the observed overlap by chance. The median FDR and 
the 95% CI around it are given below the curve. The asterisk shows that for πthr =0.4, I achieve the maximum 
number of genes that overlap with a median FDR=5% [0,19%]. 
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4.4 Estimation of the significance of the observed overlap between 
studies 
The significance of the observed overlap in the selected genes between studies, as shown 
in Figure 19 was calculated using the hypergeometric distribution.  
In order to investigate the possible bias in favour of selecting larger genes, I initially 
calculated the correlation between the number of gene-blocks and the physical length of a gene. I 
found that the physical length of a gene (in Mbases) correlated with the number of gene-blocks 
(r2=0.59). Hence, larger genes are more likely to be selected just because they contain more gene-
blocks.  This is the reason I decided to calculate all of the overlap statistics at the gene-block 
level, rather than the gene level, and I only consider replication at the gene-block level. Thus, 
while there is a bias to select large genes (which is also the case in GWAS analysis, in the sense 
that large genes are more likely by chance to be reported as associated by virtue of containing 
more SNPs), I do not think that this is adversely impacting the reported overlap statistics. 
On a similar note, a potential confounding effect might lie in the fact that larger gene-
blocks are more likely to be selected by chance because they contain more SNPs. I therefore 
compared the distribution of number of SNPs per gene-block (#SNPs) between selected and 
non-selected gene-blocks in both NARAC and WTCCC on the same chip of the study and 
cross-chip (Figure 20). As it is demonstrated from all these plots, there is an over-representation 
of selected gene-blocks in the region ~20<#SNPS<~70, and otherwise an under-representation 
of selected gene-blocks.  
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Figure 20. Comparison of typed SNP content per gene block between selected and unselected gene blocks.   
The x-axis shows the number of typed SNPs per gene-block in bins of size 10 and the y-axis the fraction of 
selected/non-selected gene-blocks in each bin. . Gene blocks selected by stability selection are depicted with a solid 
red line and gene blocks not selected (but still contained within one of the 42 pathways taken forward to stability 
selection) are depicted with a dashed black line. a,b) NARAC based stability selection;  c,d) WTCCC based stability 
selection;  a,c) # typed SNPs based on Illumina 550k chip; b,d) # typed SNPS based on Affymetrix 500k chip. 
 
Given the observed bias in the distribution of the number of typed SNPs (#SNPs) per 
selected gene block between selected and non-selected gene blocks, and in order to make sure 
that it is not inflating the overlap statistics, I simulated the null distribution of number of gene-
blocks in the overlap based on this empirical distribution of #SNPs per gene block. I 
recalculated the significance of the observed overlap assuming non-random gene block selection 
according to #SNPs. I first calculated the empirical probability of selecting a gene-block with n 
SNPs as π (n | selected) ~ #(gene selected gene blocks with n SNPS). I then smoothed this 
probability distribution by setting π (n | selected) to be equal to its average in a moving 5-SNP 
window. I then calculated the probability of selecting each given gene-block g, with #SNPs = 
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#SNPs(g) as P(g | selected) = π (#SNPs(g) | selected) * 1/#(geneblocks with 
#SNPs=#SNPs(g))  
I could then sample two vectors of selected gene-blocks, of length N1 and N2 
corresponding to the number of NARAC and WTCCC selected gene-blocks, and finally 
calculate the number of common gene-blocks selected. While I could not simulate enough data 
to get the same level of significance, I did retain significance of the overlap of selected gene-
blocks of with P<10-4. 
4.5 Gene Ontology functional enrichment analysis 
As a final step, I conducted a gene ontology (GO) enrichment analysis using GOrilla76 on 
the genes that the gene selection methodology identified. The selected genes were compared to 
all the typed genes on the chip of each study. I carried out this analysis on each study separately 
and I observed that the same functional categories were enriched. I repeated the analysis on the 
union of the identified genes to derive a stronger signal of enrichment. I also carried out a 
sensitivity analysis on the effect of different πthr on the enriched GO categories and I 
demonstrate in Chapter 5 that the enriched functional categories are robust to the selection of 
πthr.  
In terms of performance, the gene stability selection step is computationally very 
intensive in both computational time and memory resources. A single model fit varies between 
an hour (for the stringiest penalty) to a day (for the loosest penalty) and one should consider that 
I am fitting 1000 models per penalty value, which is ~16,000 in total. 
4.6 Summary 
In this chapter I described in detail the technical steps of my pathway-driven gene 
stability selection. It is a procedure that goes beyond simple pathway-based analysis of GWAS to 
identify the key responsible genes within associated pathways that are driving the pathway signal. 
I provided the generic methodological framework and I illustrated the steps and the decisions 
along the process through the application of my methodology on two independent GWAS of 
RA, the WTCCC and the NARAC study. In the next chapter, I present the results in detail and I 
discuss future directions of the findings.
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Chapter 5  
 
Application on two GWAS of  
rheumatoid arthritis  
 
 
 
 
 
 
 
In Chapter 4, I introduced my methodology on pathway-driven gene stability selection. 
In this chapter, I go on to present the results of the application  of this approach on two RA case 
control GWAS; the WTCCC RA study, of 1,860 cases and 2,938 controls typed on the 
Affymetrix 550K chip9 and the NARAC study of 908 cases and 1260 controls genotyped on the 
Illumina Humanhap5508. The generic flowchart of my approach was shown in Chapter 4, Figure 
12; the implementation of it is given in Figure 21. In all analyses the X chromosome was 
omitted, as I did not have access to the X chromosome data of the NARAC study. 
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Figure 21. Methodological flowchart of my approach as implemented on two GWAS of RA. 
5.1 Pathway associations 
The 42 associated pathways with the CT P-values and their ranks in both studies are 
listed in Table 12. Their database source is listed in Table 13. 
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Table 12.Top 42 pathways identified through pathway-based analysis in WTCCC (W) and NARAC (N) 
studies.  
The cumulative trend (CT) statistic P-values are adjusted at α=0.05 with the Benjamini-Hochberg method that 
controls the FDR. Number of SNPs per pathway might differ between studies, because they refer to the typed 
markers. The pathways appear in the order of ascending NARAC ranks. 
Pathway definition P-value Rank  #Genes #Typed SNPs 
 N W N W  
Illumina  
550k 
Affy  
500k 
Bystander B Cell Activation 1.00E-371 1.00E-98 1 11 4 66 53 
Type I diabetes mellitus 1.00E-349 1.00E-133 2 2 41 846 745 
IL-5 Signalling Pathway 1.00E-344 1.00E-118 3 7 10 164 134 
Antigen Dependent B Cell Activation  1.00E-334 1.00E-111 4 8 8 114 92 
Activation of Csk by cAMP-dependent Protein Kinase inhibited 
signaling through the T cell receptor  
1.00E-332 1.00E-123 5 5 20 246 250 
T cell receptor signaling 1.00E-331 1.00E-211 6 1 264 5215 4613 
Cell adhesion molecules 1.00E-289 1.00E-68 7 15 127 4159 3811 
The Role of Eosinophils in the Chemokine Network of Allergy 1.00E-288 1.00E-71 8 14 8 66 76 
Cytokines and Inflammatory Response 1.00E-283 1.00E-108 9 9 28 285 258 
B Lymphocyte Cell Surface Molecules 1.00E-276 1.00E-104 10 10 10 153 125 
The Co-Stimulatory Signal During T-cell Activation 1.00E-275 1.00E-130 11 3 17 227 186 
Th1/Th2 Differentiation 1.00E-270 1.00E-91 12 12 17 244 256 
Lck and Fyn tyrosine kinases in initiation of TCR Activation 1.00E-254 1.00E-122 13 6 10 153 134 
Antigen processing and presentation 1.00E-243 1.00E-85 14 13 71 615 549 
Hematopoietic cell lineage 1.00E-238 1.00E-128 15 4 81 1132 1022 
Notch signaling pathway 1.00E-74 7.90E-06 16 62 43 826 606 
Proteasome Complex 1.00E-43 1.91E-05 17 64 17 142 119 
Complement Pathway 1.00E-41 5.31E-06 18 59 16 269 242 
Classical Complement Pathway 1.00E-37 4.56E-06 19 56 13 199 190 
Natural killer cell mediated cytotoxicity 1.00E-35 9.28E-05 20 70 125 2122 1775 
Focal adhesion 1.00E-31 1.00E-48 21 16 195 5026 4586 
Cytokine-cytokine receptor interaction 1.00E-29 1.00E-42 22 17 249 2956 2854 
Calcium signaling pathway 1.00E-28 5.51E-12 23 37 168 5604 5109 
MAPK signaling 1.00E-27 1.00E-38 24 18 252 5335 4848 
Glycerophospholipid_metabolism 1.00E-25 4.63E-06 25 57 49 988 838 
Glycerolipid_metabolism 1.00E-24 7.03E-06 26 61 45 943 794 
Neuroactive ligand receptor interaction 1.00E-22 1.00E-37 27 19 234 5642 5323 
Toll like receptor 9 signaling via IRF5 1.00E-21 1.60E-06 28 53 17 169 184 
Smooth muscle contraction 1.00E-18 2.56E-06 29 54 138 4356 3871 
Phosphatidylinositol signalling system 1.00E-17 5.41E-10 30 43 85 2887 2569 
Tight junction 1.00E-17 5.92E-12 31 38 133 4125 3673 
Purine metabolism 1.00E-16 2.34E-15 32 29 143 3532 3165 
Gnrh signaling pathway 1.00E-15 5.34E-07 33 49 96 2714 2381 
Wnt signaling pathway 1.00E-14 1.00E-34 34 21 144 2830 2636 
Gap junction 1.56E-14 1.00E-22 35 25 92 2823 2582 
Valine leucine and isoleucine biosynthesis 1.77E-14 8.78E-05 36 69 12 171 183 
Cell communication 2.81E-14 8.83E-10 37 44 132 2304 2162 
Regulation of actin cytoskeleton 1.55E-13 1.00E-29 38 23 204 4206 3932 
Ecm receptor interaction 2.38E-13 1.36E-12 39 36 87 2541 2386 
Jak stat signaling pathway 1.30E-12 3.89E-15 40 30 149 1735 1699 
Taste transduction 1.70E-10 6.87E-07 41 50 49 1033 959 
Glycan structures biosynthesis 1 4.28E-08 4.81E-14 42 32 113 2985 2631 
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Table 13. Pathway collection that the 42 associated pathways were taken from 
The pathways appear in the same order as in Table 1 of the main manuscript. 
Pathway description Collection/Source 
Bystander B Cell Activation BioCarta 
Type I diabetes mellitus  KEGG 
IL-5 Signaling Pathway BioCarta 
Antigen Dependent B Cell Activation  BioCarta 
Activation of Csk by cAMP-dependent Protein Kinase 
inhibited signaling through the T-cell receptor  BioCarta 
T cell receptor signaling KEGG modified in house 
Cell adhesion molecules KEGG 
The Role of Eosinophils in the Chemokine Network of Allergy BioCarta 
Cytokines and Inflammatory Response BioCarta 
B Lymphocyte Cell Surface Molecules BioCarta 
The Co-Stimulatory Signal During T-cell Activation BioCarta 
Th1/Th2 Differentiation BioCarta 
Lck and Fyn tyrosine kinases in initiation of TCR Activation BioCarta 
Antigen processing and presentation KEGG 
Hematopoietic cell lineage KEGG 
Notch signaling pathway KEGG 
Proteasome Complex BioCarta 
Complement Pathway BioCarta 
Classical Complement Pathway BioCarta 
Natural killer cell mediated cytotoxicity KEGG 
Focal adhesion KEGG 
Cytokine cytokine receptor interaction KEGG 
Calcium signaling pathway KEGG 
MAPK signaling KEGG 
Glycerophospholipid_metabolism BioCarta 
Glycerolipid_metabolism BioCarta 
Neuroactive ligand receptor interaction KEGG 
Toll like receptor 9 signaling via IRF5 KEGG modified in house 
Smooth muscle contraction BioCarta 
Phosphatidylinositol signaling system BioCarta 
Tight junction KEGG 
Purine metabolism KEGG 
Gnrh signaling pathway KEGG 
Wnt signaling pathway KEGG 
Gap junction KEGG 
Valine leucine and isoleucine biosynthesis KEGG 
Cell communication KEGG 
Regulation of actin cytoskeleton KEGG 
Ecm receptor interaction KEGG 
Jak stat signaling pathway KEGG 
Taste transduction KEGG 
Glycan structures biosynthesis 1 KEGG 
 
5.2 Gene selection on associated pathways 
A gene composition similarity matrix, as shown in Figure 22 revealed that many of the 
significant pathways share the same genes.  
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Figure 22. Similarity matrix plot in terms of gene composition for the 42 identified pathways.  
Spots are color coded to represent the number of shared genes between two pathways as a fraction of the smallest 
pathway size under comparison. Light red stands for 100% of the genes in one pathway being involved in the other 
pathways and black stands for zero genes in common. Pathways are ordered by the rank of the CT P value in 
WTCCC and subsequently in NARAC. As an example to read the figure, the ECM-receptor interaction pathway (P <10-
11) shares 50% of its 87 genes with Cell Communication (P <10-13) and 96% of the 45 genes involved in Glycerolipid 
Metabolism (PWTCCC = 4x10-6 , PNARAC <10-17) are also present in Glycerophospholipid Metabolism (49 genes). Calcium 
signaling (PWTCCC = 5x10-12, PNARAC < 10-17) shares 20% of its 166 genes with GnRH signaling of 95 genes (PWTCCC = 
5x10-7, PNARAC = 4x10-13), which in turn is 40% similar to Focal adhesion with 195 genes (P <10-17). The 8 genes of the 
Bystander B cell activation (P <10-17) are entirely a subset the 12 genes of Antigen Dependent B Cell Activation (P <10-17, 
top left corner).  
 
I therefore speculated that there is an underlying group of genes acting in the associated 
pathways, which may be driving this correlation in pathway significance. I selected the 2156 
genes comprising the 42 pathways significant in both studies to carry forward to my gene 
stability selection procedure, as it was described in detail in Chapter 4, §4.3. To recap, this 
methodology retains genes that exhibit “stable selection”. Stable selection is inferred by stability 
paths, which in essence are plots of the selection probability of a gene in fitted models on the 
data under random sub-sampling of the individuals and varying regularization parameters of the 
variable selection algorithm. The models vary in size from the smallest possible (a single 
covariate in the model) to the largest (several genes in the model), thus genes with a constantly 
high or increasing stability path are likely to be denoted as “stably selected genes”. 
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I broadly observed that stability paths with consistently high selection probability π(g|f’) 
across f’∈Λ corresponded to the major hits found in single SNP analyses in each study; for 
instance TRAF1/C5, HLA-DRB1 and MICA in NARAC; IL2RA, PTPN22, HLA-DRA and 
MICA in WTCCC. At the other extreme, I expected that stability paths with low π(g|f’) across 
f’∈Λ comprise non-associated gene-blocks. In between these two extremes laid many stability 
paths that have low selection probability under strong regularisation and high selection 
probability under weak regularization. 
My pathway-based gene stability selection methodology identified as “stably selected” 
genes, 58 genes in WTCCC and 61 genes in NARAC (that is 60 gene-blocks in WTCCC and 64 
gene-blocks in NARAC), of which 21 are common (P = 10-21) and the median FDR is 5% with 
95% CI of [0%-19%] as shown in Figure 19 (Chapter 4, §4.3). The selected gene-blocks in 
WTCCC and NARAC are shown in Table 14 and Table 15 respectively. For the majority of 
genes, only one gene block was selected, but for ADCY2 and FHIT in WTCCC and FHIT and 
PTPRN2 in NARAC, two/three LD blocks exhibited stable selection. I considered a gene found 
in one study to replicate in the other study, only if the same gene-block was selected in both. 
Known associations comprised 10 of 58 in WTCCC; 13 of 61 in NARAC and 5 of 21 common 
genes. Of the 58 and 61 genes selected independently in NARAC and WTCCC from an original 
pool of 2,156 genes, more than 50% were either common between studies or previous RA 
associations and hence can be considered as validated. The stability paths of the selected gene-
blocks, in each study, are shown in Figure 23c/d; the subset of stability paths for previously 
known associations is shown in Figure 24a,b and the stability paths of gene blocks that were not 
selected are shown in Figure 24c,d.  
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Figure 23. Stability paths of the 60 and 64 gene-blocks selected in WTCCC (a) and NARAC (b).  
Gene names are shown in the legend followed by a number that indicates the selected gene-block. 
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Figure 24. Stability paths of known RA associations (a,b) and not selected genes (c,d).  
a, b) Stability paths of the previously reported associations with RA which were validated by the gene stability 
selection in a) WTCCC (10 genes) and b) NARAC (13 genes). c, d) Stability paths of all the genes within the selected 
pathways that were rejected as noise by my stability selection methodology in c) WTCCC and d) NARAC. The gene 
in c) plot that follows a decreasing trend is HLA-DRB1, the most well known association with RA. The paradoxical 
curve is explained by different HLA genes of the MHC being preferentially included as the models became larger. 
 
Chapter 5. Application on two GWAS of rheumatoid arthritis 
 105 
Table 14. The 60 gene-blocks selected in WTCCC.  
For the majority of genes, only one LD block was selected, but for ADCY2 and FHIT two LD blocks exhibited 
stable selection. 
Gene symbol LD block index Chrom. pos. start Chrom. pos. end 
ADCY2 1 7428754 7593069 
ADCY2 7 7594566 7712781 
ADCY8 1 131840404 131847376 
ADSS 1 242618418 242702036 
ALCAM 1 106548402 106798434 
C6 2 41160720 41312856 
CACNA1A 1 13155623 13331522 
CACNA1D 1 53474897 53575012 
CACNA2D1 7 81573468 81851660 
CACNA2D3 1 54105141 54141360 
CACNB2 13 18578665 18827827 
CACNG5 1 62283591 62287922 
CD59 1 33658907 33671217 
CDK4 1 56408269 56452431 
CSF2RB 1 35615840 35653760 
EGFR 1 55033429 55128489 
FGF14 1 101150762 101335129 
FHIT 11 59733714 59749954 
FHIT 59 60247400 60278544 
HLA-C 1 31324507 31367834 
HLA-DPB1 1 33128365 33132110 
HLA-DQA1 1 32693160 32739407 
HLA-DQA2 1 32796968 32822121 
HLA-DQB1 1 32715634 32762444 
HLA-DRA 1 32495624 32540802 
HLA-G 1 29882734 29926878 
HSPA1A 1 31871269 31913698 
ICAM1 1 10222516 1.0278291 
IFNAR2 3 33510364 33570678 
IL1RL1 1 102274193 102334507 
IL2RA 1 6073511 6164278 
IL2RB 7 35874863 35888302 
IL6R 1 152624292 152726812 
IRF5 1 128338976 128347997 
ITGA1 1 52099877 52169023 
ITGA4 1 182007979 182060813 
ITGA9 1 37448558 37577446 
ITGB3 1 42666206 42765076 
MEF2C 1 88031921 88234780 
MICA 1 31459349 31511069 
NFATC4 1 23887093 23938650 
PAPSS2 1 89389455 89517442 
PDE10A 8 165719604 165756281 
PDE1C 1 31775674 31790442 
PDE4B 1 66010515 66545937 
PDE4D 1 58280444 58658855 
PIK3R3 1 46258398 46391295 
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Table 13(continued) 
Gene symbol LD block index Chrom. pos. start Chrom. pos. end 
PPP3CA 1 102143609 102507376 
PRKCA 1 61708068 61762419 
PTPN22 1 114137960 114235857 
PTPN5 1 18685226 18703485 
RAPGEF4 1 173287843 173492013 
SHC4 1 46882243 46992983 
SOCS1 1 11235774 11277540 
SOCS6 1 66087116 66168414 
SPRY1 1 124517405 124564359 
STAT4 2 191582912 191681279 
TEC 1 47812556 47986571 
TNFAIP3 1 138210273 138266142 
VAV3 1 107894802 108046933 
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Table 15. The 64 gene-blocks selected in NARAC.  
For the majority of genes, only one LD block was selected, but for FHIT and PTPRN2 two and three LD blocks 
respectively exhibited stable selection. 
Gene symbol LD block index Chrom. pos start Chrom. pos end 
ADCY2 1 7428754 7593069 
ADCY9 1 3932523 3938631 
C5 1 122734434 122872375 
CACNA1A 1 13155623 13331522 
CACNA1D 1 53474897 53575012 
CACNA1E 3 179711393 179792378 
CACNA2D1 7 81573468 81851660 
CACNB2 13 18578665 18827827 
CD247 1 165643582 165704577 
CD28 1 204259442 204330802 
CD40 1 44158244 44181354 
CLDN10 1 94863031 94884949 
CLDN23 1 8577075 8619027 
CSF1R 1 149393048 149467669 
DGKH 1 41500888 41721888 
DGKI 1 136704876 136736520 
EGFR 1 55033429 55128489 
FGF14 1 101150762 101335129 
FGF5 1 81383976 81426987 
FGF6 1 4393568 4445041 
FGFR2 1 123207590 123218650 
FHIT 1 59689950 59732130 
FHIT 84 60551758 60707039 
FLNB 1 57949166 58153017 
GRAP2 1 38607031 38717330 
GRB2 1 70805355 70900365 
HLA-C 1 31324507 31367834 
HLA-DOB 1 32868423 32911977 
HLA-DPB1 7 33160006 33163494 
HLA-DQA1 1 32693160 32739407 
HLA-DRA 1 32495624 32540802 
HLA-DRB1 1 32634524 32685540 
HLA-G 1 29882734 29926878 
ICOSLG 1 44451149 44505262 
IL2RB 7 35874863 35888302 
IL5RA 13 3076524 3101727 
ITGA9 1 37448558 37577446 
ITPR3 1 33677138 33792326 
MAP3K4 1 161311536 161470346 
MAPKAPK2 1 204904911 204994249 
MICA 1 31459349 31511069 
MICB 1 31553833 31606880 
PDE1C 1 31775674 31790442 
PDE4B 1 66010515 66545937 
PDE4D 1 58280444 58658855 
PDGFB 1 37929247 37984993 
PIAS2 1 42626057 42771464 
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Table 14 (continued) 
Gene symbol LD block index Chrom. pos start Chrom. pos end 
PLCG2 1 80347176 80523696 
POLD2 1 44099990 44101373 
PRKCQ 1 6488953 6583069 
PSMB3 1 34142527 34194004 
PSMD13 1 206056 237102 
PTPN22 1 114137960 114235857 
PTPRN2 1 157003814 157259178 
PTPRN2 17 157740875 157857270 
PTPRN2 9 157520348 157537330 
RAPGEF5 1 22103681 22118493 
RASGRF2 1 80270614 80400810 
SH3BP2 1 2744547 2832621 
SHC4 1 46882243 46992983 
SPRED2 1 65371488 65533160 
TAP2 1 32877514 32911977 
TEC 1 47812556 47986571 
VAV3 1 107894802 108046933 
 
I then investigated whether common genes were driving the association signals of 
multiple pathways by mapping the selected genes back to their original pathways (Table 16). The 
striking majority of selected genes, to name a few: the MHC genes, ADCY2, ADCY8, 
CACNA1A, DGKH, FLNB, ITGA1, PRKCA, PRKCQ, SHC4, VAV3 were indeed involved in 
more than one of the 42 pathways. On the other hand, some selected genes such as IRF5, 
MAPKAPK2, PDE10A, PDE1C, PSMD13 and TEC were only involved in one pathway (Table 
16). I observed that the very top-ranked pathways were mostly driven by the MHC genes and 6 
pathways were driven entirely by known associations, the HLA-DRA, HLA-DRB1 and CD28 
genes in particular. The majority of pathway signals (18 pathways) were driven by a combination 
of previously reported associations as well as novel associations (Table 16).  A further 14 
pathways were driven only by the newly reported associations and surprisingly 4 pathways had 
no gene selected (Table 16).  
Finally I calculated the inverse variance weighted meta-analysis P-value for the SNP 
selected most frequently in each study in the 21 commonly selected genes using PLINK173.The 
meta-analysis P –value was less than 0.05 for all SNPs (Table 17).  
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Table 16. Mapping of the union of WTCCC and NARAC selected genes back to the 42 associated 
pathways. 
Pathways are in the same order as they appear in Table 12. Column 2 shows the number of selected genes (SG) over 
the number of pathway genes (PG).Previously reported RA associations are underlined. Genes that appear in only 1 
of the 42 pathways are followed by an asterisk (*). Genes without an * act in more than 1 of the 42 pathways. Pairs 
of genes in italics indicate genes that overlap the same selected gene-block, but are in different pathways. The first 
listed gene in each pair is from the pathway indicated, while the second listed has a higher selection probability and 
hence is reported in my final list.  
Pathway #SG\#PG Selected genes 
Bystander B Cell Activation 3\8 CD28, HLA-DRA, HLA-DRB1 
Type i diabetes mellitus 12\45 CD28, HLA-C, HLA-DOB, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-
DRB1, HLA-G, PTPRN2 
IL 5 Signaling Pathway 3\10 HLA-DRA, HLA-DRB1, IL5RA 
Antigen Dependent B Cell Activation  3\12 CD28, HLA-DRA, HLA-DRB1 
Activ. Csk by cAMP-dependent Protein 
Kinase inhibited signaling via the T cell 
receptor  
2\24 HLA-DRA, HLA-DRB1 
T cell signaling 29\273 CD28, CD247, VAV3, GRAP2*, TEC*, ITPR3, DGKH, DGKI*, PPP3CA, GRB2, RASGRF2, PRKCA, 
PTPN5, NFATC4, PIK3R3, TNFAIP3, PRKCQ, CDK4, IL6R, IL2RA, IL2RB, IL5RA, CSF2RB, PIAS2, 
SOCS1, SPRED2, SPRY1, PTPN22*, RAP1A (VAV3) 
Cell adhesion molecules 19\134 ALCAM*, CD28, CD40, CLDN10, CLDN23, HLA-C, HLA-DOB, HLA-DPB1, HLA-DQA1, HLA-
DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-G, ICAM3*, ICAM4, ICOSLG*, ITGA4, ITGA9 
Eosinophils in the Chemokine Network 
of Allergy 
2\8 HLA-DRA, HLA-DRB1 
Cytokines and Inflammatory Response 2\29 HLA-DRA, HLA-DRB1 
B Lymphocyte Cell Surface Molecules 311 ICAM1, HLA-DRA, HLA-DRB1 
The Co-Stimulatory Signal During T-cell 
Activation 
4\21 CD28, GRB2, HLA-DRA, HLA-DRB1 
Th1/Th2 Differentiation 5\19 CD28, HLA-DRA, HLA-DRB1, IL2RA, IL18R1(IL1RL1) 
Lck and Fyn tyrosine kinases in initiation 
of TCR Activation 
2\13 HLA-DRA, HLA-DRB1 
Antigen processing and presentation 15\83 HLA-C, HLA-DOB, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-
G, TAP1*, TAP2*, HSPA1A* (HSPA1B,HSPA1L), PSMB3, PSMD13* 
Hematopoietic cell lineage 10\88 CD59*, CSF1R, HLA-DRA, HLA-DRB1, IL2RA, IL5RA, IL6R, ITGA1, IGA4, ITGB3 
Notch signaling pathway 0\47 `- 
Proteasome Complex 1\17 PSMB3 
Complement Pathway 2\19 C5, C7* 
Classical Complement Pathway 2\14 C5, C6* 
Natural killer cell mediated cytotoxicity 15\132 CD247, GRB2, HLA-C, HLA-G, ICAM1, IFNAR2, MICA, MICB, NFATC4, PIK3R3, PLCG2, PPP3CA, 
PRKCA, SH3BP2*, SHC4, VAV3 
Focal adhesion 13\200 EGFR, FLNB, GRB2, ITGA1, ITGA4, ITGA9, ITGB3, PDGFB, PIK3P3, PRKCA, RAP1A (VAV3), 
SHC4, VAV3 
Cytokine cytokine receptor interaction 11\257 CD40, CSF1R, CSF2RB, EGFR, IFNAR2, IL2RA, IL2RB, IL5RA, IL6R, PDGFB, IL18R1 (IL1RL1) 
Calcium signaling pathway 12\174 ADCY2, ADCY8, ADCY9, CACNA1A, CACNA1D, CACNA1E, EGFR, ITPR3, PDE1C, PLCG2, 
PPP3CA, PRKCA 
MAPK signaling 25\257 CACNA1A, CACNA1D, CACNA1E, CACNA2D1*, CACNA2D3*, CACNB2*, CACNG5*, EGFR, 
FGF14, FGF5, FGF6, FGFR2, FLNB, GRB2, MAP3K4, MAPKAPK2*, MEF2C*, NFATC4, PDGFB, 
PPP3CA, PRKCA, PTPN5, RASGRF2, RAP1A (VAV3) 
Glycerophospholipid_metabolism 2\51 DGKH, PLCG2 
Glycerolipid_metabolism 1\46 DGKH 
Neuroactive ligand receptor interaction 0\254 `- 
TLR9 signaling via IRF5 4\17 IL1RL1, SOCS1, TNFAIP3, IRF5 
Smooth muscle contraction 9\150 ADCY2, ADCY8, ADCY9, ITPR3, PDE4B, PDE4D, PLCG2, PRKCA, PRKCQ 
Phosphatidylinositol signalling system 4\90 DGKH, PLCG2, PRKCA, PRKCQ 
Tight junction 5\136 CDK4*, CLDN10*, CLDN23*, PRKCA, PRKCQ 
Purine metabolism 11\145  ADCY2, ADCY8, ADCY9, ADSS*, FHIT*, PAPSS2*, PDE10A*, PDE1C, PDE4B, PDE4D, POLD2 
Gnrh signaling pathway 9\97 ADCY2, ADCY8, ADCY9, CACNA1D, EGFR, GRB2, ITPR3, MAP3K4, PRKCA 
Wnt signaling pathway 3\149 NFATC4, PPP3CA, PRKCA 
Gap junction 8\98 ADCY2, ADCY8, ADCY9, EGFR, GRB2, ITPR3, PDGFB, PRKCA 
Valine leucine and isoleucine 
biosynthesis 
1\12 VARS (MICB) 
Cell communication 0\138 `- 
Regulation of actin cytoskeleton 12\212 EGFR, FGF14, FGF5, FGF6, FGFR2, ITGA1, ITGA4, ITGA9, ITGB3, PDGFB, PIK3R3, VAV3 
Ecm receptor interaction 4\87 ITGA1, ITGA4,ITGA9,ITGB3 
Jak stat signaling pathway 15\153 CSF1R*, CSF2RB*, GRB2, IFNAR2, IL2RA, IL2RB, IL5RA, IL6R, PIAS2, PIK3R3, SOCS1, SOCS6*, 
SPRED2, SPRY1, STAT4 
Taste transduction 3\53 ADCY8, CACNA1A, ITPR3 
Glycan structures biosynthesis 1 0\117 `- 
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Table 17. The 21 identified genes that replicated in both WTCCC and NARAC and their most selected SNP.  
HLA-DRA, HLA-DQA1, PTPN22, IL2RB, and MICA have shown association in previous studies. The remaining 17 are novel associations cross validating in both cohorts The 
ORs were calculated with respect to the reported allele.  
Gene Chromosome Start pos End pos Most selected SNP in block Allele P (meta-analysis) OR (95% CI) 
HLA-DRA 6 32495624 32540802 rs9268853 C 4.56E-109 2.40 (2.20 - 2.60) 
HLA-DQA1 6 32693160 32739407 rs9272219 T 9.58E-46 0.52 (0.48 – 0.57) 
MICA 6 31459349 31511069 rs1063635 A 1.42E-17 0.74 (0.69 – 0.79) 
HLA-G 6 29882734 29926878 rs1610677 C 4.12E-15 0.76 (0.71 - 0.81) 
IL2RB 22 35831016 35872708 rs743777 G 2.09E-06 1.19 (1.10 – 1.30) 
HLA-C 6 31324507 31367834 rs6906846 A 2.26E-05 0.85 (0.79 – 0.92) 
EGFR 7 55033429 55128489 rs17172446 A 0.0001 0.86 (0.79 – 0.93) 
TEC 4 47812556 47986571 rs2457414 C 0.0016 0.89 (0.83 – 0.96) 
PTPN22* 1 114137960 114235857 rs2488457 G 0.0020 1.13 (1.10 – 1.20) 
PDE4D 5 58280444 58658855 rs829451 T 0.0030 1.12 (1.10 – 1.20) 
SHC4 15 46882243 46992983 rs16961743 T 0.0050 1.40 (1.10 – 1.80) 
CACNA1D 3 53474897 53575012 rs3774425 A 0.0078 0.90 (0.85 – 0.98) 
CACNA1A 19 13155623 13331522 rs3774425 A 0.0084 0.90 (0.83 – 0.97) 
VAV3 1 107894802 108046933 rs10494071 T 0.0091 1.19 (1.00 – 1.37) 
CACNB2 10 18578665 18827827 rs1757217 T 0.0132 1.15 (1.00 – 1.21) 
PDE1C 7 31775674 31790442 rs992185 A 0.0163 0.80 (0.67 – 0.96) 
FGF14 13 101150762 101335129 rs1537930 C 0.0167 1.10 (1.00 – 1.21) 
ITGA9 3 37448558 37577446 rs6788347 G 0.0196 1.08 (1.00 – 1.21) 
ADCY2 5 7594566 7712781 rs7717535 T 0.0200 0.92 (0.86 – 0.99) 
CACNA2D1 7 81573468 81851660 rs38564 T 0.0274 0.92 (0.85 – 0.99) 
PDE4B 1 66010515 66545937 rs17128076 A 0.0376 1.23 (1.00 – 1.50) 
* Original analysis on NARAC study identified rs2476601 (single SNP P=2×10-11) as the most significant SNP mapped to PTPN22 gene. I did not replicate this result as this SNP 
lies ~68kb away from the PTPN22 boundaries and I only mapped SNPs to genes within 20kb of each side of the gene. 
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5.3 Functional enrichment of selected genes  
In order to characterise the functional role of the identified genes, I collaborated with Dr 
Victoria Wright and my supervisor Prof Mike Levin, who assigned the identified genes to their 
cellular location using Ingenuity Pathways Analysis and further explored their biological function 
(Figure 25). There was a significant over-representation of genes located in the cell membrane, 
all of which are involved in signalling from the cell exterior to the interior. I then performed a 
gene ontology (GO) functional enrichment analysis using GOrilla.76 Together with my colleagues 
we   finally created a schematic map (Figure 26) of how these genes might act together in 
biological processes to determine RA susceptibility.  
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Figure 25. Cellular location of products of the selected genes.  
Genes in red were selected in both WTCCC and NARAC; in yellow are genes selected only in NARAC. and in blue 
are genes selected only in WTCCC. Pink indicates that the same gene was identified in both studies but different 
gene block in each study. Genes coding for extracellular proteins are predominantly growth factors. Genes coding 
for intracellular proteins are predominantly involved with signal transduction. Lines connecting genes indicate direct 
interactions as defined from Ingenuity Pathway Systems knowledge base. 
In addition to the expected involvement of HLA mediated processes (GO:0032395, 
P=5.1×10-14), I observed significant enrichment in multiple GO functional categories, (Table 18, 
Table 19), including membrane receptor mediated signalling, integrin-mediated signaling 
(GO:0007229, P=1.53×10-5), cytokine receptor (GO:0004896, P=1.72×10-8) and growth factor 
binding (GO:0019838, P=1.09×10-7), as well as adenylate cyclase activity (GO:000401
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P=4.7×10-5), 3’5’cyclic nucleotide phosphodiesterase activity (GO:0004114, P=9.05×10-6), 
activation of protein kinase activity (GO: 0033674, P=5.3×10-9) and voltage-gated channel 
activity (GO:0005245, P=1.11×10-10), which contain genes involved in intracellular signalling 
through second messenger systems (SMSs)174,175. The SMSs are conserved, ubiquitous systems 
that relay signals from cell surface receptors to target molecules in the cytosol or nucleus, and 
greatly amplify the strength of the signal, through release of the second messengers: cyclic 
adenosine monophosphate (cAMP), inositol triphosphate (ITP)/diacylglycerol (DAG) and 
calcium ions (Ca2+)174-176.  
Adenylate cyclase genes (ADCY2, ADCY8, ADCY9) synthesise cAMP that activates 
multiple protein kinases (Figure 26). The activity of cAMP is then terminated by the 
phosphodiesterase (PDE) enzymes, of which several genes (PDE10A, PDE4B, PDE4D) were 
identified in either WTCCC or NARAC datasets suggesting control of cAMP (GO: 0004016, 
P=4.7×10-5, GO:0004114, P=9.05×10-6) as a potential key regulation point in RA 
pathophysiology. 
The ITP/DAG system is activated by phospholipase C (PLC), which hydrolyses 
membrane phospholipids releasing DAG (Figure 26). DAG recruits calcium-dependent kinases 
that activate numerous pathways (GO: 0045859, P=6.98×10-9) including RAS, ERK and NFκB 
signalling, interacting with the p38, NFAT and STAT signalling pathways.174 The actions of 
DAG are terminated by the enzyme diacylglycerol kinase (DGK). Protein kinase C (PRKC) 
requires calcium ions generated from the action of PLC on the complex of inositol 1,4,5-
trisphosphate (ITP) and DAG. PLC releases ITP which diffuses through the cytosol and binds 
to ITP receptors (ITPR) on the endoplasmic reticulum causing the release of Ca2+ into the 
cytosol (GO: 0042325, P= 2.99×10-10). The identification of several genes in this system (DGKH, 
DGKI, PLCG2, PRKCA, PRKCQ, ITPR3) suggest the ITP/DAG signalling is another key 
regulatory step in RA (GO: 00045859, P=6.98×10-9). 
A further enriched SMS was the calcium second messenger system, which is based on 
cytosolic Ca2+ triggering numerous cellular processes.176,177 (GO:0005262, P=1.64×10-8; 
GO:0005245, P=1.11×10-11, genes CACNA1A, CACNA1D, CACNA1E, CACNA2D1, 
CACNA2D3, CACNB2, CACNG5, ITPR3, VAV3). In addition to the release of Ca2+ from the 
endoplasmic reticulum, the entrance of Ca2+ into the cytosol from the exterior is also controlled 
by voltage gated channels, receptor-operated channels (GO: 007166, P=7.08×10-23) and G-
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protein coupled receptors, with an increase in cytosolic Ca2+ activating numerous calcium 
dependent proteins including PRKC (Figure 26).  
Activation of protein kinase activity (GO: 0032147, P=2.7×10-7) and activation of 
phosphorylation (GO: 0042325, P=2.99×10-10, GO: 0001932, P=8.47×10-10,) were also enriched 
functional categories. The multiple identified genes coding for kinases and phosphatases 
(PRKCA, PRKCQ, PIK3R3, PPP3CA, PTPN22, PTPN5, MAPKAPK2, MAP3K4) are activated 
by the SMSs (Figure 26) and regulate multiple cellular functions including cell turnover, 
metabolism, secretion and growth 175,178,179.  
Many of the remaining genes identified in either study that are not directly involved in 
receptor mediated signalling or SMSs are also known to regulate these systems (Figure 26). The 
proteins encoded by VAV3, ALCAM, CD59, ITGB3 interact with those of EGFR, which 
interacts with GRB2, leading to RAS signal transduction. EGFR encoded protein also interacts 
with the SPRY1 protein which inhibits growth factor signalling. FGF5 and FGF6 are ligands for 
FGFR2 which interacts with GRB2. In terms of cytokines and their receptors, the encoded 
proteins of TNFAIP3, IRF5, SOCS1, SOCS6, STAT4 and PIAS2 are well known downstream 
regulators of cytokine induced inflammation, as are RAPGEF4, RAPGEF5, RASGRF2, PRKCQ 
and NFATC4. The biological interactions of all significant genes in both NARAC and WTCCC 
studies are shown schematically in Figure 4 as a functional cellular map, developed by my 
colleagues and myself in conjunction with my GO analysis. 
The GO enrichment functional analysis, cell location mapping and the cellular map we 
created demonstrate further concordance between the findings in the two studies at the 
functional level. Other than the 21 genes that were identified in both WTCCC and NARAC 
studies, many of the genes, which were only selected in one study, had functional roles similar to 
genes selected in the other study.  
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Table 18. Gene ontology (GO) process enriched categories as derived by Gorilla for ̟thr=0.4 
GO category Description WTCCC NARAC WTCCC 
∪NARAC 
GO:0007165 signal transduction 4.89E-20 4.04E-16 2.31E-29 
GO:0051716 cellular response to stimulus 1.67E-18 7.22E-14 2.50E-26 
GO:0007166 cell surface receptor linked signaling pathway 1.04E-14 2.43E-13 7.08E-23 
GO:0050896 response to stimulus 8.06E-14 5.98E-12 7.09E-20 
GO:0050789 regulation of biological process 1.13E-13 1.32E-10 2.08E-18 
GO:0050794 regulation of cellular process 1.79E-13 1.85E-10 8.15E-18 
GO:0065007 biological regulation 1.10E-13 1.28E-09 1.13E-17 
GO:0048583 regulation of response to stimulus 3.09E-10 8.00E-09 1.98E-17 
GO:0002682 regulation of immune system process 1.22E-09 2.05E-08 1.30E-15 
GO:0002376 immune system process 2.60E-08 2.71E-08 1.31E-14 
GO:0050776 regulation of immune response 5.42E-09 1.52E-08 1.82E-14 
GO:0023051 regulation of signaling 7.31E-09 3.75E-08 2.52E-13 
GO:0002684 positive regulation of immune system process 3.44E-11 1.60E-04 2.73E-13 
GO:0065009 regulation of molecular function 1.76E-11 3.20E-07 6.07E-13 
GO:0007169 transmembrane receptor protein tyrosine kinase signaling 
pathway 1.80E-10 6.12E-06 2.50E-12 
GO:0042325 regulation of phosphorylation 3.75E-06 1.01E-06 2.99E-10 
GO:0019220 regulation of phosphate metabolic process 5.20E-06 1.37E-06 5.32E-10 
GO:0050865 regulation of cell activation 6.76E-09 7.79E-04 5.43E-10 
GO:0001932 regulation of protein phosphorylation 1.48E-05 4.31E-06 8.47E-10 
GO:0010646 regulation of cell communication 1.37E-05 7.76E-08 9.21E-10 
GO:0051249 regulation of lymphocyte activation 3.42E-08 4.15E-04 1.53E-09 
GO:0033674 positive regulation of kinase activity 4.01E-08 2.08E-04 5.31E-09 
GO:0045859 regulation of protein kinase activity 1.23E-06 2.09E-04 6.98E-09 
GO:0051347 positive regulation of transferase activity 5.23E-08 2.39E-04 7.44E-09 
GO:0032412 regulation of ion transmembrane transporter activity 2.79E-08 4.55E-07 1.72E-08 
GO:0022898 regulation of transmembrane transporter activity 3.13E-08 5.06E-07 1.97E-08 
GO:0034765 regulation of ion transmembrane transport 4.86E-08 6.85E-07 3.28E-08 
GO:0051925 regulation of calcium ion transport via voltage-gated 
calcium channel activity 1.30E-07 5.57E-08 3.74E-08 
GO:0046058 cAMP metabolic process 6.24E-07 4.61E-07 7.21E-08 
GO:0070663 regulation of leukocyte proliferation 1.44E-06 3.08E-04 1.01E-07 
GO:0007202 activation of phospholipase C activity 1.53E-05 7.97E-06 7.05E-07 
GO:0010863 positive regulation of phospholipase C activity 1.61E-05 8.44E-06 7.60E-07 
GO:0051924 regulation of calcium ion transport 1.44E-06 1.31E-05 1.65E-06 
GO:0009187 cyclic nucleotide metabolic process 1.23E-05 9.16E-06 3.18E-06 
GO:0010959 regulation of metal ion transport 3.90E-06 2.80E-05 5.18E-06 
GO:0043269 regulation of ion transport 9.43E-06 6.24E-05 1.42E-05 
GO:0007229 integrin-mediated signaling pathway 8.29E-07 2.05E-04 1.53E-05 
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Table 19. Gene ontology (GO) functional enriched categories as derived by Gorilla for ̟thr=0.4 
GO category Description WTCCC NARAC WTCCC 
∪NARAC 
GO:0032395 MHC class II receptor activity 1.18E-08 1.54E-08 5.10E-14 
GO:0005515 protein binding 1.86E-11 1.55E-05 1.59E-13 
GO:0005245 voltage-gated calcium channel activity 3.31E-08 1.11E-10 1.11E-10 
GO:0005488 binding 9.01E-07 4.68E-04 1.42E-08 
GO:0005262 calcium channel activity 3.66E-07 1.47E-07 1.64E-08 
GO:0004896 cytokine receptor activity 1.77E-08 4.87E-04 1.72E-08 
GO:0019838 growth factor binding 4.59E-04 2.45E-05 1.09E-07 
GO:0005102 receptor binding 2.02E-06 3.89E-04 1.11E-07 
GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity 2.20E-05 1.75E-07 1.60E-06 
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity 7.80E-05 1.00E-06 9.05E-06 
GO:0004112 cyclic-nucleotide phosphodiesterase activity 8.84E-05 1.19E-06 1.07E-05 
GO:0022843 voltage-gated cation channel activity 1.15E-04 4.73E-06 1.17E-05 
GO:0004016 adenylate cyclase activity 9.16E-04 7.90E-04 4.70E-05 
GO:0042578 phosphoric ester hydrolase activity 6.96E-04 5.63E-05 5.67E-05 
GO:0022832 voltage-gated channel activity 3.97E-04 2.02E-05 6.55E-05 
GO:0005244 voltage-gated ion channel activity 3.97E-04 2.02E-05 6.55E-05 
GO:0008081 phosphoric diester hydrolase activity 2.10E-04 1.50E-04 1.08E-04 
GO:0005261 cation channel activity 2.90E-04 1.69E-04 1.08E-04 
GO:0022836 gated channel activity 5.26E-04 3.02E-04 2.32E-04 
 
Many of the remaining genes identified in either study that are not directly involved in 
receptor mediated signalling or SMSs are also known to regulate these systems (Figure 26). The 
proteins encoded by VAV3, ALCAM, CD59, ITGB3 interact with those of EGFR, which 
interacts with GRB2, leading to RAS signal transduction. EGFR encoded protein also interacts 
with the SPRY1 protein which inhibits growth factor signalling. FGF5 and FGF6 are ligands for 
FGFR2 which interacts with GRB2. In terms of cytokines and their receptors, the encoded 
proteins of TNFAIP3, IRF5, SOCS1, SOCS6, STAT4 and PIAS2 are well known downstream 
regulators of cytokine induced inflammation, as are RAPGEF4, RAPGEF5, RASGRF2, PRKCQ 
and NFATC4. The interactions of all significant genes in both NARAC and WTCCC studies are 
shown schematically in Figure 26 as a functional cellular map. 
The GO enrichment functional analysis, cell location mapping and the cellular map I 
created demonstrate further concordance between the findings in the two studies at the 
functional level. Other than the 21 genes that were identified in both WTCCC and NARAC 
studies, many of the genes, which were only selected in one study, had functional roles similar to 
genes selected in the other study.  
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Figure 26. Cellular and functional map of non HLA genes identified by stability selection.  
Purple - selected in both WTCCC and NARAC; blue- selected in WTCCC only; red – selected in NARAC only. 
Focus is given on the second messenger signalling systems (SMSs). In the cyclic AMP system (cAMP), adenylate 
cyclase (ADCY) synthesises cAMP from ATP. ADCY is activated by a range of receptors including G-protein 
coupled receptors. cAMP activates protein kinases (PKA) that phosphorylate target proteins. The enzymes 
phosphodiesterase (PDE) terminate the activity of cAMP switching off the process. The inositol 
triphosphate/diacylglycerol (ITP/DAG) system is activated by phospholipase C (PLC), which hydrolyses membrane 
phospholipids releasing DAG and ITP. DAG recruits calcium dependent protein kinase C and D (PKC, PKD). 
These activate numerous pathways including RAS and ERK leading to cell turnover, IKK and activation of NFKB 
signalling and interaction with p38 MAP kinase, NFAT and STAT signaling pathways. The actions of DAG are 
terminated by the enzyme diacylglycerol kinase, which converts DAG to phosphatidic acid. PKC requires calcium 
ions (Ca2+) and these are made available by the action of ITP in the calcium signaling pathway. ITP, released from 
the complex with DAG by PLC, diffuses through the cytosol and binds to inositol triphosphate receptors (ITPR) on 
the endoplasmic reticulum causing the release of Ca2+ into the cytosol. The calcium second messenger system is 
activated by release of ITP, which binds to the ITPR on the reticuloendothelial system triggering release of Ca2+ 
from the ER into the cytosol. Entrance of Ca2+ into the cytosol is also controlled by voltage gated channels, such as 
CACNAC, ITPR or receptor operated channels and G protein coupled receptors. The rise in Ca2+ concentrations in 
the cytosol, as a result of influx from the endoplasmic reticulum or extracellular fluids through calcium channels, 
activates numerous calcium dependent proteins including PRKC. The actions of Ca2+ are terminated by active 
transport of Ca2+ out of the cytosol using calcium ATPases or sodium calcium exchanges. 
 
5.4 Discussion 
I have shown that using both biologically driven pathway information and a robust gene 
stability selection methodology yields improved power and consistent results across two 
independent RA cohorts. I have shown that this approach can identify novel, reproducible 
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associations from GWAS as well as replicate known associations that were not validated using 
single-SNP approaches using the same GWAS data. For example, the original NARAC report8, 
presented the TRAF1-C5 association and confirmed only the MHC region and the PTPN22 
gene, whereas my approach on NARAC apart from the aforementioned, also confirmed the 
CD28, PRKCQ, CD40, IL2RB, SPRED2, CD247 and TAP2 genes, which have been previously 
reported as modest associations with disease180. Similarly, in comparison to the original WTCCC 
report9 that only confirmed the association of the MHC region and the PTPN22 gene, I also 
confirmed the associations of STAT4, TNFAIP3, IL2RA, IL2RB, IRF5 and IL6R180. 
Furthermore, of the 7 novel loci discovered in the recent meta-analysis of RA GWAS on a total 
of 41,282 samples180, I discovered 3 (IL2RA, IRF5, SPRED2) and of the 10 suggestive loci  I 
discovered 2 (CD247, IL6R) using only two studies with 4798 (WTCCC) and 2168 (NARAC) 
samples each. 
My approach would also be applicable if only one GWAS cohort was available, although 
the calibration of the selection probability πthr and expected model size to maximise the number 
of discoveries and minimise the FDR would not be possible, and I would suggest using the 
values derived in this work. If more than two GWAS cohorts were available, it would be 
straightforward to extend my approach by analyzing all studies at the pathway level separately 
and then taking the top ~10% of pathways to the gene stability selection methodology; genes 
would then be selected per study by following the exact procedure that was described in Chapter 
4, but using a multivariate hypergeometric distribution to control the false discovery rate and set 
the threshold above which genes would be denoted as “stably selected”. 
My results suggest that my pathway-based and gene stability-selection analysis is robust 
to genetic heterogeneity between different samples and to the technical heterogeneity of 
different genotyping platforms. I have replicated my findings at the pathway level by identifying 
the same pathways in both studies lying in the top 6% of the rankings; at the gene level by 
identifying 21 genes in common of the 60 and 64 selected in WTCCC and NARAC studies 
respectively and by validating 10 (WTCCC) and 12 (NARAC) known associations that were not 
validated using single-SNP approaches on the same GWAS data; at the functional level through 
demonstrating that many genes selected in only one study have functionally similar genes 
selected in the other study. A recent review45 commented that at present, there is no clear way to 
compare various pathway analysis methods against each other, but there is a need to replicate 
association results. To my knowledge, this is the first combined pathway and gene-based 
methodology that has replicated association findings in two real GWAS datasets. 
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Finally, the functional analysis of the identified genes suggests that the underlying 
concept of RA as a largely autoimmune and inflammatory disease should be broadened. My 
findings suggest that defective second messenger signalling through cAMP, ITP, DAG and Ca2+ 
may be at the heart of RA predisposition. The SMSs are used by all cells to switch on and off 
multiple processes including cell cycle, differentiation, growth, secretion and immune response 
175,176. SMSs regulate both the intensity and duration of cellular responses and the identification of 
multiple genetic variants in the SMSs suggests that RA may arise from a defect in the on /off 
switch controlling both the amplitude and duration of key cellular functions. The SMSs control 
not only immune response cells but chondrocytes, osteocytes, connective tissue and blood vessel 
cells, as well as processes such as osteoclast resorption, differentiation of chondrocyte and 
osteoblasts ,and repair and removal of senescent cells 181,182. Thus a defect in on/off signaling 
may explain the widespread cellular and connective tissue disorder in RA in addition to abnormal 
function of inflammatory cells (Figure 27).  
It is of interest that numerous cellular studies have documented alterations in cAMP, 
inositol phosphate and calcium signalling in RA, including abnormalities in these pathways in 
inflammatory cells in the joints, in in-vivo studies of osteocytes and chondrocytes 182-185 supporting 
my hypothesis. Future studies should explore the relationship between genes identified and 
functional cellular responses to test this hypothesis, particularly as all steps in the processes I 
have implicated may be amenable to pharmacological manipulation. My identification of the 
SMSs as playing a key role in RA susceptibility suggests a novel concept of the genetic 
mechanisms of the disease which potentially opens new avenues for pharmacological 
intervention to prevent and treat the disorder. 
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Figure 27. Schematic representation of how genetic variation in genes in the second messenger signalling 
systems cause altered intensity and duration of cellular responses to multiple receptor mediated stimuli. 
5.5 Summary 
In this chapter, I presented the results of the first application of my pathway-driven 
gene-stability selection methodology. I analyzed the WTCCC and the NARAC studies of ~5,000 
and ~2,000 subjects respectively. I examined 700 pathways comprising ~8,000 genes. Ranking 
pathways by significance revealed that the NARAC top-ranked ~6% laid within the top 10% of 
WTCCC. Gene selection on those pathways identified 58 genes in WTCCC and 61 in NARAC; 
21 of those were common (Poverlap<10
-21), of which 16 were novel discoveries. Amongst the 
identified genes, I confirmed 10 known RA associations in WTCCC and 13 in NARAC, which 
were not discovered using single-SNP approaches on the same data. Gene ontology functional 
enrichment analysis on the identified genes showed significant over-representation of signalling 
activity (P<10-29) in both studies. My findings suggest a novel model of RA genetic 
predisposition, which involves cell membrane receptors and genes in second messenger 
signalling systems, in addition to genes that regulate immune responses, which have been the 
focus of interest previously. 
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Chapter 6  
 
Application to Kawasaki 
disease 
 
 
 
 
 
 
 
 
As another application of the pathway-based approach to GWAS analysis, I worked on a 
hypothesis-driven investigation of the association between the TGF-β pathway and the Kawasaki 
disease. I initially analyzed a case-control GWAS and I then examined a genome-wide association 
study of family trios. For the latter, I also had to modify my CT test statistic to apply to genotype 
data from family trios. The results were further explored by RNA expression studies of the same 
pathway in patients with acute disease, using microarray and reverse transcription polymerase chain 
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reaction (RT-PCR), as well as protein analysis. All gene-expression and protein work was carried out 
by my colleagues and our collaborators in the University of San Diego and the International 
Kawasaki Disease Genetics Consortium (IKDGC), as I have stated it in the Declaration of 
Authentication. In this chapter I will describe the extension of my approach to family-trio GWAS 
and the investigation of the association between the TGF-β pathway and the Kawasaki disease 
susceptibility, severity and treatment response. 
6.1 Introduction  
Kawasaki disease (KD) is an acute, systemic vasculitis associated with cardiovascular 
sequelae that include coronary artery aneurysms (CAA), aortic root (AoR) dilatation, and myocardial 
fibrosis186,187. CAA develop in 25% of untreated patients and 3-5% of patients treated with 
intravenous immunoglobulin (IVIG) within the first 10 days after fever onset.188 AoR dilatation 
occurs in approximately 15% of treated patients.189,190 Histological examination of tissues from KD 
autopsies has revealed myocardial fibrosis, dysregulation of angiogenesis and coronary artery 
thrombosis, stenosis, and calcification191,192. The aetiology of KD remains unknown, although an 
infectious trigger affecting genetically susceptible hosts is suspected.193-197 The marked differential 
susceptibility to KD in North Asians compared to Europeans, maintained following migration to 
low incidence countries, together with a 10-fold increased relative risk in siblings strongly suggest a 
genetic predisposition to KD susceptibility. 198,199 Genetic and immunologic studies suggest that T-
cell activation has  an important role in the pathogenesis of KD.192,193,197,200,201 Transforming growth 
factor (TGF)-β modulates the balance of pro-inflammatory and anti-inflammatory T-cells through a 
complex set of interactions. The importance of cardiovascular remodelling and immune activation in 
KD suggests that TGF-β pathway may play an important role in KD pathogenesis192,193,197,200,201. In 
collaboration with the IKDGC and my supervisor Prof. Michael Levin, we investigated this 
hypothesis by analyzing the genetic variation and transcript abundance patterns for genes in the 
TGF-β pathway. Prof. Jane Burns’ group also measured levels of TGF-β2 peptide in acute and 
convalescent KD plasma samples. These studies revealed that genetic variation in the TGF-β 
pathway influences KD susceptibility, severity, and treatment response.  
Chapter 6. Application to Kawasaki disease 
 123 
6.2 Data and Methods 
6.2.1 Clinical perspective 
TGF-β is a multifunctional peptide that regulates proliferation, differentiation, apoptosis, 
and migration in many cell types. In the cardiovascular system, TGF-β can induce neoangiogenesis, 
cardiomyocyte hypertrophy, calcification, and fibrosis202,203. Alteration of TGF-β signaling (Figure 
28) has been implicated in the pathophysiology of several vascular disorders including Marfan and 
Loeys-Dietz syndromes, which are associated with CAA and AoR dilatation and vascular 
complications of sickle cell anemia204-207. In the immune system, TGF-β modulates the balance of 
pro-inflammatory and anti-inflammatory T-cells through a complex set of interactions.  
 
Figure 28. TGF-β signaling pathway 
TGF-β is secreted in a latent form and activation is mediated by several molecules including furin and emilin. Active 
TGF-β peptides (TGFB1, 2, 3) bind to the Type II receptor (TGFBR2), which recruits and activates Type I receptors 
such as TGFBR1 or ACVRL1.  The activated Type I receptor phosphorylates receptor-specific SMAD molecules: 
TGFBR1 phosphorylates SMAD2 and 3, and ACVRL1 phosphorylates SMAD1, 5 and 8.  These activated SMADs form 
a larger complex with Smad4 and translocate to the nucleus where they regulate gene transcription. Accessory receptors 
such as ENG have a role in the balance of ACVRL1 and TGFBR1 signaling to regulate endothelial cell proliferation. In 
addition to the classical SMAD signaling pathway, a SMAD-independent pathway using alternative molecules such as 
MAP3K7 can also mediate TGF-β signaling. TGFB: Transforming growth factor-β, TGFBR: Transforming growth 
factor-β receptor, EMILIN1: Elastin microfibril interfacer 1, SMAD: SMAD family member, MAP3K7: Mitogen-
activated protein kinase kinase kinase 7, ENG: Endoglin, ACVRL1: Activin A receptor type II-like 1, FURIN: Furin 
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6.2.2 Subjects  
The recruitment of KD patients and the details of their clinical presentation and diagnosis 
are described in a previous work of IKDGC208. IVIG resistance was defined as previously 
described209. A total of 771 KD subjects and 159 controls were genotyped and divided into different 
cohorts for analysis. Cohort 1 was comprised of 128 Dutch European descent KD subjects (Table 
20, Figure 29) and 159 Dutch European descent healthy adult control subjects. Cohort 2 was 
comprised of 451 biologic trios (mother, father, affected child, European descent 81% and mixed 
European descent 19%) from the US, UK and Australia (US/UK/Aus). Cohort 3 (n=435) was 
comprised of Dutch Cohort 1 KD subjects (n=125) plus subjects from the European descent 
Cohort 2 (UK n=48, Australian=186) plus additional European descent KD subjects from the UK 
(n=29) and Australia (n=47). Cohort 4 (n=237) was comprised of European descent US KD 
subjects from Cohort 2 (n=121) plus additional European descent KD subjects from the US 
(n=116) (Table 20, Figure 29). 
Multiethnic TDT 
Cohort 2
n= 451 trios
Dutch Case-control analysis 
Cohort 1
KD n=128, Control n=159Susceptibility
Case-control analysis: 
CAA + vs. CAA –
Cohort 3, KD n=435
CA Z-max
Cohort4 subset, KD n=176
Case-control analysis
IVIG responsive vs. resistant
Cohort 4 subset, KD n=193
CA status: 
AoR dilatation
IVIG treatment response
Phenotypes: Cohorts
Case-control analysis: 
CAA + vs. CAA –
Cohort 4, KD n=237
AoR Z-max
Cohort 4 subset, KD n=98
European descent
KD cases
Additional 
European descent
KD cases from
Australia and UK
n=76
Additional European descent
US KD cases n=116
UK, Australian 
n=234 cases 
US 
n=121 cases
KD subjects
n=125
 
Figure 29. The cohorts and the phenotypes that were examined in different stages of analysis 
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Table 20. Characteristics of subjects in their respective cohorts 
  
Cohort 1 
NL Case-control 
study 
Cohort 2 
US/UK/Aus TDT 
Cohort 3 
UK/NL/Aus 
Cohort 4 
US only 
  
(KD n=128, Controls 
n=159) 
(KD n=451) (KD n=435) (KD n=237) 
    n % n % N % n % n % 
Gender: Male 77 60.1 74 46.5 270 59.9 261 60.0 153 64.6 
 Female 50 39.1 57 35.9 181 40.1 174 40.0 84 35.4 
 Unknown 1 0.8 28 17.6 0 0 0  0 0 
CA status: CAA+ 28 21.9 NA NA 71 15.7 73 16.8 51 21.5 
 CAA- 97 75.8 NA NA 349 77.4 362 83.2 186 78.5 
 Unknown 3 2.3 NA NA 31 6.9 0  0 0 
Z worst:  
 CA NA NA NA NA NA NA NA NA 176 74.3 
 Aortic root NA NA NA NA NA NA NA NA 98 41.4 
IVIG 
treatment 
response*  Resistant NA NA NA NA NA NA NA NA 46 19.4 
 Responsive NA NA NA NA NA NA NA NA 147 62.0 
*44 US KD subjects could not be classified because they had either no treatment, other treatment or no information was 
available  
NA: not available; NL: Netherlands, US: United States; UK: United Kingdom; Aus: Australia; TDT: Transmission 
disequilibrium test; CA: coronary artery; CAA: coronary artery aneurysm; IVIG: intravenous immunoglobulin 
 
6.2.3 Materials 
Blood samples. RNA was isolated from whole blood collected in PAXgene tubes from US 
KD subjects (Table 21,Figure 30) as described in Popper et al.209 Plasma (sodium citrate) for ELISA 
was collected from KD patients during acute (pre-IVIG) and convalescent (≥1 month after fever 
onset and normalization of erythrocyte sedimentation rate and platelet count) phases. Blood samples 
were processed within 48 hours of collection and plasma was stored at -70°C. 
 
 
Figure 30. Subjects analyzed in expression studies 
Yellow cells: subjects used for Lymphochip microarray, Blue cells: subjects used for Agilent microarray, 4 of 20 subjects 
were also used for RT-PCR, 4 of 20 subjects were also used for ELISA assay and 1 of 20 was used for both RT-PCR 
and ELISA. Green cells: subjects used for RT-PCR, Red cells: subjects used for ELISA assay, Purple cells:  subjects used 
for genotype assays 
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Table 21. Characteristics of subjects in microarrays, RT-PCR and ELISA 
 
Echocardiography. All KD subjects had echocardiographic assessment during the acute 
and convalescent stages of their illnesses. For all cohorts, coronary artery (CA) lesions (aneurysm or 
ectasia) were defined according to the Japanese Ministry of Health criteria210. The coronary artery 
status of the US subjects (Cohort 4) was assessed by echocardiography during the acute and sub-
acute phase and serially thereafter as dictated by patient status. Measurements of the internal 
diameters of the proximal right (RCA) and left anterior descending (LAD) coronary arteries were 
normalized for body surface area and expressed as standard deviation units from the mean (Z 
scores)211. The worst-ever Z-score for either the RCA or LAD at any time point or the Z score of 
the largest aneurysm was used for the continuous variable analysis (CA Z-max).  
AoR dimensions (annulus and sinus) were measured at only two US sites (Rady Children’s 
Hospital San Diego and Boston Children’s Hospital). Measurements performed within 1 year from 
the onset of KD were normalized for body surface area and expressed as Z-scores.212 The variable, 
(AoR Z-max), which was the largest dimension of the AoR at any timepoint during the first year 
after disease onset, was used for the continuous variable analysis. For subjects who were not seen 
within the first year after disease onset, we used measurement of the AoR from the first available 
echocardiogram.  
Genotyping. Genomic DNA from whole blood or mouth wash samples was extracted as 
described in a previous study of the same group208. SNPs (n=164) that were selected from HapMap 
Caucasian populations with minor allele frequencies ≥ 0.1, from 15 genes in the TGF-β signaling 
  Microarrays RT-PCR ELISA 
  Lymphochip Agilent array   
    n % n % n % n % 
Total subjects n 19  20  15  18  
Gender Male  12 63 9 45 11 73 8 44 
CA status CAA+   2 11 1 5 2 13 3 17 
 CAA-  17 89 19 95 13 87 15 83 
IVIG treatment Resistant 2 11 8 40 5 33 5 28 
 Responder 17 89 12 60 10 67 4 22 
 Others*  0  0  0  9 50 
Ethnicity Asian 7 37 1 5 0 0 1 6 
 Caucasian 4 21 6 30 8 53 13 71 
 Hispanic 4 21 7 35 4 27 2 11 
 ≥2 races 3 16 6 30 3 20 1 6 
 African American 1 5 0 0 0 0 1 6 
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pathway (Figure 28) were genotyped using a custom Illumina Oligo Pool Assay.208 All SNPs met 
quality control criteria with genotype call rate ≥ 93% and no deviation from Hardy-Weinberg 
equilibrium in controls and parents of KD subjects.   
Microarray analysis. Two different types of microarray platforms (Stanford University 
Lymphochip, 19 KD subjects, and Agilent G4112F Human Whole Genome Oligo Arrays (design 
#14850), 20 KD subjects) were used to study two independent cohorts of KD subjects209,213 (Table 
21, Figure 30). For the Lymphochip array, 55 clones from 15 genes in the TGF-β pathway were 
filtered to meet quality standards as described in Popper et al209. Data from individual cDNA clones 
were included if paired acute and convalescent measurements were available for at least 10 of the 19 
KD subjects, and data from clones associated with a single Unigene cluster were averaged. 
Differences in transcript abundance in acute and convalescent samples were assessed using a paired 
t-test.  For the Agilent arrays, 22 clones from 15 genes in the TGF-β pathway were examined.  They 
were subject to the calculation of average difference, P-value of Student t-test, and q-value of FDR, 
based on the 22 tests, between acute and convalescent stages. Regarding the quality control (QC) of 
the arrays, the signal intensity of at least 80% of the samples tested was 2.5-fold above background 
in either the Cy5 (sample) or Cy3 (reference) channel, and a regression correlation for the two 
channels was at least 0.6 across each measured element. 
RT-PCR. To validate the microarray results, transcript abundance levels were measured by 
RT-PCR for SMAD1, SMAD3, ACVRL1, FURIN, TGFBR3 and TGFBR2 for 14 KD subjects 
with acute and convalescent paired whole blood RNA samples (Table 21, Figure 30). Relative 
abundance of the target transcripts was normalized to the expression level of the house keeping 
gene, TATA box binding protein-associated factor, RNA polymerase I, B (TAF1B), as described in 
Popper et al209 SMAD1 (ABI Assay ID Hs00195432_m1), SMAD3 (ABI Assay ID 
Hs00969208_m1), ACVRL1 (ABI Assay ID Hs00953798_m1), FURIN (ABI Assay ID 
Hs00159829_m1), TGFBR3 (ABI Assay ID Hs00234257_m1) and TGFBR2 (ABI Assay ID 
Hs00234253_m1) Of the 14 subjects, none overlapped with the 19 subjects used for the 
Lymphochip analysis and five of 20 were also studied on the Agilent microarrays. 
ELISA. The concentrations of TGFB2 in paired acute and convalescent plasma samples 
were compared in 18 KD subjects (Quantikine, R&D system) (Table 21, Figure 30).  
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6.2.4 Methods 
6.2.4.1 Pathway analysis 
Pathway analysis was applied using the CT test statistic as described in Chapter 2. I extended 
the statistic to be applicable to family trios by replacing the Cochran-Armitage test statistic with the 
transmission disequilibrium test (TDT)214, as they are both approximated by a χ2 distribution with 1 
df.  
The TDT is a family-based test of linkage and association. The TDT requires two unaffected 
parents and an affected offspring, which is usually called a family-trio as depicted in Figure 31. In the 
lack of association between the disease and the marker in the population, the parental genotypes are 
random. In the lack of linkage between the marker and the disease locus, the transmission of the 
marker allele is independent of transmission of the disease. In this respect, TDT tests for both 
population association and linkage.  
 
 
Figure 31. Pedigree of a family trio.  
Square stands for male and round for female individual. Color filled rectangle stands for affected and no fill stands for 
unaffected. M and m are the two alleles of a bi-allelic marker. In this trio, one M from the father and the m from the 
mother were transmitted to the offspring. 
Let us assume a marker locus with alleles M and m as depicted in Figure 31. Imagine that we 
have n family trios of n affected children, whose 2n unaffected parents and their alleles can be 
summarized in a 2x2 table: 
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Table 22. Contigency table of transmitted and not-transmitted alleles in family trios. 
 Not-transmitted allele  
Transmitted allele M m Total 
M a b a+b 
m c d c+d 
Total a+c b+d 2n 
The counts a and d are uninformative, as they correspond to homozygous parents and so 
transmitted and untrasmitted alleles are the same. For that reason, only heterozygous parents are 
informative and thus taken into account. If there is no association or no linkage, the numbers of 
transmitted M and not-trasmitted M should be the same. The same applies to allele m. The TDT 
assesses whether the proportions b/(b+c) and c/(b+c) have 0.5 and 0.5 probabilities respectively. 
TDT tests this hypothesis using a χ2 test statistic with one df: 
     
2
2 ( )b c
b c
χ
−
=
+
          (6.1) 
 
To obtain the cumulative trend test statistic for pathway association, I sum the TDT over all 
of the n SNPs in a given pathway. If I denote as TDTi the TDT statistic for the i
th SNP, then the 
cumulative trend test statistic for the pathway is 
1
n
pathway i
i
CT TDT
=
=∑ ,                                                          (6.2) 
where n is the number of SNPs in the pathway.  
Permutations of the trio data were performed by randomizing the transmitted allele. I 
applied this analysis to Cohort 2 (451 biological trios). I also applied the CT test statistic, as 
described in Chapter 2 for a case-control design to Cohort 1 (128 KD cases-159 controls). Finally, I 
applied a unified pathway analysis to the merged dataset of Cohort 1 and the affected children of 
Cohort 2 (579 KD cases -159 controls).  
6.2.4.2  Single-SNP analyses 
The transmission disequilibrium test (TDT) was applied to test for the single-SNP 
association between the disease and the single markers on the family-trio data215.  
Case-control association analysis between the single SNPs and the disease, as well as the CA 
status was conducted using the general linear model:  Yi = α + β Xi + ϵi.  The genetic models that 
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were considered were the dominant model (genotype model:11 vs.12+22) and the additive model 
(allele model: 1 vs. 2).  Under the dominant model, Xi=1 if the i
th subject has at least one minor allele 
or Xi=0 otherwise. Under the additive model, Xi indicates the i
th subject’s number of minor alleles. 
This is equivalent to the test based on the allele frequency. All P-values were adjusted via means of 
the Bonferroni procedure to correct for multiple testing. 
Association analyses between genetic variants and the Z-max for the coronary arteries were 
performed using non-parametric tests due to the non-normality of the Z-score. Associations 
between the genetic variants and AoR Z-max were analyzed using a general linear model. The 
genetic models that were considered were the additive, dominant and recessive models. Analysis was 
performed using the SNPassoc and DGCgenetics packages in the R software (http://www.r-
project.org/). 
Paired t-tests were conducted to compare transcript abundance levels, as well as to compare 
transcript abundance levels and plasma TGFB2 levels (PRISM v5.01). Association between genetic 
variants and gene expression or TGFB2 protein levels were analyzed with either the Kruskal-Wallis 
test or the Mann-Whitney test (PRISM v5.01).   
6.3 Results 
6.3.1 TGF-β signaling pathway and KD susceptibility 
Analysis of the cumulative variation of 15 genes in the TGF-β pathway in the merged 
dataset of Cohorts 1 and 2 showed evidence of association between the pathway and KD 
susceptibility. In particular, I analyzed 6 different versions of the TGF-β pathway, as they were 
perceived and assembled by Dr. Chisato Shimizu (Table 23). I observed moderate association signals 
in all the versions of the pathway and the merged dataset of Cohort 1 and affected children of 
Cohort 2; the most significant association signal was observed for the 15 genes altogether  with 
P=0.00065 (Table 23).  
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Table 23. Versions of the TGF-β pathway and CT test statistic results.  
P-values are given for the analysis of Cohort 1 [P(1)], Cohort 2 [P(2)] and the merged dataset [P(merged)] 
Pathway  #Genes Genes  P (1) P (2) P (merged) 
TGF-β 15 TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, 
ACVRL1, SMAD1, SMAD2, SMAD3, SMAD4, 
SMAD5, ENG, MAP3K7, FURIN, ENDOGLIN 
0.280 0.289 0.00065 
TGF-β #1 6 TGFB2, TGFBR2, ACVRL1, SMA2, SMAD3, 
ENDOGLIN 
0.219 0.062 0.0041 
TGF-β #2 8 TGFB3, TGFBR1, TGFB2, TGFBR2, ACVRL1, 
SMAD2, SMAD3, ENDOGLIN 
0.249 0.085 0.0025 
TGF-β #3 7 TGFB1, TGFB2, TGFBR2, ACVRL1, SMAD2, 
SMAD3, ENDOGLIN 
0.227 0.082 0.0018 
TGF-β #4 6 TGFB1, TGFB2, ACVRL1, SMAD2, SMAD3, 
ENDOGLIN 
0.099 0.004 0.0017 
TGF-β #5 7 TGFB3, TGFBR1, TGFB2, ACVRL1, SMA2, SMAD3, 
ENDOGLIN 
0.115 0.007 0.0011 
Gene-based analysis on the merged dataset identified TGFB2 (P=0.006), TGFBR2 (P=0.08), 
ACVRL1 (P=0.04), SMAD3 (P=0.06) and FURIN (P=0.01) as the ones driving the pathway signal. 
Gene-based analyzed was performed exactly as pathway-based analysis, but only on the SNPs of 
each gene. 
Single-SNP analysis of the case-control Cohort 1 (128 KD vs 159 control subjects) identified 
SNPs in 6 genes in the pathway with a modest influence on KD susceptibility (P∈[0.0031-0.047] 
(Table 25). The significance of genetic variation in 3 of these 6 genes (SMAD3, TGFB2, and 
TGFBR2) was replicated in the TDT analysis of the independent US/UK/Aus subjects (Cohort 2: 
451 trios) that identified 7 different SNPs associated with KD susceptibility (Table 24, Figure 32). 
Five of the 7 SNPs were in SMAD3, with the most significant result for an intronic SNP (A/G, 
rs4776338) for which 272 of the 453 heterozygous parents transmitted the G allele to their affected 
offspring (P=0.003, OR 1.50, 95%CI 1.25-1.81, calculated using the DGCgenetics package in R).  
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Figure 32. Significant SNP locations for TGFB2 (A), TGFBR2 (B) and SMAD3 (C) 
Arrows show the location of significant SNPs genotyped in this study. Gene structure and the location of SNPs are 
shown: boxes= exons and 3’ and 5’ untranslated regions;. Underlined text highlights SNPs with P<0.01. Letter code 
above SNP rs# refers to type of analysis and cohort: CC: susceptibility in Cohort 1 (Table 25), TDT: susceptibility in 
Cohort 2 (Table 24), CAA3 and CAA4: association with CAA in Cohort 3 and Cohort 4, respectively (Table 26), CAZ: 
association with CA Z-worst (Table 27), AoR; association with AoR Z-worst (Table 28), IVIG; association with IVIG 
treatment response (Table 29). LD maps are shown for SNPs of interest. 
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Table 24. TDT analysis of genetic variants and KD susceptibility in US/UK/Australian trios (n=451). 
* Results are shown only for SNPs with a P-value <0.05. OR: odds ratio, CI: confidence interval 
      Allele 2         
Gene rs number Allele 1/2 Frequency Transmitted Not transmitted OR 95%CI P†  
TGFB2 rs2796817 A/C 0.13 139 98 1.42 1.10 1.84 0.0092 
TGFBR2 rs11466480 A/C 0.03 12 27 0.44 0.23 0.88 0.024 
rs4776338 A/G 0.42 272 181 1.50 1.25 1.81 0.000022 
rs7162912 C/A 0.31 229 174 1.32 1.08 1.60 0.0071 
rs12901071 A/G 0.29 230 169 1.36 1.12 1.66 0.0026 
rs1438386 A/G 0.41 190 237 0.80 0.66 0.97 0.026 
SMAD3  
rs6494633 G/A 0.43 174 219 0.80 0.65 0.97 0.026 
 
Table 25. Association of genetic variants and KD susceptibility in Dutch KD subjects and controls 
Results are shown only for SNPs with a nominal P-value <0.05 
        Allele 2 frequencies Allele 2 vs. Allele 1 
Chr. Gene 
symbol 
SNP Allele 
1/2  
KD n=128 Control 
n=159 
OR 95% CI P-value 
1 TGFB2 rs10495098 C/A 0.35 0.44 0.68 0.48 0.96 0.028 
  rs4846476 G/C 0.17 0.27 0.54 0.36 0.82 0.0032 
3 TGFBR2 rs2043136 A/G 0.2 0.29 0.59 0.39 0.89 0.0095 
  rs4955104 T/A 0.17 0.24 0.66 0.43 1.01 0.052 
  rs9310940 C/A 0.44 0.54 0.65 0.46 0.91 0.01 
  rs876688 G/A 0.42 0.3 1.66 1.18 2.34 0.0031 
  rs877572 C/G 0.4 0.49 0.72 0.52 1.00 0.047 
  rs9843143 C/G 0.54 0.42 1.57 1.13 2.18 0.006 
4 SMAD1 rs6537355 A/G 0.12 0.11 1.08 0.65 1.78 0.041 
  rs2118438 G/A 0.17 0.22 0.71 0.47 1.08 0.11 
9 ENG rs4451422 A/C 0.48 0.38 1.46 1.05 2.03 0.023 
  rs10760503 A/G 0.5 0.4 1.47 1.06 2.04 0.02 
  rs1330684 G/A 0.45 0.36 1.41 1.01 1.97 0.045 
12 ACVRL1  rs706819 G/A 0.24 0.35 0.62 0.44 0.88 0.007 
15 SMAD3 rs1065080 G/A 0.14 0.08 1.7 1.01 2.89 0.045 
    rs11629568 A/C 0.39 0.47 0.72 0.51 1.00 0.052 
6.3.2 TGF-β signaling pathway and coronary artery outcome 
Genetic variation in TGFB2, TGFBR2, and SMAD3 consistently influenced coronary artery 
outcome in 2 independent, non-overlapping cohorts: Cohort 3 from the UK, Australia, and the 
Netherlands (CAA-: n=362, CAA+: n=73) and Cohort 4 from the US (CAA-: n=186, CAA+: 
n=51) (Table 26). Although the associated SNPs in Cohort 3 and 4 were different, many of the 
SNPs co-localized to the first intron of each of the 3 genes (TGFB2, TGFBR2 and SMAD3) (Figure 
32).  
The collaborators in this study analyzed the association between genetic variants and CA Z-
max from a subset of Cohort 4 (US, n=176). Significant differences were revealed in the distribution 
of CA Z-max for 11 SNPs in 4 genes in the pathway (Table 27). Whether the analysis was 
performed using Z-max (n=176) or using the presence or absence of aneurysms in the complete 
Chapter 6. Application to Kawasaki disease 
 134 
Cohort 4 (176 + 61= 237), 3 SNPs in TGFB2 (rs10482751, rs2027567, rs12029576) and 2 SNPs in 
SMAD3 (rs12910698, rs4776339) were consistently associated. (Table 26, Table 27, Figure 32).    
Table 26. Case-control analysis of genetic variants and coronary artery aneurysms (CAA) in US subjects 
(CAA-: n=186, CAA+: n=51) and UK/Aus/NL subjects (CAA-: n=362, CAA+: n=73). Results are shown only for 
SNPs with a nominal P-value <0.05. 
      Cohort 3 Cohort 4 
   Allele2 frequency  Allele2 frequency  
Chr. Gene SNP CAA- CAA+ P CAA- CAA+ P 
1 TGFB2 rs10495098 0.37 0.46 0.016    
  rs10482751    0.30 0.41 0.019 
  rs2027567    0.21 0.31 0.028 
  rs12029576    0.27 0.42 0.0011 
  rs1317681 0.15 0.24 0.0090    
3 TGFBR2 rs9790292    0.46 0.39 0.029 
  rs6809777 0.27 0.18 0.034    
  rs3773636 0.25 0.32 0.035    
  rs877572 0.47 0.34 0.027    
  rs2276768 0.10 0.18 0.039    
  rs3773663 0.41 0.53 0.025    
4 SMAD1 rs6537355 0.14 0.08 0.018    
5 SMAD5 rs3764942 0.08 0.03 0.008    
12 ACVRL1 rs11169953 0.33 0.26 0.014    
15 SMAD3 rs12901071 0.39 0.32 0.030    
  rs12910698    0.44 0.54 0.014 
  rs4776881    0.44 0.54 0.014 
  rs4776339    0.47 0.58 0.014 
  rs10152544 0.45 0.50 0.015    
  rs7173811    0.48 0.40 0.038 
  rs11632754    0.23 0.12 0.0032 
19 TGFB1 rs8179181 0.24 0.14 0.015    
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Table 27. Analysis of genetic variants and CA Z-max in US KD subjects (n=176) 
CA: coronary artery. SNPs with an asterisk * were found also significantly associated with CA Z-max in Cohort 4. 
Results are shown only for SNPs with a nominal P-value <0.05. 
Chr. Gene  SNP Genotype N CA Z-max Interquartile range Mann-Whitney P 
1 TGFB2 rs10482751* GG 78 1.50 (0.95- 2.60) 0.0008 
   AG+AA 98 1.97 (1.32- 4.44)  
  rs2027567* AA 99 1.70 (0.99- 2.65) 0.0032 
   AG+GG 77 1.94 (1.30- 4.60)  
  rs12029576* AA 83 1.52 (0.99- 2.60) 0.0009 
   AC+CC 93 2.00 (1.30- 4.10)  
3 TGFBR2 rs6770038 GG 122 1.91 (1.20- 3.70) 0.03 
   AG+AA 54 1.43 (1.00- 2.75)  
  rs9310940 CC 54 1.85 (1.60- 4.02) 0.049 
   AC+AA 121 1.64 (1.00- 3.10)  
  rs3773658 AA 136 1.90 (1.19- 3.73) 0.0052 
   AG+GG 40 1.29 (0.89- 2.15)  
  rs3773661 GG 137 1.90 (1.20- 3.70) 0.0033 
   CC+CG 39 1.28 (0.89- 2.10)  
15 SMAD3  rs12910698* CC 52 1.43 (0.99- 2.25) 0.023 
   AC+AA 123 1.94 (1.20- 3.40)  
  rs4776881 AA 52 1.43 (0.99- 2.25) 0.022 
   AG+GG 124 1.94 (1.20- 3.40)  
  rs4776339* AA 42 1.40 (0.84- 1.99) 0.0058 
   AG+GG 134 1.93 (1.20- 3.63)  
15 FURIN  rs2071410 GG 80 2.05 (1.30- 3.92) 0.014 
      CC+CG 92 1.60 (1.00- 2.45)  
6.3.3 TGF-β signaling pathway and aortic root dimension 
The maximal internal diameter for the aortic root normalized for body surface area (AoR Z-
max) was available for a subset of the US subjects (n=98) (Table 20). Twenty SNPs in 8 genes in the 
pathway, including TGFB2, TGFBR2 and SMAD3, were significantly associated with AoR Z-max 
(Table 28). One SNP (rs9310940) within TGFBR2 and one SNP (rs12901071) within SMAD3 were 
significant in both the analysis of CA outcome and the analysis of AoR dilatation (Figure 32).  
6.3.4 TGF-β signaling pathway and IVIG treatment response in the US subjects  
Case-control analysis of treatment response as a function of genotype was performed for the 
US subjects (IVIG-resistant n=46, IVIG-responsive n=147) (Table 29). The same 3 genes (TGFB2, 
TGFBR2 and SMAD3) that were associated with KD susceptibility, coronary artery aneurysm 
formation, and aortic root dilatation were again associated with IVIG treatment response.  
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Table 28. Association of genetic variants with Ao Z-max in US KD subjects (n=98)  
Results are shown only for SNPs with a nominal P-value <0.05. SD=standard deviation. The SNP followed by an 
asterisk * was also significantly associated in both the analysis of CA outcome and the analysis AoR dilatation. 
Chr. Gene symbol SNP Genotype n AoR Z-max (mean) SD P 
1 TGFB2 rs900 AA 46 1.60 0.10 0.022 
   AT+TT 52 1.27 0.10  
  rs991967 AA 42 1.60 0.11 0.028 
   AC+CC 55 1.29 0.10  
3 TGFBR2 rs9310940* CC 34 1.63 0.12 0.038 
   CA+AA 63 1.32 0.09  
  rs2276767 CC 49 1.27 0.10 0.029 
   CA+AA 48 1.59 0.10  
4 SMAD1 rs714195 GG 33 1.63 0.13 0.042 
   GA+AA 65 1.32 0.08  
  rs11100886 AA 32 1.63 0.14 0.043 
   AG+GG 66 1.32 0.08  
6 MAP3K7 rs205347 AA 40 1.23 0.11 0.021 
   AG+GG 55 1.56 0.09  
  rs3799897 AA 59 1.54 0.10 0.04 
   AG+GG 39 1.24 0.10  
9 TGFBR1 rs6478974 AA 29 1.67 0.15 0.023 
   AT+TT 69 1.32 0.08  
9 ENG rs1330684 GG 38 1.24 0.11 0.039 
   GA+AA 60 1.54 0.09  
15 SMAD3 rs4776338 GG 27 1.68 0.17 0.027 
   GA+AA 70 1.32 0.07  
  rs12901071 AA 40 1.24 0.10 0.036 
   AG+GG 58 1.55 0.10  
  rs7163381 GG 46 1.57 0.11 0.049 
   GA+AA 52 1.29 0.09  
  rs4776892 AA 55 1.56 0.10 0.032 
   AT+TT 42 1.25 0.10  
19 TGFB1 rs10417924 GG 62 1.30 0.09 0.021 
      GA+AA 35 1.64 0.12  
 
 
Table 29. Association of genetic variants with IVIG treatment response in US KD subjects  
Results are shown only for SNPs with a nominal P-value <0.05. 
       Allele 2 frequencies Allele2 vs. Allele 1 Genotype 11 
Chr. Gene  SNP Allele Resistant Responsive OR 95%CI P P 
1 TGFB2 rs3892225 A/G 0.34 0.14 0.41 0.21 0.77 0.0035 0.029 
3 TGFBR2 rs3773649 G/A 0.8 0.47 0.59 0.36 0.96 0.034 0.043 
rs746994 G/A 0.62 0.3 0.53 0.32 0.89 0.016 0.014 5 SMAD5 
rs10056474 C/G 0.82 0.44 0.57 0.34 0.94 0.029 0.026 
15 SMAD3 rs7163381 G/A 0.29 0.39 1.97 1.07 3.61 0.046 0.079 
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6.3.5 TGF-β pathway transcript abundance and plasma levels in acute and 
convalescent KD  
To discover differences in transcript abundance levels of genes in the TGF-β pathway 
between acute and convalescent KD samples, in collaboration with Prof. Jane Burn’s group we 
analyzed two independent microarray experiments each with 19 paired samples (Lymphochip array: 
2 subjects had CAA and 2 had IVIG-resistance; Agilent array: 1 subject had CAA and 8 had IVIG-
resistance). We found differential transcript abundance for all 15 genes of TGF-β pathway in both 
platforms. Transcript abundance levels for SMAD3 and TGFBR3 were significantly lower during the 
acute compared to convalescent stage on both platforms; transcript abundance for ACVRL1, 
SMAD1, and FURIN were higher during the acute phase on both array platforms (Table 30, Figure 
33).  
 
Figure 33. Heatmaps for Lymphchip array and Agilent array results for 5 genes of interest 
Yellow: Convalescent levels higher than Acute levels, Red: Acute levels higher than Convalescent levels. 
After Bonferroni correction, all transcripts on the Lymphochip array except for SMAD3 
remained significant. All transcripts on the Agilent array were under the q value of FDR. To validate 
the microarray results, they performed RT-PCR on cDNA for transcripts of ACVRL1, SMAD1, 
FURIN, SMAD3, and TGFBR3. Increased transcript levels for ACVRL1 (p=0.02), SMAD1 
(p=0.001) and decreased TGFBR3 (p=0.02) were documented during the acute phase (Figure 34A, 
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B, D). FURIN was detected in only three of 14 acute whole blood RNA samples and in none of the 
convalescent samples. To test whether the change in expression levels was simply a function of 
neutrophil number, they examined the correlation between ACVRL1, SMAD1, SMAD3, TGFBR3 
and FURIN gene expression levels and found only weak associations: r2 ≤ 0.36 for absolute 
neutrophil count (Agilent array) and r2 ≤ 0.58 for percent neutrophil change (Lymphochip array). 
Therefore, the dynamic changes in gene expression levels could not be explained simply by 
differences in cell populations in the peripheral blood. Genotype data were available for 14 of 15 
subjects whose gene expression levels were measured by RT-PCR, (Figure 30). We analyzed the 
association between changes in transcript levels and genotype for the most significant SNPs in 
ACVRL1 rs11169953, SMAD1 rs6537355 and SMAD3 rs4776338 (Figure 34E-G). No significant 
association was detected in this small number of subjects. Plasma concentrations of TGF-β2 during 
the acute phase were lower compared to the convalescent phase (P=0.002) (Figure 35) (n=18, 3 had 
CAA and 5 were IVIG-resistant). For the 13 subjects whose genotypes were available, we analyzed 
the association between changes of TGF-β2 plasma levels and genetic variants of rs12029576, the 
most significantly associated SNP in TGFB2 (P=0.0011, Table 26). No significant association was 
detected in this small number of subjects. 
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Figure 34. RT-PCR analysis of transcript abundance in whole blood from KD patients during the acute and 
convalescent phase and association between genotype and gene expression  
Relative transcript abundance levels were normalized by TAF1B for ACVRL1 (A), SMAD1 (B), SMAD3 (C) and 
TGFBR3 (D). Solid line: subjects with normal coronary arteries, Dashed line: subjects with coronary artery aneurysms. p 
value by paired t-test. (E-G) Association between acute and convalescent gene expression levels and  ACVRL1 
rs11169953 (risk allele= G, GG: n=7, GA: n=5, AA: n=2)  (E), SMAD1 rs6537355 (risk allele=A, AA: n=9, AG: n=5, 
no subject had GG genotype). (F), SMAD3 rs4776338 (risk allele= G , AA: n=6, AG: n=5, GG: n=3) (G). p value by 
Kruskal-Wallis test (E, G) and Mann Whitney test (F). 
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Figure 35. (A) Plasma levels of TGF-β2 in KD patients during the acute and convalescent phase 
Solid line: subjects with normal coronary arteries, Dashed line: subjects with coronary artery aneurysms. p value by 
paired t-test. (B) Association between acute and convalescent plasma levels of TGF-β2 and rs12029576 in TGF-β2 (risk 
allele= C, AA: n=7, AC: n=6, no subject had CC genotype). P-value by Mann Whitney test. 
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Table 30. Transcript abundance patterns for differentially expressed genes in the TGF-β pathway. 
Results are shown only for genes with SNPs with a P-value <0.05 
  Lymphochip array Agilent array 
Gene  Transcript abundance  P Fold P Fold change 
ACVRL1  0.0024 1.34 4.29E-08 2.03 
SMAD1 0.00027 1.25 3.84E-06 2.37 
FURIN 
↑Acute, ↓Conv.  
0.0012 1.37 6.27E-07 2.38 
SMAD3 0.015 0.91 9.59E-07 0.6 
TGFBR3 
↓Acute, ↑Conv.  
0.001 0.58 0.0007 0.47 
6.4 Discussion  
Several lines of evidence presented in this study suggest that the TGF-β signaling pathway 
plays an important role in KD pathogenesis and that genetic variation in three genes in the pathway 
(TGFB2, TGFBR2 and SMAD3) influence KD susceptibility, CAA formation, AoR dilatation and 
IVIG treatment response (Figure 32, Table 24, Table 26, Table 27 ,Table 28, Table 29). This is the 
first genetic analysis to find an association between CA and aortic root Z-scores and genotype. 
Genetic variants associated with KD phenotypes clustered in discrete regions based on single-SNP 
analysis. On the basis of the Venter genome analysis, individuals of European descent are likely to 
carry 200 to 500 non-synonymous, rare (minor allele frequency <5%) and/or novel variants that 
affect protein function.6,216 Sequencing the implicated regions of the three genes, TGFB2, TGFBR2 
and SMAD3, may identify novel or rare genetic variants associated with KD pathogenesis. The 
significance of genetic variation in this pathway was further highlighted by the finding of dynamic 
changes in transcript abundance and plasma protein levels during the course of the illness. An 
analysis of the dynamic change in transcript or protein levels as a function of genotype failed to 
show an association, potentially because the sample size was very small. Future studies with a bigger 
sample size will be needed to more definitively address the effect of these polymorphisms on gene 
expression. 
Each of the three genes identified as important by this study has a plausible role in KD 
pathogenesis. The first gene, TGFB2, encodes one of the three isoforms of TGF-β and is expressed 
in both a tissue-specific and a developmentally regulated fashion.  Only TGFB2 is expressed and 
required for endocardial cushion cell transformation in the mouse217 and Tgfb2 knockout mice suffer 
from a variety of cardiovascular anomalies.218-220  Plasma levels of TGF-β2 in the KD subjects were 
low in the acute compared to the convalescent phase. Similar findings have been reported for TGF-
β1 plasma levels and transcript abundance in acute KD but were not measured in this study.221-223  
Chapter 6. Application to Kawasaki disease 
 141 
The second gene highlighted by this study was TGFBR2, which was associated with KD 
susceptibility, CAA formation, AoR dilatation and response to IVIG treatment. Genetic variation in 
this gene is linked to several aneurysm syndromes including Loey-Dietz and abdominal aortic 
aneurysm.224,225 Immunohistochemistry of histologically normal and aneurysmal coronary arteries 3-
12 years after disease onset demonstrated TGF-β1, TGFBR1 and TGFBR2 in intimal or medial 
smooth muscle cells226,227. This was not seen in age-matched autopsy tissues from children dying of 
other conditions, suggesting the importance of this pathway in arterial remodeling late after KD. 
The third gene, SMAD3, has an essential role in down-regulating T-cells and increasing 
expression of FoxP3, an essential step in the differentiation of regulatory T cells228. Imbalance of 
pro-inflammatory Th17 and regulatory T-cells has been reported in acute coronary syndrome229. 
Recent data from Prof. Jane Burns’ laboratory documented the emergence of peripherally induced 
regulatory T-cells in acute KD subjects, suggesting that this pathway may be important in disease 
recovery.230  SMAD3 also has an important role in cardiovascular remodeling and fibrosis after 
injury, both active processes in the recovery phase from KD.231  
Naturally, there are several limitations to this study. First, only the tag-SNPs with a minor 
allele frequency of >=10% were genotyped. Thus, other rare, but important, genetic variants would 
not have been detected by this analysis. Secondly, although I and my collaborators, we have 
identified genetic variants that influence disease susceptibility and CAA outcome, none of these 
intronic variants have a known function. The clustering of significant SNPs in introns suggests the 
possibility of regulatory elements that might be encoded for by these regions. Although this is the 
first analysis to find an association between CA and aortic root Z-scores and SNPs, the number of 
subjects with CAA and AoR dilatation was limited and the findings will need to be validated in 
independent cohorts. The cohorts that were used may have been biased toward cases with CAA 
because of sample availability (CAA 73/362 (20%), and 51/186 (27%) in cohort 3 and 4). This may 
have affected the analysis of KD susceptibility. This issue can only be clarified by testing the findings 
in larger cohorts of subjects without CAA. KD is highly prevalent in Asian populations and this 
study only addressed genetic variation in subjects of European descent. Future studies must also 
address the mechanism by which these variants exert their effect. Studies of T-cell activation and 
differentiation of regulatory T-cells in cultured peripheral blood mononuclear cells from individuals 
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of known genotype will contribute to our understanding of how modulation of the TGF-β pathway 
impacts KD pathogenesis. 
This study supports the importance of the TGF-β signaling pathway in KD pathogenesis.  
Recently, Onouchi et al232 discovered a functional polymorphism in inositol 1,4,5-triphosphate 3-
kinase C that increases calcineurin/NFAT signaling and leads to increased levels of IL2 and T-cell 
activation in KD subjects. Genetic variation in the TGF-β pathway may lead to an imbalance of pro-
inflammatory and regulatory T-cells by affecting Foxp3 expression mediated through SMAD3 and 
NFAT.228 The TGF-β pathway is also important in inflammation and tissue remodeling mediated by 
endothelial cells, fibroblasts, and smooth muscle cells. Investigation of the association between the 
calcineurin/NFAT and TGF-β pathways in T-cells and immunohistochemical study of tissue will 
further our understanding these pathways in patients with KD. Both of these pathways have 
important potential for pharmacologic intervention with the availability of calcineurin inhibitors (eg. 
cyclosporine and tacrolimus) and modulators of the TGF-β signaling pathway (eg. angiotensin 
receptor blockers). Therefore, further study of these pathways may lead to important new 
therapeutic intervention strategies for KD patients. 
6.5 Summary 
In this chapter I described the extension of my methodology on family-trio GWAS, other 
than the typical case-control design. I presented the application of my approach on two GWAS of 
Kawasaki disease, (one case-control, one family-trio), where I examined the association between the 
TGF-β pathway and the disease. The evidence of association was further examined by microarray, 
RT-PCR and protein-level experiments and the results were validated. This chapter was a stand-
alone application of my methodology. In the next chapter, I go on to present the conclusions I 
arrived to after 3-years of my PhD and close by my general view of the field and its future.
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Chapter 7  
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the time I commenced my PhD project, there were very few published studies that 
utilised pathway-driven methodologies in the analysis of GWAS. In fact, my work evolved 
concurrently with a publication bloom on studies introducing various pathway-based approaches. 
For that reason, the real challenge has been the need to address the several conceptual and technical 
difficulties in a field that was and possibly still is at the very early stages of development.  
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7.1 What has this thesis achieved 
All in all, in the last three years, with the guidance of my supervisors and the contribution of 
the scientists in our group and our collaborators, I reviewed the relevant literature and gained insight 
on the technical challenges, the relative advantages and disadvantages of pathway and gene-based 
analyses of GWAS (Chapter 1). I developed a novel test statistic that summarizes the cumulative 
genetic variation along a biological pathway and then tests the association between the disease and 
the pathway as a single entity (Chapter 2). I applied this approach to the three autoimmune GWAS 
of the WTCCC dataset (CD, T1D, RA) and I identified several associations with inflammatory 
pathways. My methodology validated almost all previously reported associated genes; it identified 
associations that were missed at the time of the original publication and were only found 
subsequently in large meta-analyses; it revealed new plausible gene associations with the diseases in 
question (Chapter 3). I then went on to utilize the pathway-driven methodology to build predictive 
models of disease and assessed them robustly via cross-validation and out-of-sample replication. 
Specifically, to my knowledge this was the first study at the time to have presented such a highly 
predictive genetic model of disease in T1D and RA. I validated the findings derived from the 
WTCCC dataset analysis on a population dataset of NFBC1966 (Chapter 3).  I showed that 
pathway-driven markers can assist disease prediction and that pathway-based model building 
outperforms in predictive power non-pathway-based model building (Chapter 3). 
I refined my original methodology to a pathway-driven gene stability selection approach that 
identifies pathways associated with a disease and it then narrows down the signal of association to a 
kernel of genes that predominantly account for the effect. On the grounds that biological pathways 
usually share multiple gene constituents, it identifies the genes within those pathways that drive 
jointly the signal of these multiple pathway associations (Chapter 4). I showcased that my 
methodology provides reproducible results at the pathway, gene and in-silico function level on two 
independent GWAS datasets of RA (Chapter 5). My findings on RA suggest a new model of 
predisposition to RA, where cellular signalling might be at the heart of RA susceptibility, compared 
to the MHC scenario that has been the dominant hypothesis until today (Chapter 5). Lastly I 
extended my approach to be applicable on GWAS of family-trios and analyzed one case-control and 
one family-trio dataset on KD. I demonstrated evidence for the association between the TGF-β 
pathway and the disease that was then validated by gene-expression and protein studies on this 
pathway and on the same individuals. 
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I have completed a thesis that has brought to light new interesting directions on the analysis 
of GWAS and has equipped me with a strong background on the field. At the same time, I have 
addressed only in a suboptimal way the several implications that are inherent in the pathway-driven 
analysis of GWAS. Although I suggest potential solutions and provide results to support them, I do 
not imply that the challenges have been resolved. As I discuss in the overview of gene-based and 
pathway-driven methodologies (Chapter 1), the challenges that will need to be further explored in 
the future include the as yet limited understanding of what constitutes a pathway; the accuracy of 
information that is deposited on public pathway databases and how to manage the overlapping 
pathways; the question of how to assign SNPs to genes;  how to account for the confounding effects 
of LD patterns and gene size; how to address the single SNP hits or the large number of genes in a  
pathway that might elevate the pathway statistics; and how to identify the genes within associated 
pathways predominantly responsible for the pathway effect, and finally how to validate the findings 
on independent datasets given the genetic heterogeneity between studies. 
At the same time, the evolution of technology on genotyping platforms that allows >1M 
SNPs to be typed per study (e.g. Omni 2.5M and Omni 5M chips are already available) and the 1000 
Genomes project (http://www.1000genomes.org/) that will make available ~5 million SNPs to be 
used for imputation will vastly increase the computational burden, which is an issue not to be 
disregarded. My pathway-based methodology will not be able to scale up to millions of typed SNPs 
in a straightforward way, as I have already demonstrated that it is positively biased towards very large 
number of SNPs. In such a case, I would have to apply PCA separately on cases and controls and 
test the association of the first principal components of a gene rather than each SNP; I would then 
sum the statistics in the same manner I have described in this thesis. One way that my approach 
could accommodate for CNV pathway-based analysis, would be to test for the association between 
each CNV with the disease by fitting a logistic regression model. Then I could derive the z-statistic 
of the coefficient it, square it and it would then follow a χ2 distribution with 1 df under the null 
hypothesis of no association. I could then derived a similar pathway-based test statistic by summing 
the squared  z-statistic in the same manner that I have described the sum of Cochran-Armitage test 
statistics. 
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7.2 Future directions 
I anticipate that in the omics-era, where the advance of technology and the public awareness 
of genetic studies is expected to result in an overwhelming amount of generated data as well as typed 
individuals world-wide, pathway-driven analysis methodologies of GWAS will play a pivotal role.   
As depicted in Figure 36, pathway and gene-driven analysis of GWAS could act as a guide to 
define the broad pathway functional setting and to then prioritize genes for further functional 
studies. By prioritizing the genes at the genetic level and then validating the findings at the gene-
expression level, researchers would maximize the chances of pinning down functionally relevant 
genes to be knocked-down on animal models. Genes can be prioritized based on their strength of 
pathway association, statistical evidence of individual gene expression, and statistical evidence of 
coordinated altered gene expression of the pathways that they are involved in. An open-source 
solution to studies that do not have SNPs and gene-expression data on the same individuals would 
be the ArrayExpress Archive (AEA)44 of the European Bioinformatics Institute (EBI). AEA is a 
database of 19,923 gene-expression experiments comprising 554,961 assays on 18419 conditions that 
can be downloaded and analyzed with any of the pathway-based gene expression approaches that are 
numerous and they are very well presented in a recent review.46 On the linking of genetic and gene-
expression data, a pathway approach would most probably take the form of a “network-based” 
approach. Researchers that have tried to combine information across these two genomic levels have  
so far attempted to identify the SNPs that affect gene expression and then build de novo gene-
networks based on the correlation of differentially expressed genes.233 These networks are 
subsequently tested for “enrichment” in biological processes and functions, using any of the 
discussed methods. 
Metabonomic or proteomic analysis on the end product or intermediate products of a 
pathway could verify the pathway effect on disease susceptibility. The Human Metabolome 
Database (HMDB) is a freely available electronic database containing detailed information about 
small molecule metabolites found in the human body. Many data fields are hyperlinked to other 
databases (KEGG, PubChem, MetaCyc, ChEBI, PDB, Swiss-Prot, and GenBank), so the end-user 
can actually see which metabolites act in which pathways. 
Another direction could be the prediction of novel, not-discovered pathways, through 
capitalizing the cumulative evidence of genes that show association at multiple omics data.  
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Rare variants from sequencing studies would be expected to be grouped together in order to 
reveal their joint effect at a population rather than an individual’s level. Therefore a pathway-driven 
approach could also be a natural way for researchers to look at rare variants, as rare variants could 
be fitted in the same pathway-based model and each of them explain different portion of the genetic 
variation – with an effect on disease - in the population.  
On a similar note, the progress in next generation sequencing, epigenetic and proteomics 
studies open new exciting routes but yet poses new challenges on how pathway-based analyses will 
be able to extract and aggregate the knowledge across the different levels of genetic information.  
Disease risk prediction
Rare variants
CNVs
Pathway-based 
analysis of GWAS
Animal models
Single-SNP analysis 
of GWAS
Translation to clinical 
practice
Transcriptomics
Proteomics
Epigenomics
 
Figure 36. Pathway-based analyses of GWAS in the perspective of an integrative genomics approach 
 
7.3 Closing remark 
Pathway and gene-based analyses of GWAS differ to a great extend from each other, they 
have several technical challenges yet to tackle and as this concept is still in its infancy, no best 
pathway-based practice exists as yet. The same applies to the work presented in this thesis. 
Nevertheless, if I were to place my proposed methodology in the setting of relevant approaches, I 
would say that it has succeeded in three respects: 1) it addresses the majority of technical challenges 
and 2) it goes beyond other pathway-driven methodologies in that it identifies pathway-disease 
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associations and then identifies the genes within the top associated pathways that are driving the 
signal of multiple pathway associations. The latter is of great importance, as it has not been given 
enough attention to date and to my knowledge this methodology is the first to present such an 
integrated pathway and gene-based approach. 3) It has been applied and has produced replicated 
results in several GWAS datasets, at a time when the majority of similar methods have presented 
results on a single study only or simulated data. 
As a general comment, pathway-based analysis strategies of GWAS are powerful new tools 
to mine deeper the plethora of generated data and if their main limitations are addressed, they are 
expected to play an instrumental role in the forthcoming years. It is crucial for researchers to realize 
that some common standards should be adopted to allow for comparison of results between studies. 
Sceptical and careful interpretation of pathway association results should be adopted. As our 
knowledge of the gene complex interplay is incomplete, any pathway-disease association scenario 
could be plausible. Validation, replication and follow up of results should be considered essential. As 
nowadays validation on an independent dataset is essential for a single SNP to be considered truly 
associated, validation should be a natural step for a pathway to be denoted associated. Researchers 
are also advised to cite database versions, chip annotations, human genome reference sets and any 
other types of annotations used to ensure that results are fully reproducible. Pathway-based 
approaches have a long way to go. Their initial application has delivered promising results and they 
are expected to play central role in the integrative genomics era. I hope that the work presented in 
this thesis will contribute to the evolution of this approach and I aspire to contribute more in my 
future work to the application of pathway-driven methods to understand human disease. 
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